

chain nodes :

7 8 9

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

chain bonds :

3-7 7-8

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-20 17-18 18-19 19-20 21-22
21-25 22-23 23-24 24-25 26-27 26-30 26-31 27-28 27-31 28-29 29-30

exact/norm bonds :

3-7 7-8 11-15 14-15 16-20 19-20 21-25 24-25 26-27 26-30 26-31 27-28 27-31 28-29 29-30

exact bonds :

11-12 12-13 13-14 16-17 17-18 18-19 21-22 22-23 23-24

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 11 : 16 : 21 : 26 :

G1:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom


25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom

Generic attributes :

8:
Saturation : Unsaturated

=>

Uploading C:\Program Files\Stnexp\Queries\10809944.str



chain nodes :

7 8 9

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
27 28 29 30 31

chain bonds :

3-7 7-8

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-20
17-18 18-19 19-20 21-22 21-25 22-23 23-24 24-25 26-27 26-30 26-31 27-28
27-31 28-29 29-30

exact/norm bonds :

3-7 7-8 11-15 14-15 16-20 19-20 21-25 24-25 26-27 26-30 26-31 27-28
27-31 28-29 29-30

exact bonds :

11-12 12-13 13-14 16-17 17-18 18-19 21-22 22-23 23-24

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 11 : 16 : 21 : 26 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 12:21:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED

1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\10809944 (a).str



chain nodes :

7 8 9

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
27 28 29 30 31

```

chain bonds :
3-7 7-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-20
17-18 18-19 19-20 21-22 21-25 22-23 23-24 24-25 26-27 26-30 26-31 27-28
27-31 28-29 29-30
exact/norm bonds :
3-7 7-8 11-15 14-15 16-20 19-20 21-25 24-25 26-27 26-30 26-31 27-28
27-31 28-29 29-30
exact bonds :
11-12 12-13 13-14 16-17 17-18 18-19 21-22 22-23 23-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 11 : 16 : 21 : 26 :

```

```
G1:[*1],[*2],[*3],[*4]
```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom

```

```
L3          STRUCTURE UPLOADED
```

```
=> d l3
```

```
L3 HAS NO ANSWERS
```

```
L3          STR
```

```
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

Structure attributes must be viewed using STN Express query preparation.

```
=> s l3 sss sam
```

```
SAMPLE SEARCH INITIATED 12:22:34 FILE 'REGISTRY'
```

```
SAMPLE SCREEN SEARCH COMPLETED -          574 TO ITERATE
```

```
100.0% PROCESSED          574 ITERATIONS
```

```
50 ANSWERS
```

```
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
```

```
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
```

```
                        BATCH  **COMPLETE**
```

```
PROJECTED ITERATIONS:      10043 TO      12917
```

```
PROJECTED ANSWERS:         948 TO      1972
```

```
L4          50 SEA SSS SAM L3
```

```
=> =>
```

```
Uploading C:\Program Files\Stnexp\Queries\10809944 (b).str
```



chain nodes :

7 8 9

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
27 28 29 30 31

chain bonds :

3-7 7-8

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-20
17-18 18-19 19-20 21-22 21-25 22-23 23-24 24-25 26-27 26-30 26-31 27-28
27-31 28-29 29-30

exact/norm bonds :

3-7 7-8 11-15 14-15 16-20 19-20 21-25 24-25 26-27 26-30 26-31 27-28
27-31 28-29 29-30

exact bonds :

11-12 12-13 13-14 16-17 17-18 18-19 21-22 22-23 23-24

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 11 : 16 : 21 : 26 :

G1:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom

Generic attributes :

8:

Saturation : Unsaturated

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s 15 sss sam

SAMPLE SEARCH INITIATED 12:23:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 574 TO ITERATE

100.0% PROCESSED 574 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 10043 TO 12917

PROJECTED ANSWERS: 833 TO 1807

L6 50 SEA SSS SAM L5

=> => s 15 sss ful

FULL SEARCH INITIATED 12:27:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 10768 TO ITERATE

100.0% PROCESSED 10768 ITERATIONS

1187 ANSWERS

SEARCH TIME: 00.00.01

L7 1187 SEA SSS FUL L5

=> => s 17

L8 35 L7

=> d 18 1-35 bib,ab,hitstr

L8 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:318550 CAPLUS
 DN 144:370117
 TI Preparation of HIV inhibiting 5-heterocyclyl pyrimidines
 IN Guillemont, Jerome Emile Georges; Heeres, Jan; Lewi, Paulus Joannes
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 67 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006035067	A2	20060406	WO 2005-EP54930	20050929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2004-104812 A 20040930

OS MARPAT 144:370117

AB HIV replication inhibitors I [-a1=a2-a3=a4- = -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N-, -N=N-CH=CH-, -b1=b2-b3=b4- = -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N-, -N=N-CH=CH-; R1 = H, aryl, formyl, alkylcarbonyl, etc.; R2 = OH, halo, (un)substituted alkyl, alkenyl, etc.; R2a = CN, (un)substituted amino, (un)substituted alkyl, etc.; X1 = NR1, O, C(O), CH2, CHOH, S, S(O)p; R3 = CN, amino, alkyl, etc.; R4 = halo, OH, (un)substituted alkyl, alkenyl, etc.; R5 = 5-6 membered completely unsatd. ring system wherein 1-4 ring members are N, O or S, which ring may optionally be substituted and may optionally be annelated with a benzene ring; Q = H, alkyl, halo, etc.; n, m = 0-4; p = 1-2; and N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof]. E.g., a multi-step synthesis of II, starting from 2,4-dichloro-5-nitropyrimidine and 4-(2-cyanoethenyl)-2,6-dimethylphenylamine, was given. The antiviral activity of the compds. I was evaluated in the presence of the wild type HIV and HIV mutants bearing mutations at the reverse transcriptase gene (data given). The invention also relates to the use of compds. I for the prevention or the treatment of HIV infection.

IT 882054-44-6P 882054-45-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of HIV inhibiting 5-heterocyclyl pyrimidines)

RN 882054-44-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882054-45-7 CAPLUS


CN Benzonitrile, 4-[[5-(2-amino-5-thiazolyl)-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L8 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:193566 CAPLUS
 DN 144:267267
 TI Method of treatment and compositions for a disease associated with
 antinuclear antibodies
 IN Benigni, Ariela; Zoja, Carla; Remuzzi, Giuseppe; Giannella-Borradori,
 Athos
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021803	A2	20060302	WO 2005-GB3350	20050825
	WO 2006021803	A3	20060420		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	GB 2004-19175	A	20040827		
	GB 2004-19176	A	20040827		
AB	The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as systemic lupus erythematosus. Mice treated with CYC202 at the doses of 200 and 100 mg/kg survived significantly longer than vehicle-treated mice.				
IT	364334-88-3 693228-63-6 693229-59-3 870780-24-8 870780-29-3 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (method of treatment and compns. for disease associated with antinuclear antibodies)				
RN	364334-88-3 CAPLUS				
CN	1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)				




RN 693228-63-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-59-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870780-24-8 CAPLUS

CN Acetamide, N-[[4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-29-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(acetamidomethyl)phenyl]- (9CI) (CA INDEX NAME)

10/809,944

(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:183501 CAPLUS

DN 144:343077

TI Differential Binding of Inhibitors to Active and Inactive CDK2 Provides Insights for Drug Design

AU Kontopidis, George; McInnes, Campbell; Pandalaneni, Sravan R.; McNae, Iain; Gibson, Darren; Mezna, Mokdad; Thomas, Mark; Wood, Gavin; Wang, Shudong; Walkinshaw, Malcolm D.; Fischer, Peter M.

CS James Lindsay Place, Cyclacel Ltd., Dundee, DD1 5J, UK

SO Chemistry & Biology (Cambridge, MA, United States) (2006) 13(2), 201-211
CODEN: CBOLE2; ISSN: 1074-5521

PB Cell Press

DT Journal

LA English

AB The cyclin-dependent kinases (CDKs) have been characterized in complex with a variety of inhibitors, but the majority of structures solved are in the inactive form. We have solved the structures of six inhibitors in both the monomeric CDK2 and binary CDK2/cyclinA complexes and demonstrate that significant differences in ligand binding occur depending on the activation state. The binding mode of two ligands in particular varies substantially in active and inactive CDK2. Furthermore, energetic anal. of CDK2/cyclin/inhibitors demonstrates that a good correlation exists between the in vitro potency and the calculated energies of interaction, but no such relationship exists for CDK2/inhibitor structures. These results confirm that monomeric CDK2 ligand complexes do not fully reflect active conformations, revealing significant implications for inhibitor design while also suggesting that the monomeric CDK2 conformation can be selectively inhibited.


IT 364333-96-0 364334-88-3 507487-89-0
693228-63-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(differential binding of inhibitors to active and inactive CDK2 provides insights for drug design)


RN 364333-96-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-
(9CI) (CA INDEX NAME)



RN 693228-63-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 44

THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1289100 CAPLUS
 DN 144:36367
 TI Preparation of 2-substituted 4-thiazolylpyrimidines as protein kinase inhibitors with improved solubility properties
 IN Wang, Shudong; Wood, Gavin; Duncan, Kenneth; Meades, Christopher; Gibson, Darron; Mclachlan, Janice; Fischer, Peter
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 216 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005116025	A2	20051208	WO 2005-GB2134	20050526
	WO 2005116025	A3	20060223		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI GB 2004-11791 A 20040526

OS MARPAT 144:36367

AB The present invention relates to 2-substituted 4-thiazolylpyrimidines (shown as I; variables defined below; e.g. (3-methylsulfonylphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine (shown as II)), their preparation, pharmaceutical compns. containing them and their use as inhibitors of ≥ 1 protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders. For I: 1 of X1 and X2 is S, and the other is N; Z is NH, NHCO, NHCOCH₂, NHSO₂, NHCH₂, CH₂, CH₂CH₂, CH:CH, O, S, SO₂, or SO; R1, R2, R3, R4, R5, R6, R7 and R8 = H, alkyl, alkyl-R9, aryl, aryl-R9, aralkyl, aralkyl-R9, halo, et al. or two of R4-R8 are linked to form a cyclic ether containing ≥ 1 oxygens; R9 = solubilizing group = mono, di- or polyhydroxylated alicyclic, di- or polyhydroxylated aliphatic or aromatic, carbohydrate derivative, O- and/or S-containing heterocyclic group, et al.;

addnl.

details including provisos are given in the claims. Protein kinase inhibition properties of many I for many kinases are tabulated. Although the methods of preparation are not claimed, preps. and/or characterization data for 220 examples of I are included. For example, [4-(2-tert-butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methyl-3-nitrophenyl)amine was prepared by condensation of 1-(2-tert-butylamino-4-methylthiazol-5-yl)-3-dimethylaminopropenone and N-(4-methyl-3-nitrophenyl)guanidine nitrate. Compds. I are also claimed useful in an assay for identifying further candidate compds. capable of inhibiting various enzymes.

IT 870780-10-2P, 1-[4-[3-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone
 870780-83-9P, 1-[4-[4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-


2-yl]amino]phenyl]piperazin-1-yl]ethanone 870780-84-0P,
 1-[4-[4-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870781-42-3P,
 N-[3-[[4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide

RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);
 RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
 (Uses)

(drug candidate; preparation of 2-substituted 4-thiazolylpyrimidines as
 protein kinase inhibitors with improved solubility properties)


RN 870780-10-2 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870780-83-9 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870780-84-0 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870781-42-3 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 870780-07-7P, [3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]acetic acid 2-methoxyethyl ester 870780-08-8P, [4-(2-tert-Butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl] (4-methyl-3-nitrophenyl)amine 870780-11-3P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3-methylsulfonylphenyl)amine 870780-12-4P, N-[3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]methanesulfonamide 870780-15-7P, N-[3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]methanesulfonamide 870780-16-8P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl] [3-(piperazin-1-yl)phenyl]amine 870780-17-9P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] [3-(piperazin-1-yl)phenyl]amine 870780-18-0P, N-[3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]benzamide 870780-19-1P, N-[3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]-1,1,1-trifluoromethanesulfonamide 870780-20-4P, N-[3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]-1,1,1-trifluoromethanesulfonamide 870780-23-7P, N-[3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]-1,1,1-trifluoromethanesulfonamide 870780-24-8P, N-[4-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]acetamide 870780-26-0P, N-[4-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzyl]acetamide 870780-27-1P, N-[4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]acetamide 870780-28-2P, N-[4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]acetamide 870780-29-3P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl] (4-methylsulfonylphenyl)amine 870780-30-6P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-31-7P, 3-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-32-8P, (4-Methylsulfonylphenyl) [4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 870780-33-9P, N-Methyl-3-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-35-1P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide 870780-36-2P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl] (3,4,5-trimethoxyphenyl)amine 870780-37-3P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl] (3,4,5-trimethoxyphenyl)amine 870780-38-4P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3,4,5-trimethoxyphenyl)amine 870780-39-5P, 3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide 870780-40-8P, (3-Methylsulfonylphenyl) [4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 870780-41-9P, [4-(2-Ethylamino-4-methylthiazol-5-

yl)pyrimidin-2-yl](3-methylsulfonylphenyl)amine 870780-42-0P,
 N-Ethyl-3-[[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-44-2P, 3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-ethylbenzenesulfonamide 870780-45-3P, N-Ethyl-3-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-46-4P,
 N-(3-Methoxyphenyl)-3-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-49-7P, 3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide 870780-50-0P, 4-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-51-1P, 4-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-52-2P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-methyl-3-[(morpholin-4-yl)sulfonyl]phenyl]amine 870780-55-5P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl][4-methyl-3-[(morpholin-4-yl)sulfonyl]phenyl]amine 870780-56-6P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-methyl-3-[(morpholin-4-yl)sulfonyl]phenyl]amine 870780-57-7P, 4-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-58-8P, N-(2-Methoxyethyl)-4-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-59-9P, 4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-60-2P, (3-Bromo-4-methylphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 870780-63-5P, 4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-64-6P, [3-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]acetic acid 2-methoxyethyl ester 870780-65-7P, [3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]acetic acid 2-methoxyethyl ester 870780-66-8P, 1-[4-[3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870780-67-9P, [3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-5-hydroxymethylphenyl]methanol 870780-70-4P, [3-Hydroxymethyl-5-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]methanol 870780-71-5P, N-[3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]methanesulfonamide 870780-72-6P, (3-Bromophenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870780-75-9P, [4-(2-tert-Butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 870780-76-0P, N,N-Diethyl-4-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-78-2P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-80-6P, N-(2-Methoxyethyl)-3-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-81-7P, 3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-82-8P, 3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-85-1P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(piperazin-1-yl)phenyl]amine 870780-86-2P, [4-(4-Benzylpiperazin-1-yl)phenyl][4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870780-87-3P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(piperazin-1-yl)phenyl]amine 870780-88-4P, [3-[[[4-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]sulfonyl]amino]phenyl]acetic acid ethyl ester 870780-90-8P, N-Acetyl-3-[[4-(4-methyl-

2-methylaminothiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide 870780-92-0P, N-Acetyl-3-[[4-(2-amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-93-1P, 4-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870780-95-3P, 4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-ethylbenzenesulfonamide 870780-97-5P, N-(2-Hydroxyethyl)-4-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-98-6P, 4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870780-99-7P, 4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870781-00-3P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-isopropylbenzenesulfonamide 870781-02-5P, N-Benzyl-4-[[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-04-7P, N-Benzyl-4-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-05-8P, 4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-benzylbenzenesulfonamide 870781-06-9P, N-Benzyl-4-[[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-07-0P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870781-09-2P, N-(2-Hydroxyethyl)-3-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-10-5P, 3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870781-11-6P, 3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870781-13-8P, N-Benzyl-3-[[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-15-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-(morpholin-4-yl)sulfonyl]phenyl]amine 870781-17-2P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-methyl-3-(morpholin-4-yl)sulfonyl]phenyl]amine 870781-18-3P, 3-[[4-(2-(2-Methoxyethylamino)-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-20-7P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxy-1,1-dimethylethyl)benzenesulfonamide 870781-29-6P, (3-Aminomethylphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870781-30-9P, Pyridine-2-carboxylic acid N-[3-[[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]amide 870781-39-8P, [4-(2-(2-Ethylpyridin-4-yl)-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-41-2P, [4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-43-4P, 4-[[4-(2-(2-Ethylpyridin-4-yl)-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870781-44-5P, N-[4-[[4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-45-6P, N-[4-[[4-[2-(2-Ethylpyridin-4-yl)-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-46-7P, N-[3-[[4-[2-(2-Ethylpyridin-4-yl)-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-47-8P, [4-[4-Methyl-2-(6-methylpyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-49-0P, [4-[2-[3-(2-Methoxyethoxy)-5-trifluoromethylpyridin-2-yl]-4-methylthiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-51-4P, N-[3-[[4-[4-Methyl-2-(6-methylpyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide

870781-52-5P, N-[3-[[4-[2-(3-Chloro-5-trifluoromethylpyridin-2-yl)-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide
870781-54-7P, N-(2-Methoxyethyl)-4-[[4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide
870781-56-9P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-methoxy-2-methylphenyl]amine 870781-58-1P,
[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-methoxy-2-methylphenyl]amine 870781-59-2P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][5-methoxy-2-methylphenyl]amine 870781-61-6P,
[4-(4-Benzylpiperazin-1-yl)phenyl][4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870781-62-7P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][5-methoxy-2-methylphenyl]amine 870781-63-8P,
(3-Aminomethylphenyl)[4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870781-64-9P, [4-[2-[(Benzyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-66-1P,
N-[3-[[4-[2-[(Benzyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-67-2P, 1-[4-[4-[[4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870781-68-3P, [4-[2-[(Ethyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine
870781-70-7P, [4-(2,6-Dimethylmorpholin-4-yl)phenyl][4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870781-72-9P,
1-[4-[4-[[4-[2-[(Benzyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870781-74-1P,
[4-[2-[(3,5-Dichlorophenyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-76-3P,
[4-[2-[(4-Chlorophenyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-78-5P,
N-[3-[[4-[2-[(3,5-Dichlorophenyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-79-6P,
[3,5-Dichloro-4-(morpholin-4-yl)phenyl][4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870781-81-0P,
[3-Chloro-4-(morpholin-4-yl)phenyl][4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870781-82-1P, [3-Chloro-4-(morpholin-4-yl)phenyl][4-[2-[(3,5-dichlorophenyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl]amine 870781-83-2P, [4-[4-Methyl-2-(thiophen-2-yl)thiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine
870781-84-3P, N-[3-[[4-[4-Methyl-2-(thiophen-2-yl)thiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-85-4P,
1-[4-[4-[[4-[4-Methyl-2-(thiophen-2-yl)thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870781-86-5P,
[5-[2-[(4-Dimethylaminophenyl)amino]pyrimidin-4-yl]-4-methylthiazol-2-yl]methanol 870781-89-8P, [3,5-Dichloro-4-(morpholin-4-yl)phenyl][4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine
870781-90-1P, [3-Chloro-4-(morpholin-4-yl)phenyl][4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870781-91-2P,
[4-(4,2'-Dimethyl-[2,4']bithiazolyl-5-yl)pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-93-4P, [3-Chloro-4-(morpholin-4-yl)phenyl][4-(4,2'-dimethyl-[2,4']bithiazolyl-5-yl)pyrimidin-2-yl]amine
870781-94-5P, [3,5-Dichloro-4-(morpholin-4-yl)phenyl][4-(4,2'-dimethyl-[2,4']bithiazolyl-5-yl)pyrimidin-2-yl]amine 870781-95-6P
, [4-[4-Methyl-2-[(thien-2-yl)sulfonyl]methyl]thiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-97-8P,
[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][2-methyl-4-(morpholin-4-yl)phenyl]amine 870781-99-0P, [4-[2-(2,4-Dimethylphenyl)-4-methylthiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine
870782-01-7P, [3-Chloro-4-(morpholin-4-yl)phenyl][4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870782-02-8P,

[3,5-Dichloro-4-(morpholin-4-yl)phenyl][4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870782-03-9P, [4-(2-tert-Butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-04-0P, [4-[2-(2-Methoxyethylamino)-4-methylthiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-05-1P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl][2-methyl-4-(morpholin-4-yl)phenyl]amine 870782-06-2P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][2-methyl-4-(morpholin-4-yl)phenyl]amine 870782-07-3P, [4-[4-Methyl-2-[4-(morpholin-4-yl)phenyl]thiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-09-5P, 1-[4-[4-[4-[4-Methyl-2-[4-(morpholin-4-yl)phenyl]thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870782-10-8P, N'-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N-methyl-2-trifluoromethylbenzene-1,4-diamine 870782-12-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][3-[(morpholin-4-yl)methyl]phenyl]amine 870782-14-2P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-2-[(morpholin-4-yl)methyl]phenol 870782-16-4P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][3-(morpholin-4-yl)phenyl]amine 870782-18-6P, [4-[4-Methyl-2-[(methyl)(pyridin-3-yl)amino]thiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-20-0P, [4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl](3,4,5-trimethoxyphenyl)amine 870782-21-1P, (3,5-Dimethoxyphenyl)[4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870782-22-2P, [3-Methoxy-4-(morpholin-4-yl)phenyl][4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870782-24-4P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methoxy-4-(morpholin-4-yl)phenyl]amine 870782-25-5P, [4-(4-Methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-27-7P, (3,5-Dimethoxyphenyl)[4-(4-methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-28-8P, (3,5-Dimethoxyphenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870782-29-9P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3,5-dimethoxyphenyl)amine 870782-30-2P, 1-[4-[4-[4-(4-Methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870782-31-3P, 1-[4-[4-[4-[4-Methyl-2-[(methyl)(pyridin-3-yl)amino]thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870782-32-4P, [4-(4-Methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl](3,4,5-trimethoxyphenyl)amine 870782-33-5P, [4-(4-Benzylpiperazin-1-yl)phenyl][4-(4-methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-34-6P, [4-(4-Methyl-2-phenylaminothiazol-5-yl)pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-36-8P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3,4,5-trimethoxyphenyl)amine 870782-37-9P, [4-(2,6-Dimethylmorpholin-4-yl)phenyl][4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870782-38-0P, (3,5-Dimethoxyphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-39-1P, (3,5-Dimethoxyphenyl)[4-(4-methyl-2-phenylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-40-4P, 1-[4-[4-[4-(4-Methyl-2-phenylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870782-41-5P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][3-methoxy-4-(morpholin-4-yl)phenyl]amine 870782-42-6P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-[(morpholin-4-yl)methyl]phenyl]amine 870782-44-8P, (3,5-Dimethoxyphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870782-45-9P, [4-(4-Benzylpiperazin-1-yl)phenyl][4-(4-methyl-2-phenylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-46-0P, (Benzodioxol-5-yl)[4-[4-

methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine
 870782-47-1P, (Benzodioxol-5-yl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870782-48-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](benzodioxol-5-yl)amine
 870782-49-3P, (2,3-Dihydrobenzo[1,4]dioxin-6-yl)[4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870782-50-6P,
 (2,3-Dihydrobenzo[1,4]dioxin-6-yl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870782-51-7P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methoxy-4-(morpholin-4-yl)phenyl]amine 870782-52-8P, (2,3-Dihydrobenzo[1,4]dioxin-6-yl)[4-(4-methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl]amine
 870782-53-9P, (4-Methoxy-3-methylphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-55-1P,
 [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methoxy-3-methylphenyl)amine 870782-56-2P, (4-Methoxy-3-methylphenyl)[4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine
 870782-57-3P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methoxy-3-methylphenyl)amine 870782-58-4P,
 [4-Methyl-5-[2-[[4-(morpholin-4-yl)phenyl]amino]pyrimidin-4-yl]thiazol-2-yl]methanol 870782-59-5P
 , 4-[4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylic acid ethyl ester 870782-61-9P, 2-[4-[4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]-N-isopropylacetamide 870782-63-1P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl][4-(4-methylpiperazin-1-yl)phenyl]amine 870782-64-2P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-(piperidin-1-yl)phenyl]amine 870782-66-4P,
 [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(piperidin-1-yl)phenyl]amine 870782-67-5P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(piperidin-1-yl)phenyl]amine 870782-68-6P,
 [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(4-methylpiperazin-1-yl)phenyl]amine 870782-69-7P, [4-Methyl-5-[2-[[4-(piperidin-1-yl)phenyl]amino]pyrimidin-4-yl]thiazol-2-yl]methanol 870782-70-0P
 , [4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl][4-(pyrrolidin-1-yl)phenyl]amine 870782-72-2P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-(pyrrolidin-1-yl)phenyl]amine 870782-73-3P,
 [5-[2-[[3-Methoxy-4-(morpholin-4-yl)phenyl]amino]pyrimidin-4-yl]-4-methylthiazol-2-yl]methanol 870782-74-4P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(4-thiomorpholinyl)phenyl]amine
 870782-76-6P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-(4-thiomorpholinyl)phenyl]amine 870782-77-7P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(4-thiomorpholinyl)phenyl]amine
 870782-78-8P, [4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl][4-(4-thiomorpholinyl)phenyl]amine 870782-79-9P,
 [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(piperidin-1-yl)phenyl]amine 870782-81-3P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(piperidin-1-yl)phenyl]amine
 870782-82-4P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(piperidin-1-yl)phenyl]amine 870782-83-5P,
 [3-Methyl-4-(piperidin-1-yl)phenyl][4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870782-84-6P, [4-Methyl-5-[2-[[3-methyl-4-(piperidin-1-yl)phenyl]amino]pyrimidin-4-yl]thiazol-2-yl]methanol
 870782-85-7P, 5-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-2-(morpholin-4-yl)benzamide 870782-87-9P,
 5-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-2-(morpholin-4-yl)benzamide 870782-88-0P, 5-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-2-(morpholin-4-yl)benzamide 870782-89-1P
 , Cyclopropyl[4-[4-[[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-


yl]aminolphenyl]piperazin-1-yl]methanone 870782-91-5P,
 [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-methyl-3-(morpholin-4-yl)phenyl]amine 870782-93-7P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-methoxy-3-[(morpholin-4-yl)methyl]phenyl]amine 870782-95-9P, [5-[2-[[3-Methoxy-4-(piperidin-1-yl)phenyl]amino]pyrimidin-4-yl]-4-methylthiazol-2-yl]methanol 870782-97-1P, [4-Methyl-5-[2-[[3-methyl-4-(morpholin-4-yl)phenyl]amino]pyrimidin-4-yl]thiazol-2-yl]methanol 870782-99-3P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(morpholin-4-yl)phenyl]amine 870783-00-9P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(morpholin-4-yl)phenyl]amine 870783-01-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(morpholin-4-yl)phenyl]amine

RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-substituted 4-thiazolylpyrimidines as protein kinase inhibitors with improved solubility properties)


RN 870780-07-7 CAPLUS

CN Benzeneacetic acid, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 870780-08-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(1,1-dimethylethyl)amino]-4-methyl-5-thiazolyl]-N-(4-methyl-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 870780-11-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-12-4 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-15-7 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-16-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[3-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-17-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(1-piperazinyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 870780-18-0 CAPLUS

CN Benzamide, N-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-19-1 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 870780-20-4 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 870780-23-7 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 870780-24-8 CAPLUS

CN Acetamide, N-[[4-[[4-(2-ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-26-0 CAPLUS

CN Acetamide, N-[[4-[[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-27-1 CAPLUS

CN Acetamide, N-[[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 870780-28-2 CAPLUS


CN Acetamide, N-[[4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 870780-29-3 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-

(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-30-6 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-31-7 CAPLUS

CN Benzenesulfonamide, 3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-32-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-33-9 CAPLUS

CN Benzenesulfonamide, N-methyl-3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-35-1 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 870780-36-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870780-37-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870780-38-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870780-39-5 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 870780-40-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylanino)-5-thiazolyl]-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-41-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-42-0 CAPLUS

CN Benzenesulfonamide, N-ethyl-3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-44-2 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-ethyl- (9CI) (CA INDEX NAME)




RN 870780-45-3 CAPLUS

CN Benzenesulfonamide, N-ethyl-3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-46-4 CAPLUS

CN Benzenesulfonamide, N-(3-methoxyphenyl)-3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-49-7 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 870780-50-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-[4-methyl-2-(methyamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-51-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(ethyamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-52-2 CAPLUS

CN Morpholine, 4-[[5-[[4-[2-(ethyamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-2-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870780-55-5 CAPLUS

CN Morpholine, 4-[[2-methyl-5-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870780-56-6 CAPLUS

CN Morpholine, 4-[[5-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870780-57-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-58-8 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-59-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-60-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromo-4-methylphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 870780-63-5 CAPLUS


CN Benzenesulfonamide, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 870780-64-6 CAPLUS


CN Benzeneacetic acid, 3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-

pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 870780-65-7 CAPLUS

CN Benzenecacetic acid, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 870780-66-8 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870780-67-9 CAPLUS

CN 1,3-Benzenedimethanol, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-70-4 CAPLUS

CN 1,3-Benzenedimethanol, 5-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-71-5 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-72-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870780-75-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(1,1-dimethylethyl)amino]-4-methyl-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 870780-76-0 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-78-2 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-80-6 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-81-7 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-82-8 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-85-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-86-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 870780-87-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-88-4 CAPLUS

CN Benzeneacetic acid, 3-[[[4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]sulfonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 870780-90-8 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870780-92-0 CAPLUS

CN Acetamide, N-[[3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870780-93-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-95-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-ethyl- (9CI) (CA INDEX NAME)




RN 870780-97-5 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[[4-(4-methyl-2-(methylamino)-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-98-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 870780-99-7 CAPLUS


CN Benzenesulfonamide, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 870781-00-3 CAPLUS


CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

pyrimidinyl]amino]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 870781-02-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 870781-04-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 870781-05-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 870781-06-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 870781-07-0 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870781-09-2 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870781-10-5 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870781-11-6 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870781-13-8 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 870781-15-0 CAPLUS

CN Morpholine, 4-[[3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870781-17-2 CAPLUS

CN Morpholine, 4-[[5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870781-18-3 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-[(2-methoxyethyl)amino]-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870781-20-7 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 870781-29-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 870781-30-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-39-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(2-ethyl-4-pyridinyl)-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-41-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-43-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(2-ethyl-4-pyridinyl)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870781-44-5 CAPLUS

CN Acetamide, N-[[4-[[4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-45-6 CAPLUS

CN Acetamide, N-[[4-[[4-[2-(2-ethyl-4-pyridinyl)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-46-7 CAPLUS

CN Acetamide, N-[[3-[[4-[2-(2-ethyl-4-pyridinyl)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-47-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(6-methyl-3-pyridinyl)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-49-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[3-(2-methoxyethoxy)-5-(trifluoromethyl)-2-pyridinyl]-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-51-4 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-(6-methyl-3-pyridinyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-52-5 CAPLUS

CN Acetamide, N-[[3-[[4-[2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-54-7 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870781-56-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870781-58-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870781-59-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(5-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870781-61-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 870781-62-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(5-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870781-63-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870781-64-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[(phenylmethyl)amino]-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-66-1 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-[(phenylmethyl)amino]-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-67-2 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870781-68-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylmethylamino)-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-70-7 CAPLUS

CN 2-Pyrimidinamine, N-[4-(2,6-dimethyl-4-morpholinyl)phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 870781-72-9 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-[methyl(phenylmethyl)amino]-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870781-74-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(3,5-dichlorophenyl)methylamino]-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-76-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(4-chlorophenyl)methylamino]-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-78-5 CAPLUS

CN Acetamide, N-[[3-[[4-[2-[(3,5-dichlorophenyl)methylamino]-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




.RN 870781-79-6 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-dichloro-4-(4-morpholinyl)phenyl]-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870781-81-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870781-82-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-[2-[(3,5-dichlorophenyl)methylamino]-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870781-83-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(2-thienyl)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-84-3 CAPLUS

CN Acetamide, N-[[3-[[4-(4-methyl-2-(2-thienyl)-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-85-4 CAPLUS


CN Piperazine, 1-acetyl-4-[4-[[4-(4-methyl-2-(2-thienyl)-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870781-86-5 CAPLUS
 CN 2-Thiazolemethanol, 5-[2-[[4-(dimethylamino)phenyl]amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 870781-89-8 CAPLUS
 CN 2-Pyrimidinamine, N-[3,5-dichloro-4-(4-morpholinyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 870781-90-1 CAPLUS
 CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870781-91-2 CAPLUS
 CN 2-Pyrimidinamine, 4-(2',4'-dimethyl[2,4'-bithiazol]-5-yl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-93-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-(2',4-dimethyl[2,4'-bithiazol]-5-yl)- (9CI) (CA INDEX NAME)




RN 870781-94-5 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-dichloro-4-(4-morpholinyl)phenyl]-4-(2',4-dimethyl[2,4'-bithiazol]-5-yl)- (9CI) (CA INDEX NAME)




RN 870781-95-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[(2-thienylsulfonyl)methyl]-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-97-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[2-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-99-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(2,4-dimethylphenyl)-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-01-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 870782-02-8 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-dichloro-4-(4-morpholinyl)phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 870782-03-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(1,1-dimethylethyl)amino]-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-04-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(2-methoxyethyl)amino]-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870782-05-1 CAPLUS


CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylanino)-5-thiazolyl]-N-[2-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870782-06-2 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[2-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-07-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[4-(4-morpholinyl)phenyl]-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-09-5 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-[4-(4-morpholinyl)phenyl]-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870782-10-8 CAPLUS

CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1-methyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 870782-12-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-14-2 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 870782-16-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-18-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methyl-3-pyridinylamino)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-20-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870782-21-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-22-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-4-(4-morpholinyl)phenyl]-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-24-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[3-methoxy-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-25-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-27-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-28-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-29-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870782-30-2 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870782-31-3 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-(methyl-3-pyridinylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870782-32-4 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870782-33-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]-N-[4-(4-(phenylmethyl)-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-34-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(phenylamino)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-36-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870782-37-9 CAPLUS

CN 2-Pyrimidinamine, N-[4-(2,6-dimethyl-4-morpholinyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-38-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-39-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[4-methyl-2-(phenylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-40-4 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-(phenylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870782-41-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-methoxy-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-42-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-44-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 870782-45-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(phenylamino)-5-thiazolyl]-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 870782-46-0 CAPLUS

CN 2-Pyrimidinamine, N-1,3-benzodioxol-5-yl-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-47-1 CAPLUS

CN 2-Pyrimidinamine, N-1,3-benzodioxol-5-yl-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-48-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-1,3-benzodioxol-5-yl- (9CI) (CA INDEX NAME)




RN 870782-49-3 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-50-6 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-51-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[3-methoxy-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-52-8 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-53-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy-3-methylphenyl)-4-[4-methyl-2-(methanimino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-55-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-methoxy-3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870782-56-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy-3-methylphenyl)-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-57-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-methoxy-3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870782-58-4 CAPLUS

CN 2-Thiazolemethanol, 4-methyl-5-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 870782-59-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 870782-61-9 CAPLUS

CN 1-Piperazineacetamide, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 870782-63-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-64-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-66-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-67-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-68-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-69-7 CAPLUS

CN 2-Thiazolemethanol, 4-methyl-5-[2-[[4-(1-piperidiny)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 870782-70-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870782-72-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870782-73-3 CAPLUS


CN 2-Thiazolemethanol, 5-[2-[[3-methoxy-4-(4-morpholinyl)phenyl]amino]-4-

pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 870782-74-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-76-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-77-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-78-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-[4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-79-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-methyl-4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-81-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[3-methyl-4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-82-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[3-methyl-4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-83-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-methyl-4-(1-piperidinyl)phenyl]-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-84-6 CAPLUS

CN 2-Thiazolemethanol, 4-methyl-5-[2-[[3-methyl-4-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 870782-85-7 CAPLUS

CN Benzamide, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 870782-87-9 CAPLUS

CN Benzamide, 5-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 870782-88-0 CAPLUS

CN Benzamide, 5-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 870782-89-1 CAPLUS

CN Piperazine, 1-(cyclopropylcarbonyl)-4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870782-91-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-methyl-3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-93-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-methoxy-3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-95-9 CAPLUS

CN 2-Thiazolemethanol, 5-[2-[[3-methoxy-4-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 870782-97-1 CAPLUS

CN 2-Thiazolemethanol, 4-methyl-5-[2-[[3-methyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 870782-99-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[3-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870783-00-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[3-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870783-01-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1262395 CAPLUS
 DN 144:22936
 TI Preparation of aminopyrimidine derivatives as aurora 2 kinase inhibitors
 for treatment of cancer
 IN Tomozane, Hideo; Ando, Ryoichi; Oike, Shinsuke
 PA Mitsubishi Pharma Corporation, Japan
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113550	A1	20051201	WO 2005-JP9119	20050519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2004-150962 A 20040520

OS MARPAT 144:22936

AB The title aminopyrimidine derivs. I [wherein R1 and R2 = independently halo, alkyl, OH, alkoxy, amino, alkylamino, or acylamino; R3 and R4 = independently H, halo, alkyl, OH, or alkoxy; R5 = H, alkyl, or acyl; R6 and R7 = independently H, halo, alkyl, OH, etc.; R8 = (un)substituted COH, CO2H, CONH2, etc.; R9 = H, alkyl, OH, alkoxy, etc.], or pharmaceutically acceptable salts, hydrates, or solvates thereof were prepared as aurora 2 kinase inhibitors for the treatment of cancer. For example, the compound II was prepared in a multi-step synthesis. II inhibited aurora 2 kinase with IC50 of 4 nM.


IT 870458-86-9P 870459-09-9P 870459-17-9P
 870459-18-0P 870459-19-1P 870459-20-4P
 870459-21-5P 870459-24-8P 870459-30-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of aminopyrimidine derivs. as aurora 2 kinase inhibitors for treatment of cancer)


RN 870458-86-9 CAPLUS

CN 1,3-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N'-hydroxy- (9CI) (CA INDEX NAME)




RN 870459-09-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-17-9 CAPLUS

CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 870459-18-0 CAPLUS


CN Benzenemethanesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-19-1 CAPLUS


CN Butanamide, 4-bromo-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-20-4 CAPLUS

CN Carbamic acid, [2-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 870459-21-5 CAPLUS

CN Carbamic acid, [3-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 870459-24-8 CAPLUS

CN Propanamide, 3-amino-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-30-6 CAPLUS

CN Urea, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




IT 693229-35-5P 870458-87-0P 870458-88-1P
 870458-89-2P 870458-90-5P 870458-91-6P
 870458-92-7P 870458-93-8P 870458-94-9P
 870458-95-0P 870458-96-1P 870458-97-2P
 870458-98-3P 870458-99-4P 870459-00-0P
 870459-01-1P 870459-02-2P 870459-03-3P
 870459-04-4P 870459-05-5P 870459-06-6P
 870459-07-7P 870459-08-8P 870459-10-2P
 870459-11-3P 870459-12-4P 870459-13-5P
 870459-14-6P 870459-15-7P 870459-16-8P
 870459-22-6P 870459-23-7P 870459-25-9P
 870459-26-0P 870459-27-1P 870459-28-2P
 870459-29-3P 870459-31-7P 870459-32-8P
 870459-33-9P 870459-34-0P 870459-35-1P
 870459-36-2P 870459-37-3P 870459-38-4P
 870459-39-5P 870459-40-8P 870459-41-9P
 870459-42-0P 870459-43-1P 870459-44-2P
 870459-45-3P 870459-46-4P 870459-47-5P
 870459-48-6P 870459-49-7P 870459-50-0P
 870459-51-1P 870459-52-2P 870459-53-3P
 870459-54-4P 870459-57-7P 870459-59-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidine derivs. as aurora 2 kinase inhibitors for treatment of cancer)


RN 693229-35-5 CAPLUS

CN Acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870458-87-0 CAPLUS

CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 870458-88-1 CAPLUS

CN Acetamide, N-(acetyloxy)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870458-89-2 CAPLUS

CN Butanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 870458-90-5 CAPLUS

CN Butanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-(1-oxobutoxy)- (9CI) (CA INDEX NAME)




RN 870458-91-6 CAPLUS

CN Benzamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 870458-92-7 CAPLUS

CN Benzamide, N-(benzoyloxy)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870458-93-8 CAPLUS

CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 870458-94-9 CAPLUS

CN Butanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870458-95-0 CAPLUS

CN Propanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 870458-96-1 CAPLUS

CN Benzamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870458-97-2 CAPLUS

CN Benzeneacetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870458-98-3 CAPLUS


CN Benzenepropanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870458-99-4 CAPLUS


CN Cyclopropanecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-00-0 CAPLUS

CN Cyclohexanecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-01-1 CAPLUS

CN Pentanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-02-2 CAPLUS

CN Octanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-03-3 CAPLUS

CN 2-Thiophenecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-04-4 CAPLUS

CN 2-Thiopheneacetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-05-5 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-06-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-07-7 CAPLUS

CN 2-Thiophenecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 870459-08-8 CAPLUS

CN 5-Thiazolecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 870459-10-2 CAPLUS

CN Acetamide, 2-chloro-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-11-3 CAPLUS

CN Methanesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-12-4 CAPLUS

CN 1-Butanesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-13-5 CAPLUS

CN Benzenesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-14-6 CAPLUS

CN 4-Morpholineacetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-15-7 CAPLUS


CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2-[(2-hydroxyethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 870459-16-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 870459-22-6 CAPLUS

CN Carbamic acid, [4-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 870459-23-7 CAPLUS


CN Acetamide, 2-amino-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 870459-25-9 CAPLUS

CN Butanamide, 4-amino-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-26-0 CAPLUS

CN Acetamide, 2-(acetamido)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-27-1 CAPLUS

CN Propanamide, 3-(acetylamino)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-28-2 CAPLUS

CN Butanamide, 4-(acetylamino)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-29-3 CAPLUS

CN Ethanesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 870459-31-7 CAPLUS

CN Glycine, N-[[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 870459-32-8 CAPLUS

CN Glycine, N-[[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 870459-33-9 CAPLUS

CN Propanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-3,3,3-trifluoro- (9CI) (CA INDEX NAME)



RN 870459-34-0 CAPLUS


CN Butanamide, 4-(dimethylamino)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 870459-35-1 CAPLUS

CN Thiourea, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 870459-36-2 CAPLUS

CN Thiourea, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 870459-37-3 CAPLUS

CN 3-Pyridinepropanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-38-4 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-39-5 CAPLUS

CN 4-Morpholinepropanesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-40-8 CAPLUS

CN Benzenesulfonamide, 4-(bromomethyl)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-41-9 CAPLUS

CN Carbamic acid, [3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 870459-42-0 CAPLUS

CN Carbamic acid, [3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 870459-43-1 CAPLUS


CN Acetamide, N-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-44-2 CAPLUS


CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

methylphenyl]- (9CI) (CA INDEX NAME)




RN 870459-45-3 CAPLUS

CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 870459-46-4 CAPLUS

CN Acetamide, N-[5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 870459-47-5 CAPLUS

CN Acetamide, N-[3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-48-6 CAPLUS

CN Acetamide, N-[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-49-7 CAPLUS

CN Methanesulfonamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-50-0 CAPLUS


CN Ethanesulfonamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 870459-51-1 CAPLUS


CN Benzenemethanesulfonamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-52-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-53-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-54-4 CAPLUS


CN 4-Morpholineacetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 870459-57-7 CAPLUS


CN Acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2-[(2-hydroxyethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 870459-59-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




IT 364333-82-4P 364334-16-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aminopyrimidine derivs. as aurora 2 kinase inhibitors for treatment of cancer)


RN 364333-82-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 364334-16-7 CAPLUS

CN 1,3-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1155926 CAPLUS

DN 144:165710

TI Evaluation of phenylaminopyrimidines as antifungal protein kinase inhibitors

AU Pillonel, Christian

CS Syngenta Crop Protection AG, Basel, CH-4002, Switz.

SO Pest Management Science (2005), 61(11), 1069-1076

CODEN: PMSFCF; ISSN: 1526-498X

PB John Wiley & Sons Ltd.

DT Journal

LA English

AB The effects of diverse phenylaminopyrimidines (PAP), namely PAP-pyridines (type A), PAP-pyrazoles (type B) and PAP-thiazoles (type C), on *Neurospora crassa* has been investigated. Type A strongly inhibit the in vitro growth of *N. crassa*, whereas types B and C are much less active. A significant correlation was observed between the *Neurospora* growth inhibition and the intrinsic activity of type A compds. on the cyclin-dependent protein kinase p34CDC2 of starfish, suggesting that the target of phenylaminopyrimidines in fungi is a cyclin-dependent protein kinase (CDK). The phenylaminopyrimidine-binding CDKs Phoss (major band) and CDC2 (minor band) involved in phosphorus uptake, glycogen synthesis and the cell cycle were identified from *N. crassa* by affinity chromatog. on phenylaminopyrimidine-sepharose. Comparative expts. with different protein kinases revealed the importance of the side chain of phenylaminopyrimidines for their target selectivity. A type B compound was found to selectively inhibit the MAP-kinase OS-2 involved in the osmoregulatory pathway of *Neurospora*.

IT 509086-68-4 509086-73-1 509086-76-4

509086-77-5 509086-80-0 509086-84-4

509087-07-4 509087-28-9 874810-54-5


874810-55-6

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(phenylaminopyrimidines as antifungal protein kinase inhibitors)


RN 509086-68-4 CAPLUS

CN Benzenemethanol, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 509086-73-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 509086-76-4 CAPLUS

CN Benzenemethanol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- α -methyl- (9CI) (CA INDEX NAME)




RN 509086-77-5 CAPLUS

CN Phenol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509086-80-0 CAPLUS

CN Ethanone, 1-[3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)




RN 509086-84-4 CAPLUS

CN Benzoic acid, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 509087-07-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 509087-28-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(3-methylphenyl)-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 874810-54-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[4-(4-fluorophenyl)-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 874810-55-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:823700 CAPLUS
 DN 143:229876
 TI Preparation of thiazolyl-substituted pyrimidineamines as protein kinase inhibitors
 IN Duncan, Kenneth; Gibson, Darren; Wang, Shudong; Zheleva, Daniella; Fischer, Peter
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005075468	A2	20050818	WO 2005-GB405	20050207
	WO 2005075468	A3	20051013		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI GB 2004-2653 A 20040206

OS MARPAT 143:229876

AB Title compds. I [Z1 = N, CH; Z2-3 = N, CR7; R1-7 = H, hydrocarbyl, halo, etc.; Z1 = CH or Z2 = N or Z1 = CH and Z2 = N with some exceptions] are prepared For instance, (6-chloropyridin-3-yl)(4-(thiazol-2-yl)pyrimidin-2-yl)amine (II) is prepared from 3-dimethylamino-1-(thiazol-2-yl)propenone and 6-chloropyridin-3-ylamine and aqueous cyanamide solution II has $K_i = 0.016$ for protein kinase GSK3. I are useful for the treatment of one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.


IT 862592-85-6P, (6-Chloropyridin-3-yl)(4-(thiazol-2-yl)pyrimidin-2-yl)amine 862592-86-7P, N-[4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl]benzene-1,3-diamine 862592-87-8P, 3-[4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl]amino]phenol 862592-88-9P, [4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl](3-trifluoromethylphenyl)amine 862592-89-0P, [4-Chloro-3-(trifluoromethyl)phenyl][4-(4,5-dimethylthiazol-2-yl)pyrimidin-2-yl]amine 862592-90-3P, [4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl](3-nitrophenyl)amine 862592-91-4P, (6-Methoxypyridin-3-yl)[4-(thiazol-2-yl)pyrimidin-2-yl]amine 862592-92-5P, [4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl](6-methoxypyridin-3-yl)amine 862592-93-6P, (6-Chloropyridin-3-yl)[4-(4,5-dimethylthiazol-2-yl)pyrimidin-2-yl]amine 862592-94-7P, [4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 862592-95-8P, [4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl](4-methyl-3-nitrophenyl)amine 862592-96-9P, 4-[4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl]amino]phenol 862592-97-0P, [6-(Pyrrolidin-1-yl)pyridin-3-yl][4-(thiazol-2-yl)pyrimidin-2-yl]amine 862592-98-1P, (6-Chloro-5-methylpyridin-3-yl)[4-(thiazol-2-yl)pyrimidin-2-yl]amine 862593-02-0P, 1-[2-[2-(4-Chlorophenylamino)pyrimidin-4-yl]-4-

methylthiazol-5-yl]ethanone 862593-04-2P, (4-Chlorophenyl)[4-(4-methylthiazol-2-yl)pyrimidin-2-yl]amine 862593-05-3P, 2-[2-(4-Chlorophenylamino)pyrimidin-4-yl]-4-hydroxythiazole-5-carboxylic acid ethyl ester 862593-06-4P, 1-[2-[2-(6-Chloropyridin-3-ylamino)pyrimidin-4-yl]-4-methylthiazol-5-yl]ethanone 862593-08-6P, 2-[2-(6-Chloropyridin-3-ylamino)pyrimidin-4-yl]-4-hydroxythiazole-5-carboxylic acid ethyl ester 862593-10-0P, 2-[2-(6-Chloropyridin-3-ylamino)pyrimidin-4-yl]-5-methylthiazol-4-ol 862593-11-1P, 2-[2-(6-Chloropyridin-3-ylamino)pyrimidin-4-yl]-5-(2-hydroxyethyl)thiazol-4-ol 862593-18-8P, (4-Chlorophenyl)[4-(4-phenylthiazol-2-yl)pyrimidin-2-yl]amine 862593-20-2P, 2-[2-(4-Chlorophenylamino)pyrimidin-4-yl]-4-methylthiazole-5-carboxylic acid ethyl ester 862593-22-4P, [2-[2-(4-Chlorophenylamino)pyrimidin-4-yl]thiazol-4-yl]acetic acid methyl ester
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazolyl-substituted pyrimidineamines as protein kinase inhibitors)


RN 862592-85-6 CAPLUS

CN 2-Pyrimidinamine, N-(6-chloro-3-pyridinyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 862592-86-7 CAPLUS

CN 1,3-Benzenediamine, N-[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 862592-87-8 CAPLUS

CN Phenol, 3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 862592-88-9 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 862592-89-0 CAPLUS

CN 2-Pyrimidinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4,5-dimethyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 862592-90-3 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 862592-91-4 CAPLUS

CN 2-Pyrimidinamine, N-(6-methoxy-3-pyridinyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 862592-92-5 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 862592-93-6 CAPLUS

CN 2-Pyrimidinamine, N-(6-chloro-3-pyridinyl)-4-(4,5-dimethyl-2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 862592-94-7 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 862592-95-8 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-(4-methyl-3-nitrophenyl)-
(9CI) (CA INDEX NAME)




RN 862592-96-9 CAPLUS

CN Phenol, 4-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA
INDEX NAME)




RN 862592-97-0 CAPLUS

CN 2-Pyrimidinamine, N-[6-(1-pyrrolidinyl)-3-pyridinyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 862592-98-1 CAPLUS

CN 2-Pyrimidinamine, N-(6-chloro-5-methyl-3-pyridinyl)-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 862593-02-0 CAPLUS

CN Ethanone, 1-[2-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-5-
thiazolyl]- (9CI) (CA INDEX NAME)




RN 862593-04-2 CAPLUS


CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(4-methyl-2-thiazolyl)- (9CI) (CA
INDEX NAME)




RN 862593-05-3 CAPLUS
 CN 5-Thiazolecarboxylic acid, 2-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 862593-06-4 CAPLUS
 CN Ethanone, 1-[2-[2-[(6-chloro-3-pyridinyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 862593-08-6 CAPLUS
 CN 5-Thiazolecarboxylic acid, 2-[2-[(6-chloro-3-pyridinyl)amino]-4-pyrimidinyl]-4-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 862593-10-0 CAPLUS
 CN 4-Thiazolol, 2-[2-[(6-chloro-3-pyridinyl)amino]-4-pyrimidinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 862593-11-1 CAPLUS
 CN 5-Thiazoleethanol, 2-[2-[(6-chloro-3-pyridinyl)amino]-4-pyrimidinyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 862593-18-8 CAPLUS
 CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(4-phenyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 862593-20-2 CAPLUS
 CN 5-Thiazolecarboxylic acid, 2-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 862593-22-4 CAPLUS
 CN 4-Thiazoleacetic acid, 2-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)


10/809,944




L8 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:821022 CAPLUS
 DN 143:367267
 TI Expedient parallel synthesis of 2-amino-4-heteroarylpyrimidines
 AU Bursavich, Matthew G.; Lombardi, Sabrina; Gilbert, Adam M.
 CS Exploratory Medicinal Chemistry, Chemical and Screening Sciences, Wyeth
 Research, Pearl River, NY, 10965, USA
 SO Organic Letters (2005), 7(19), 4113-4116
 CODEN: ORLEF7; ISSN: 1523-7060
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 143:367267
 AB An expedient synthesis of diverse 2-amino-4-heteroarylpyrimidines via a
 2-chloropyrimidine intermediate is described. A series of potentially
 biol. active analogs were synthesized in two parallel steps to afford
 focused arrays.
 IT 477769-42-9P 477769-45-2P 477769-51-0P
 477769-60-1P 477769-75-8P 866112-02-9P
 866112-03-0P 866112-04-1P 866112-05-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 2-anilino- and 2-amino acid-4-heteroarylpyrimidines via
 nucleophilic substitution)
 RN 477769-42-9 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI)
 (CA INDEX NAME)




RN 477769-45-2 CAPLUS
 CN 2-Pyrimidinamine, N-(4-nitrophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX
 NAME)




RN 477769-51-0 CAPLUS
 CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX
 NAME)




RN 477769-60-1 CAPLUS
 CN Benzenesulfonamide, 4-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477769-75-8 CAPLUS
 CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 866112-02-9 CAPLUS
 CN 2-Pyrimidinamine, N-phenyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 866112-03-0 CAPLUS
 CN 2-Pyrimidinamine, N-(2-methylphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 866112-04-1 CAPLUS
 CN Acetamide, N-[[4-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 866112-05-2 CAPLUS
 CN 2-Pyrimidinamine, N-[4-(4-morpholinyl)phenyl]-4-(2-thiazolyl)- (9CI) (CA
 INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:493687 CAPLUS
 DN 143:40009
 TI Homology model of CDK4 kinase for use in screening and design of drugs for
 treating proliferative disorders
 IN Mcinnes, Campbell; Thomas, Mark; Wang, Shudong; McLachlan, Janice; Meades,
 Christopher; Kontopidis, George; Wood, Gavin; Fischer, Peter
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 152 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005052147	A2	20050609	WO 2004-GB4793	20041111
	WO 2005052147	A3	20051124		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI GB 2003-27380 A 20031125

AB The present invention relates to a homol. model for CDK4 kinase, and the
 use thereof in assays for the identification of small mol. CDK4 kinase
 modulators. The atomic structure coordinates of the CDK4 kinase homol. model
 are provided. The invention further relates to CDK4 kinase modulators
 identified by said assays, and their use in the treatment of CDK4
 kinase-related disorders such as proliferative disorders, e.g., cancer.
 Preparation of CDK4 kinase-modulating aminopyrimidine compds. is reported.


IT 693228-65-8P 693229-61-7P 693230-49-8P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)

(preparation of CDK4 kinase modulators; homol. model of CDK4 kinase for use
 in screening and design of drugs for treating proliferative disorders)

RN 693228-65-8 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-
 (9CI) (CA INDEX NAME)



RN 693229-61-7 CAPLUS


CN Acetamide, N-[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-

pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 693230-49-8 CAPLUS

CN 1,4-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)



IT 693228-73-8P 693228-77-2P 693228-83-0P


693229-59-3P 693229-65-1P 693229-69-5P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of CDK4 kinase modulators; homol. model of CDK4 kinase for use in screening and design of drugs for treating proliferative disorders)


RN 693228-73-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-77-2 CAPLUS

CN 1-Piperazineethanol, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693228-83-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-59-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 693229-65-1 CAPLUS


CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 693229-69-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[4-methyl-2-(methylamino)-5-

thiazolyl]- (9CI) (CA INDEX NAME)




IT 693228-71-6 693229-57-1

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of CDK4 kinase modulators; homol. model of CDK4 kinase for use
 in screening and design of drugs for treating proliferative disorders)


RN 693228-71-6 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-
 pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 693229-57-1 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-
 pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:451562 CAPLUS
 DN 143:3240
 TI Use of crystal structure of Plk1 kinase in screening for inhibitors for treatment of cancer, glomerulonephritis, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disorder
 IN McInnes, Campbell; McLachlan, Janice; Mezna, Mokdad; Fischer, Peter
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 184 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005047526	A2	20050526	WO 2004-GB4762	20041112
	WO 2005047526	A3	20051208		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI GB 2003-26396 A 20031112

AB The preset invention provides use of crystal structure of protein Plk1 kinase in screening for inhibitors for treatment of cancer, glomerulonephritis, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disorder. Plk1 kinase inhibitors include 5'-thioadenosine, staurosporine, wortmannin, purvalanol A, LY294002, quercetin, morin hydrate and their derivs. and 4-[4-(4-methyl-2-methylaminothiazol-5-yl)-pyrimidin-2-ylamino]-phenol, 4-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol, and 4-[4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol.


IT 364334-10-1 364334-30-5 364334-83-8

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(as protein Plk1 kinase inhibitor; crystal structure of Plk1 kinase and its use in screening for inhibitors in treating cancer, glomerulonephritis, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disorder)

RN 364334-10-1 CAPLUS


CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 364334-30-5 CAPLUS
 CN Phenol, 4-[[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-
 (9CI) (CA INDEX NAME)



RN 364334-83-8 CAPLUS
 CN Phenol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
 (CA INDEX NAME)



L8 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:409513 CAPLUS
 DN 142:463748
 TI Preparation of pyrimidinylthiazolone compounds as protein kinase inhibitors
 IN Wang, Shudong; Wood, Gavin; Duncan, Kenneth W.; Meades, Christopher; Gibson, Darren; McLachlan, Janice C.; Perry, Alex; Blake, David; Zheleva, Daniella I.; Fischer, Peter M.
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042525	A1	20050512	WO 2004-GB4465	20041021
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IE, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004285745	A1	20050512	AU 2004-285745	20041021
	CA 2542880	AA	20050512	CA 2004-2542880	20041021
	EP 1678171	A1	20060712	EP 2004-768981	20041021
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	GB 2003-24599	A	20031021		
	GB 2003-30013	A	20031224		
	WO 2004-GB4465	W	20041021		

OS MARPAT 142:463748

AB Title compds. I [wherein R1, R5 = H or (un)substituted hydrocarbyl; R2 - R4 = H, (un)substituted alkyl or alkenyl; etc., or pharmaceutically acceptable salts thereof] were prepared as inhibitors of one or more protein kinases. For example, cyclization of NH₂COSK with 3-chloropentane-2,4-dione in acetone to a thiazolone (100% yield) II (R = H) followed by N-alkylation with iodoethane in the presence of KOH afforded II (R = Et) (64% yield). This ketone underwent condensation with DMF di-Me acetal (30% yield) and subsequent cyclization with N-(6-methoxypyridin-3-yl)guanidine nitrate to give III. Biol. data showed that the invented compds. were inhibitors of CDK and GSK enzymes and so on. Therefore, I and their pharmaceutical compns. are useful for treating diseases, such as proliferative disorders and diabetes.


IT 851439-16-2P, 4-Methyl-5-[2-(3-nitrophenylamino)pyrimidin-4-yl]-3H-thiazol-2-one 851439-17-3P, 4-Methyl-5-[2-(4-methyl-3-nitrophenylamino)pyrimidin-4-yl]-3H-thiazol-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(kinase inhibitor; preparation of pyrimidinylthiazolone compds. as protein kinase inhibitors)

RN 851439-16-2 CAPLUS

CN 2(3H)-Thiazolone, 4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)



RN 851439-17-3 CAPLUS
CN 2(3H)-Thiazolone, 4-methyl-5-[2-[(4-methyl-3-nitrophenyl)amino]-4-
pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:120927 CAPLUS
 DN 142:219301
 TI Preparation of pyridinylaminopyrimidine derivatives as protein kinase inhibitors
 IN Wang, Shudong; Meades, Christopher; Gibson, Darren; Fischer, Peter
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012298	A1	20050210	WO 2004-GB3282	20040730
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004261482	A1	20050210	AU 2004-261482	20040730
	CA 2533870	AA	20050210	CA 2004-2533870	20040730
	EP 1648887	A1	20060426	EP 2004-743608	20040730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	GB 2003-17842	A	20030730		
	GB 2003-18347	A	20030805		
	WO 2004-GB3282	W	20040730		
OS	MARPAT 142:219301				
AB	Title compds. I [R1 = O; R2, R5-6 = R7; R10 = H, alkyl; X = S, O, (un)substituted amino; Y = N, (un)substituted alkyl; one of Z1-3 = amino, ammonium or (un)substituted alkyl; R7 = H, halo, amino, alkoxy, etc.] are prepared For instance, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][pyridin-3-yl]amine (II) is prepared from 3-dimethylamino-1-(2,4-dimethylthiazol-5-yl)propanone and N-(pyridin-3-yl)guanidine (2-methoxyethanol, reflux, 18 h) in 24% yield. II has Ki = 0.11 µM for CDK2/cyclin E. I are useful in the treatment of proliferative, viral, and CNS disorders as well as for the treatment of strokes, alopecia and/or diabetes.				
IT	837420-17-4P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][pyridin-3-yl]amine 837420-18-5P, 3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-1-methylpyridinium iodide 837420-20-9P, (6-Chloropyridin-3-yl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 837420-21-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](6-methoxypyridin-3-yl)amine 837420-22-1P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](6-methoxypyridin-3-yl)amine 837420-23-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](6-chloropyridin-3-yl)amine 837420-24-3P, (6-Methoxypyridin-3-yl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 837420-25-4P, (6-Chloropyridin-3-yl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 837420-26-5P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](6-methoxypyridin-3-yl)amine 837420-28-7P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](6-methoxypyridin-3-				


yl)amine 837420-29-8P, [4-[2-((2-Methoxyethyl)amino)-4-methylthiazol-5-yl]pyrimidin-2-yl](6-methoxypyridin-3-yl)amine 837420-30-1P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](6-(pyrrolidin-1-yl)pyridin-3-yl)amine 837420-31-2P, [4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-yl][6-(4-methylpiperazin-1-yl)pyridin-3-yl]amine 837420-32-3P, (6-Methoxypyridin-3-yl)[4-(4-methyl-2-(morpholin-4-yl)thiazol-5-yl)pyrimidin-2-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridinylaminopyrimidine derivs. as protein kinase inhibitors)


RN 837420-17-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 837420-18-5 CAPLUS


CN Pyridinium, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I⁻


RN 837420-20-9 CAPLUS

CN 2-Pyrimidinamine, N-(6-chloro-3-pyridinyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 837420-21-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-22-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-23-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(6-chloro-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-24-3 CAPLUS

CN 2-Pyrimidinamine, N-(6-methoxy-3-pyridinyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 837420-25-4 CAPLUS

CN 2-Pyrimidinamine, N-(6-chloro-3-pyridinyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 837420-26-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-28-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-29-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(2-methoxyethyl)amino]-4-methyl-5-thiazolyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-30-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[6-(1-pyrrolidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 837420-31-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 837420-32-3 CAPLUS

CN 2-Pyrimidinamine, N-(6-methoxy-3-pyridinyl)-4-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:1124644 CAPLUS
 DN 142:74589
 TI 2-Aminopyrimidine derivatives as Raf kinase inhibitors, process for their preparation, and their use, e.g., in the treatment of proliferative diseases such as cancer
 IN Batt, David Bryant; Ramsey, Timothy Michael; Sabio, Michael Lloyd
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110452	A1	20041223	WO 2004-EP6317	20040611
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004246800	A1	20041223	AU 2004-246800	20040611
CA 2529090	AA	20041223	CA 2004-2529090	20040611
EP 1635835	A1	20060322	EP 2004-739809	20040611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1805748	A	20060719	CN 2004-80016328	20040611
PRAI US 2003-478709P	P	20030613		
WO 2004-EP6317	W	20040611		
OS MARPAT 142:74589				

AB The application discloses compds. that inhibit Raf kinase, having formula I [wherein R1 is an (un)substituted Ph or heteroaryl radical; and R2 is an (un)substituted Ph radical; or an N-oxide or pharmaceutically acceptable salt thereof]. Also disclosed are methods of treating diseases characterized by excessive signaling through the MAP kinase pathway by administering a RAF kinase-inhibiting amount of a compound I. In particular, I are useful for the treatment of proliferative diseases such as cancer. Over 30 compds. I were prepared For instance, amidation of 4-methyl-N3-[4-(pyrazin-2-yl)pyrimidin-2-yl]benzene-1,3-diamine with 3-CF3C6H4CO2H using BOP reagent and DIEA in DMF gave invention compound II. The prepared compds. I inhibited human Raf proteins as follows (IC50): wild-type C-Raf 0.01-0.7 µM; wild-type B-Raf 0.04-1.5 µM; and mutant B-Raf (V599E) 0.006-1.6 µM.

IT 812699-79-9P, N-[4-Methyl-3-[[4-(thiazol-2-yl)pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of aminopyrimidine derivs. as Raf kinase inhibitors for treatment of proliferative diseases such as cancer)

RN 812699-79-9 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-3-

(trifluoromethyl)- (9CI) (CA INDEX NAME)

*Reaction*


IT 812700-18-8, 4-Methyl-N3-[4-(thiazol-2-yl)pyrimidin-2-yl]benzene-1,3-diamine

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of aminopyrimidine derivs. as Raf kinase inhibitors for treatment of proliferative diseases such as cancer)

RN 812700-18-8 CAPLUS

CN 1,3-Benzenediamine, 4-methyl-N3-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:857595 CAPLUS
 DN 141:350190
 TI Preparation of thiazoles as inhibitors of protein kinases
 IN Brenchley, Guy; Farmer, Luc J.; Harrington, Edmund Martin; Knegtel, Ronald; O'Donnell, Michael; Salituro, Francesco G.; Studley, John R.; Wang, Jian
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 139 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

*Common Div
 Copending*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087699	A2	20041014	WO 2004-US9166	20040325
	WO 2004087699	A3	20041209		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004225977	A1	20041014	AU 2004-225977	20040325
	CA 2523126	AA	20041014	CA 2004-2523126	20040325
	US 2005004150	A1	20050106	US 2004-809946	20040325
	EP 1605946	A2	20051221	EP 2004-758338	20040325
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-457468P	P	20030325		
	WO 2004-US9166	W	20040325		

*Same
 eff. filing*

OS MARPAT 141:350190


AB The title compds. [I; R1, R2 = R, halo, CN, NO2, etc.; R = H, (un)substituted alkyl; Ar1 = (un)substituted aryl, heteroaryl, etc.; R3, R4 = ZR7; or R3 and R4 are taken together to form (un)substituted (un)saturated 3-8 membered ring having 0-3 heteroatoms; Z = a bond, alkylidene, etc.; R7 = halo, CN, NO2, etc.], useful of inhibitors of protein kinases, were prepared E.g., a multi-step synthesis of II, starting from benzothiazole, was given. The compds. I were tested against SYK and ZAP-70 kinases (data given for representative compds. I). The invention also provides pharmaceutically acceptable compns. comprising said compds. I and methods of using the compns. in the treatment of various disease, conditions, or disorders.

IT 774229-46-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of thiazoles as inhibitors of protein kinases)

RN 774229-46-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-chloro-2-thiazolyl)-N-(3,4,5-trimethoxyphenyl)-(9CI) (CA INDEX NAME)



IT	774228-01-2P	774228-02-3P	774228-03-4P
	774228-04-5P	774228-05-6P	774228-06-7P
	774228-07-8P	774228-08-9P	774228-09-0P
	774228-10-3P	774228-11-4P	774228-12-5P
	774228-13-6P	774228-14-7P	774228-15-8P
	774228-16-9P	774228-17-0P	774228-18-1P
	774228-19-2P	774228-20-5P	774228-21-6P
	774228-22-7P	774228-23-8P	774228-24-9P
	774228-25-0P	774228-26-1P	774228-27-2P
	774228-28-3P	774228-29-4P	774228-30-7P
	774228-31-8P	774228-32-9P	774228-33-0P
	774228-34-1P	774228-35-2P	774228-36-3P
	774228-37-4P	774228-38-5P	774228-39-6P
	774228-40-9P	774228-41-0P	774228-42-1P
	774228-43-2P	774228-44-3P	774228-45-4P
	774228-46-5P	774228-47-6P	774228-48-7P
	774228-49-8P	774228-50-1P	774228-51-2P
	774228-52-3P	774228-53-4P	774228-54-5P
	774228-55-6P	774228-56-7P	774228-57-8P
	774228-58-9P	774228-59-0P	774228-60-3P
	774228-61-4P	774228-62-5P	774228-63-6P
	774228-64-7P	774228-65-8P	774228-66-9P
	774228-67-0P	774228-68-1P	774228-69-2P
	774228-70-5P	774228-71-6P	774228-72-7P
	774228-73-8P	774228-74-9P	774228-75-0P
	774228-76-1P	774228-77-2P	774228-78-3P
	774228-79-4P	774228-80-7P	774228-82-9P
	774228-83-0P	774228-84-1P	774228-85-2P
	774228-86-3P	774228-87-4P	774228-88-5P
	774228-89-6P	774228-90-9P	774228-91-0P
	774228-92-1P	774228-93-2P	774228-94-3P
	774228-95-4P	774228-96-5P	774228-97-6P
	774228-98-7P	774228-99-8P	774229-00-4P
	774229-01-5P	774229-02-6P	774229-03-7P
	774229-04-8P	774229-05-9P	774229-06-0P
	774229-07-1P	774229-08-2P	774229-09-3P
	774229-10-6P	774229-11-7P	774229-13-9P
	774229-14-0P	774229-15-1P	774229-16-2P
	774229-17-3P	774229-18-4P	774229-19-5P
	774229-21-9P	774229-23-1P	774229-25-3P
	774229-26-4P	774229-28-6P	774229-29-7P
	774229-30-0P	774229-31-1P	774229-33-3P
	774229-34-4P	774229-35-5P	774229-36-6P
	774229-37-7P	774229-38-8P	774229-39-9P
	774229-40-2P	774229-41-3P	774229-42-4P
	774229-43-5P	774229-44-6P	774229-45-7P
	774229-47-9P	774229-48-0P	774229-49-1P
	774229-50-4P	774229-51-5P	774229-52-6P


774229-53-7P 774229-54-8P 774229-55-9P
 774229-56-0P 774229-57-1P 774229-58-2P
 774229-59-3P 774229-60-6P 774229-61-7P
 774229-62-8P 774229-63-9P 774229-64-0P
 774229-65-1P 774229-66-2P 774229-67-3P
 774229-68-4P 774229-69-5P 774229-70-8P
 774229-71-9P 774229-72-0P 774229-73-1P
 774229-74-2P 774229-75-3P 774229-76-4P
 774229-77-5P 774229-78-6P 774229-79-7P
 774229-80-0P 774229-81-1P 774229-82-2P
 774229-83-3P 774229-84-4P 774229-85-5P
 774229-86-6P 774229-87-7P 774229-88-8P
 774229-89-9P 774229-90-2P 774229-91-3P
 774229-92-4P 774229-93-5P 774229-94-6P
 774229-95-7P 774229-96-8P 774229-97-9P
 774229-98-0P 774229-99-1P 774230-00-1P
 774230-01-2P 774230-02-3P 774230-03-4P
 774230-04-5P 774230-05-6P 774230-06-7P
 774230-07-8P 774230-08-9P 774230-09-0P
 774230-10-3P 774230-11-4P 774230-12-5P
 774230-13-6P 774230-14-7P 774230-15-8P
 774230-16-9P 774230-17-0P 774230-18-1P
 774230-19-2P 774230-20-5P 774230-21-6P
 774230-22-7P 774230-23-8P 774230-24-9P
 774230-25-0P 774230-26-1P 774230-27-2P
 774230-28-3P 774230-29-4P 774230-30-7P
 774230-31-8P 774230-32-9P 774230-33-0P
 774230-34-1P 774230-35-2P 774230-36-3P
 774230-37-4P 774230-38-5P 774230-39-6P
 774230-40-9P 774230-41-0P 774230-42-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of thiazoles as inhibitors of protein kinases)


RN 774228-01-2 CAPLUS

CN 1H-Benzimidazol-5-amine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]-2-
 (trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774228-02-3 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI)
 (CA INDEX NAME)




RN 774228-03-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-04-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-05-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluoro-4-methoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-06-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3-aminophenyl)sulfonyl]phenyl]-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-07-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[4-[(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 774228-08-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromo-4-methylphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-09-0 CAPLUS

CN 1H-Indazol-6-amine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-10-3 CAPLUS

CN Phenol, 2-[(diethylamino)methyl]-4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-11-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-(5-methyl-2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 774228-12-5 CAPLUS

CN 1,4-Benzenediamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]-N'-phenyl-
(9CI) (CA INDEX NAME)




RN 774228-13-6 CAPLUS

CN 2-Pyrimidinamine, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-14-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-ethoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-15-8 CAPLUS

CN Benzamide, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-16-9 CAPLUS

CN 2-Pyrimidinamine, N-(6-methoxy[1,1'-biphenyl]-3-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-17-0 CAPLUS

CN Phenol, 2-methoxy-5-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-18-1 CAPLUS

CN 1H-Indol-5-amine, 2-methyl-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-19-2 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxy[1,1'-biphenyl]-4-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-20-5 CAPLUS

CN 1H-Indol-5-amine, 2,3-dihydro-1-(methanesulfonyl)-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-21-6 CAPLUS

CN 8-Quinolinamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-22-7 CAPLUS

CN 2H-1-Benzopyran-2-one, 4-(methoxymethyl)-7-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-23-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 774228-24-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 774228-25-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-26-1 CAPLUS

CN 9H-Carbazol-3-amine, 9-ethyl-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-27-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-28-3 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-29-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-chloro-3-methylphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-30-7 CAPLUS

CN Ethanone, 1-[3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774228-31-8 CAPLUS

CN 1H-Indol-5-amine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-32-9 CAPLUS

CN 1,3-Benzenediamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-33-0 CAPLUS

CN Phosphonic acid, [[4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 774228-34-1 CAPLUS

CN 2H-1-Benzopyran-2-one, 4-methyl-7-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-35-2 CAPLUS

CN Acetamide, N-[2-methyl-4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774228-36-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-37-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774228-38-5 CAPLUS

CN Benzeneacetonitrile, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-39-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-benzothiazolyl)-N-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774228-40-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-benzothiazolyl)-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774228-41-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-42-1 CAPLUS

CN 2-Pyrimidinamine, 4-(4-bromo-2-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-43-2 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 774228-44-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[(dimethylamino)methyl]-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-45-4 CAPLUS

CN 1,3-Propanediamine, N'-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 774228-46-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(1-piperidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-47-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(4-ethyl-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-48-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(4-morpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-49-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 774228-50-1 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1H-inden-5-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-51-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dichlorophenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-52-3 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-53-4 CAPLUS

CN 1,3-Propanediamine, N'-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 774228-54-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-(1-piperidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-55-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-[(4-ethyl-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-56-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-(4-morpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-57-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-[(dimethylamino)methyl]-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-58-9 CAPLUS

CN 3-Pyrrolidinol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 774228-59-0 CAPLUS


CN 4-Piperidinol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 774228-60-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774228-61-4 CAPLUS

CN 1-Piperazineethanol, 4-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 774228-62-5 CAPLUS

CN 4-Thiazolecarbonitrile, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-63-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-benzothiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-64-7 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(bromomethyl)-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-65-8 CAPLUS

CN 4-Thiazoleacetonitrile, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-66-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-(methoxymethyl)-2-thiazolyl]-
(9CI) (CA INDEX NAME)




RN 774228-67-0 CAPLUS

CN Glycine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 774228-68-1 CAPLUS

CN Glycine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 774228-69-2 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 774228-70-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(4,5-dimethyl-2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 774228-71-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-bromo-2-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI)
(CA INDEX NAME)




RN 774228-72-7 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-,
acetate (ester) (9CI) (CA INDEX NAME)




RN 774228-73-8 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[[3-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 774228-74-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(1-piperidinyl)-2-thiazolyl]-
(9CI) (CA INDEX NAME)




RN 774228-75-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-ethyl-2-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 774228-76-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(aminomethyl)-2-thiazolyl]-N-(3,5-dimethylphenyl)-
(9CI) (CA INDEX NAME)




RN 774228-77-2 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-,
carbamate (ester) (9CI) (CA INDEX NAME)




RN 774228-78-3 CAPLUS

CN Acetamide, N-[3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 774228-79-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(4-nitrophenyl)- (9CI) (CA
INDEX NAME)




RN 774228-80-7 CAPLUS

CN Benzonitrile, 4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 774228-82-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-(5-methyl-2-
thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-83-0 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-84-1 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774228-85-2 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-propyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 774228-86-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774228-87-4 CAPLUS

CN Ethanol, 2-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]methylamino]- (9CI) (CA INDEX NAME)




RN 774228-88-5 CAPLUS

CN 1-Propanol, 3-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-89-6 CAPLUS

CN 1,3-Benzenediamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774228-90-9 CAPLUS

CN Benzonitrile, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 774228-91-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 774228-92-1 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-93-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(1-piperazinyl)-2-thiazolyl]-
(9CI) (CA INDEX NAME)




RN 774228-94-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(dimethylamino)-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-95-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 774228-96-5 CAPLUS


CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 774228-97-6 CAPLUS


CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-(5-methyl-2-thiazolyl)- (9CI)

(CA INDEX NAME)




RN 774228-98-7 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774228-99-8 CAPLUS

CN Benzeneacetonitrile, 4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-00-4 CAPLUS

CN 2-Pyrimidinamine, N-(2,6-dimethylphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774229-01-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-ethylphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774229-02-6 CAPLUS

CN Phenol, 2-methyl-4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 774229-03-7 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(2-propylphenyl)- (9CI) (CA
INDEX NAME)




RN 774229-04-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[2-(phenylmethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 774229-05-9 CAPLUS

CN Benzoic acid, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, methyl
ester (9CI) (CA INDEX NAME)




RN 774229-06-0 CAPLUS

CN Benzoic acid, 2-methyl-4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 774229-07-1 CAPLUS

CN Benzoic acid, 2-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, butyl ester (9CI) (CA INDEX NAME)




RN 774229-08-2 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[[3-methyl-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-09-3 CAPLUS


CN Phenol, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774229-10-6 CAPLUS
 CN Carbamic acid, [4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 774229-11-7 CAPLUS
 CN Benzenemethanol, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 774229-13-9 CAPLUS
 CN 5-Benzothiazolamine, 2-methyl-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-14-0 CAPLUS
 CN 5-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 774229-15-1 CAPLUS

CN Ethanone, 1-[4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 774229-16-2 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1H-inden-2-yl)-4-(5-methyl-2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 774229-17-3 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 774229-18-4 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-19-5 CAPLUS

CN 2-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-(5-methyl-2-thiazolyl)-(9CI) (CA INDEX NAME)




RN 774229-21-9 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 774229-23-1 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(3,4,5-trimethoxyphenyl)-(9CI) (CA INDEX NAME)




RN 774229-25-3 CAPLUS

CN 5-Thiazoleethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 774229-26-4 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(3-pyridinylamino)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-28-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(4-pyridinylamino)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-29-7 CAPLUS

CN 1(3H)-Isobenzofuranone, 6-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 774229-30-0 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774229-31-1 CAPLUS

CN 1H-Benzotriazol-5-amine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 774229-33-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[3-(methylthio)phenyl]- (9CI)
(CA INDEX NAME)




RN 774229-34-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[4-(methylthio)phenyl]- (9CI)
(CA INDEX NAME)




RN 774229-35-5 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-5-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)



RN 774229-36-6 CAPLUS


CN 4-Thiazolecarboxylic acid, 2-[2-[[3-bromo-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-5-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)




RN 774229-37-7 CAPLUS

CN Piperazine, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-


thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 774229-38-8 CAPLUS


CN 6-Benzothiazolamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 774229-39-9 CAPLUS

CN 1H-Indazol-5-amine, 3-methyl-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]-
(9CI) (CA INDEX NAME)


RN 774229-40-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-N-
phenyl- (9CI) (CA INDEX NAME)




RN 774229-41-3 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-aminoethyl)-2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774229-42-4 CAPLUS


CN 1H-Benzimidazol-2-amine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 774229-43-5 CAPLUS


CN 1,4-Benzenediamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774229-44-6 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(phenylamino)methyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-45-7 CAPLUS

CN 1,2-Ethanediamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-47-9 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[[3-hydroxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-48-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(1-piperazinyl)-2-thiazolyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774229-49-1 CAPLUS

CN 4-Thiazolmethanol, 2-[2-[[3-hydroxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-50-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-chloro-2-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774229-51-5 CAPLUS

CN 1,3-Benzenediamine, 5-methyl-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-52-6 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[[2-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 774229-53-7 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[[2-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774229-54-8 CAPLUS


CN 2-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 774229-55-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 774229-56-0 CAPLUS

CN Carbamic acid, [3-[[4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 774229-57-1 CAPLUS

CN Acetamide, N-[3-methyl-5-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774229-58-2 CAPLUS

CN Methanesulfonamide, N-[3-methyl-5-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774229-59-3 CAPLUS

CN 1,3-Benzenediamine, 5-(methoxymethyl)-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-60-6 CAPLUS


CN Acetamide, N-[4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

RN 774229-61-7 CAPLUS


CN Benzoic acid, 4-[[[4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 774229-62-8 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-nitro-2-thiazolyl)- (9CI)
(CA INDEX NAME)

RN 774229-63-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-2-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI)
(CA INDEX NAME)


RN 774229-64-0 CAPLUS

CN Ethanol, 2-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-65-1 CAPLUS

CN 1-Propanol, 3-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-66-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[[2-(1-piperidinyl)ethyl]amino]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-67-3 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[[2-(1-piperazinyl)ethyl]amino]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-68-4 CAPLUS

CN 4-Morpholineethanamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-69-5 CAPLUS

CN Ethanol, 2-[[2-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-70-8 CAPLUS

CN 1,2-Ethanediamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 774229-71-9 CAPLUS

CN 1,2-Ethanediamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 774229-72-0 CAPLUS

CN 1,2-Ethanediamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 774229-73-1 CAPLUS

CN 1,2-Ethanediamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]-N'-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 774229-74-2 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(methylthio)-, ethyl ester (9CI) (CA INDEX NAME)




RN 774229-75-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(methylthio)- (9CI) (CA INDEX NAME)




RN 774229-76-4 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 774229-77-5 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-(1-piperidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774229-78-6 CAPLUS


CN 2-Pyrimidinamine, 4-[4-[(cyclohexylamino)methyl]-5-(methylthio)-2-thiazolyl]- (9CI) (CA INDEX NAME)

thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774229-79-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-(4-morpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-80-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-(1-piperazinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-81-1 CAPLUS

CN Ethanol, 2-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(methylthio)-4-thiazolyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-82-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-[[2-(1-piperazinyl)ethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-83-3 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-[[phenylmethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-84-4 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-[[3-pyridinylmethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-85-5 CAPLUS


CN 4-Thiazolecarboxamide, 5-[(cyclohexylmethyl)amino]-2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774229-86-6 CAPLUS
 CN 4-Thiazolecarboxamide, 5-(cyclohexylamino)-2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-87-7 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(1-piperidiny)- (9CI) (CA INDEX NAME)




RN 774229-88-8 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(1-piperidiny)- (9CI) (CA INDEX NAME)

(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 774229-89-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 774229-90-2 CAPLUS

CN 4-Thiazolecarboxamide, 5-(dimethylamino)-2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-91-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 774229-92-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 774229-93-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 774229-94-6 CAPLUS

CN 5-Thiazolecarbonitrile, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-95-7 CAPLUS

CN Methanedianiline, N'-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 774229-96-8 CAPLUS

CN 1,2-Ethanediamine, N'-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 774229-97-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(1-piperazinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-98-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(4-methyl-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-99-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[[[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-00-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[[2-(1H-imidazol-1-yl)ethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-01-2 CAPLUS

CN Ethanol, 2-[[2-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 774230-02-3 CAPLUS


CN Phenol, 3-[[4-[5-(4-morpholinylmethyl)-2-thiazolyl]-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 774230-03-4 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[2-[2-[[3-hydroxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774230-04-5 CAPLUS

CN Phenol, 3-[[4-[5-(1-piperidinylmethyl)-2-thiazolyl]-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774230-05-6 CAPLUS

CN Phenol, 3-[[4-[5-(1-piperazinylmethyl)-2-thiazolyl]-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 774230-06-7 CAPLUS


CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[5-(4-morpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774230-07-8 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774230-08-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[5-(1-piperazinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-09-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[5-(1-piperidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-10-3 CAPLUS

CN Phenol, 3-[[4-[5-[[[(tetrahydro-2-furanyl)methoxy]methyl]-2-thiazolyl]-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774230-11-4 CAPLUS

CN Phenol, 3-[[4-(4-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774230-12-5 CAPLUS

CN Phenol, 3-[[4-[4-methyl-5-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-thiazolyl]-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774230-13-6 CAPLUS

CN 5-Thiazoleethanol, 2-[2-[[3-hydroxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 774230-14-7 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-bis(trifluoromethyl)phenyl]-4-(5-ethenyl-4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774230-15-8 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-bis(trifluoromethyl)phenyl]-4-[5-(2-methoxyethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-16-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-bromo-5-(trifluoromethyl)phenyl]-4-(5-ethenyl-4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 774230-17-0 CAPLUS


CN 2-Pyrimidinamine, N-[3-bromo-5-(trifluoromethyl)phenyl]-4-[5-(2-methoxyethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774230-18-1 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-ethenyl-4-methyl-2-

thiazolyl)- (9CI) (CA INDEX NAME)




RN 774230-19-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(2-methoxyethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-20-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-(5-ethenyl-4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774230-21-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[5-(2-methoxyethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-22-7 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-bis(trifluoromethyl)phenyl]-4-[4-methyl-5-[2-(4-morpholinyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-23-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-(dimethylamino)ethyl]-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774230-24-9 CAPLUS

CN Phenol, 3-[[4-(5-ethenyl-4-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774230-25-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-[2-(4-morpholinyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-26-1 CAPLUS

CN 5-Thiazoleethanol, 4-methyl-2-[2-[[3-methyl-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774230-27-2 CAPLUS

CN 5-Thiazoleethanol, 4-methyl-2-[2-[[3-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774230-28-3 CAPLUS

CN 5-Thiazoleethanol, 2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 774230-29-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-ethenyl-4-methyl-2-thiazolyl)-N-[3-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774230-30-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[4-methyl-5-[2-(4-morpholinyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-31-8 CAPLUS

CN Ethanol, 2-[[2-[2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 774230-32-9 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)




RN 774230-33-0 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-[3-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 774230-34-1 CAPLUS


CN Phenol, 3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 774230-35-2 CAPLUS


CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-[3-methyl-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774230-36-3 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 774230-37-4 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 774230-38-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[(dimethylamino)methyl]-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774230-39-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-(4-morpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-40-9 CAPLUS

CN Ethanol, 2-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]methyamino]- (9CI) (CA INDEX NAME)




RN 774230-41-0 CAPLUS

CN Ethanol, 2-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 774230-42-1 CAPLUS

CN 1-Piperazineethanol, 4-[2-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




IT 774230-43-2P 774230-44-3P 774230-45-4P
 774230-46-5P 774230-47-6P 774230-48-7P
 774230-49-8P 774230-50-1P 774230-51-2P
 774230-52-3P 774230-53-4P 774230-54-5P
 774230-55-6P 774230-56-7P 774230-57-8P
 774230-58-9P 774230-59-0P 774230-60-3P
 774230-61-4P 774230-62-5P 774230-63-6P
 774230-64-7P 774230-65-8P 774230-66-9P
 774230-67-0P 774230-68-1P 774230-69-2P
 774230-70-5P 774230-71-6P 774230-72-7P
 774230-73-8P 774230-74-9P 774230-75-0P
 774230-76-1P 774230-77-2P 774230-78-3P
 774230-79-4P 774230-80-7P 774230-81-8P
 774230-82-9P 774230-83-0P 774230-84-1P
 774230-85-2P 774230-86-3P 774230-87-4P
 774230-88-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazoles as inhibitors of protein kinases)


RN 774230-43-2 CAPLUS

CN 1-Propanol, 3-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 774230-44-3 CAPLUS

CN 1,2-Ethanedione, 1-[2-[[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-45-4 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 774230-46-5 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 774230-47-6 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 774230-48-7 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 774230-49-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 774230-50-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-[(4-methyl-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-51-2 CAPLUS

CN Cyclohexanol, 4-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 774230-52-3 CAPLUS

CN 4-Piperidinol, 1-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 774230-53-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-([1,4'-bipiperidin]-1'-ylmethyl)-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 774230-54-5 CAPLUS


CN 2-Pyrimidinamine, 4-[5-[(cyclohexylmethylamino)methyl]-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 774230-55-6 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774230-56-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-[(methylamino)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-57-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-(1-piperazinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-58-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 774230-59-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[(diethylamino)methyl]-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774230-60-3 CAPLUS

CN Ethanol, 2-[[[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 774230-61-4 CAPLUS

CN Ethanol, 2-[2-[[[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 774230-62-5 CAPLUS


CN 1,2-Ethanediamine, N-[[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 774230-63-6 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(3-

ethoxyphenyl)amino]methyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-64-7 CAPLUS

CN 1,2-Ethanediamine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 774230-65-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-[[[2-(2-pyridinyl)ethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774230-66-9 CAPLUS


CN 1-Piperazineethanol, 4-[3-[3-[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 774230-67-0 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[3-[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774230-68-1 CAPLUS

CN Ethanol, 2-[[3-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]propyl]methylamino]- (9CI) (CA INDEX NAME)




RN 774230-69-2 CAPLUS

CN Ethanol, 2-[[3-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 774230-70-5 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-[3-[3-(4-methyl-1-piperazinyl)propoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774230-71-6 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 774230-72-7 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-ethyl- (9CI) (CA INDEX NAME)




RN 774230-73-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[4-methyl-5-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-74-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(aminomethyl)-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774230-75-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-(1-pyrrolidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-76-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-(1-piperidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-77-2 CAPLUS

CN 4-Morpholineethanamine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 774230-78-3 CAPLUS

CN 3-Piperidinemethanol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 774230-79-4 CAPLUS

CN 1-Piperazineethanol, 4-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 774230-80-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methoxymethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-81-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(ethoxymethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-82-9 CAPLUS

CN Ethanol, 2-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methoxy]- (9CI) (CA INDEX NAME)




RN 774230-83-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-N,N,4-trimethyl- (9CI) (CA INDEX NAME)




RN 774230-84-1 CAPLUS

CN 5-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)




RN 774230-85-2 CAPLUS

CN Glycine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 774230-86-3 CAPLUS

CN Glycine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 774230-87-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 774230-88-5 CAPLUS

CN 4-Thiazolecarboxaldehyde, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)



L8 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:857594 CAPLUS
 DN 141:332212
 TI Preparation of aminopyrimidinyl-substituted thiazoles useful as inhibitors of protein kinases
 IN Farmer, Luc J.; Harrington, Edmund Martin; Salituro, Francesco G.; Wang, Jian
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Appl PCT

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087698	A2	20041014	WO 2004-US9061	20040325
	WO 2004087698	A3	20041209		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004225965	A1	20041014	AU 2004-225965	20040325
	CA 2523125	AA	20041014	CA 2004-2523125	20040325
	US 2004235834	A1	20041125	US 2004-809944	20040325
	EP 1610793	A2	20060104	EP 2004-758287	20040325
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-457218P	P	20030325		
	WO 2004-US9061	W	20040325		
OS	CASREACT 141:332212; MARPAT 141:332212				
AB	Title compds. I [R1-2 = halo, CN, NO2, etc.; Ar1 = aryl, etc.; R3-4 = ZR7; Z = bond, alkylidene; R7 = halo, NO2, CN, alkoxy, etc.] are prepared General procedures are provided, e.g., [4-[2-((3,5-dimethylphenyl)amino)pyrimidin-4-yl]thiazol-2-yl]methanol. Selected example compds. of the invention exhibit Ki < 5 µM for Syk kinase. I are useful for the treatment of autoimmune disorders.				
IT	769933-80-4P 769933-81-5P 769933-83-7P 769933-84-8P 769933-85-9P 769933-86-0P 769933-87-1P 769933-88-2P 769933-89-3P 769933-90-6P 769933-91-7P 769933-92-8P 769933-93-9P 769933-94-0P 769933-95-1P 769933-96-2P 769933-97-3P 769933-98-4P 769933-99-5P 769934-00-1P 769934-01-2P 769934-02-3P 769934-03-4P 769934-04-5P 769934-05-6P 769934-06-7P 769934-07-8P 769934-08-9P 769934-09-0P 769934-10-3P 769934-11-4P 769934-12-5P 769934-13-6P 769934-14-7P 769934-15-8P 769934-16-9P 769934-17-0P 769934-18-1P 769934-19-2P 769934-20-5P 769934-21-6P 769934-22-7P 769934-23-8P 769934-24-9P 769934-25-0P				


769934-26-1P 769934-27-2P 769934-28-3P
 769934-29-4P 769934-30-7P 769934-31-8P
 769934-32-9P 769934-33-0P 769934-34-1P
 769934-35-2P 769934-36-3P 769934-37-4P
 769934-38-5P 769934-39-6P 769934-40-9P
 769934-41-0P 769934-43-2P 769934-44-3P
 769934-45-4P 769934-46-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyrimidinyl-substituted thiazoles useful as inhibitors of protein kinases for autoimmune disorders)


RN 769933-80-4 CAPLUS

CN Ethanone, 1-[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 769933-81-5 CAPLUS

CN 2-Thiazolemethanol, 4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769933-83-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-84-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-(4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-85-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(4-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 769933-86-0 CAPLUS

CN Phenol, 3-[[4-(4-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)-
(9CI) (CA INDEX NAME)




RN 769933-87-1 CAPLUS

CN 1H-Benzimidazol-5-amine, N-[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]-2-(trifluoromethyl)-
(9CI) (CA INDEX NAME)




RN 769933-88-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-(2-methyl-4-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 769933-89-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-methylphenyl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-90-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-91-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluoro-4-methoxyphenyl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-92-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3-aminophenyl)sulfonyl]phenyl]-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-93-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methyl-4-thiazolyl)-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 769933-94-0 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromo-4-methylphenyl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-95-1 CAPLUS

CN 1H-Indazol-5-amine, N-[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769933-96-2 CAPLUS

CN Phenol, 2-[(diethylamino)methyl]-4-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 769933-97-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-98-4 CAPLUS

CN 1,4-Benzenediamine, N-[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 769933-99-5 CAPLUS

CN 2-Pyrimidinamine, N-1,3-benzodioxol-5-yl-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769934-00-1 CAPLUS

CN 2-Pyrimidinamine, N-(4-ethoxyphenyl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 769934-01-2 CAPLUS


CN Benzamide, 3-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 769934-02-3 CAPLUS


CN 2-Pyrimidinamine, N-(6-methoxy[1,1'-biphenyl]-3-yl)-4-(4-thiazolyl)- (9CI)

(CA INDEX NAME)




RN 769934-03-4 CAPLUS

CN Phenol, 2-methoxy-5-[[4-(4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 769934-04-5 CAPLUS

CN Ethanone, 1-[4-[[2-(2-methyl-1H-indol-5-yl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 769934-05-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxy[1,1'-biphenyl]-4-yl)-4-(4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769934-06-7 CAPLUS

CN 1H-Indol-5-amine, 1-(methanesulfonyl)-N-[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769934-07-8 CAPLUS

CN Ethanone, 1-[4-[2-(8-quinolinylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI)
(CA INDEX NAME)




RN 769934-08-9 CAPLUS

CN 2H-1-Benzopyran-2-one, 4-(methoxymethyl)-7-[[4-(4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 769934-09-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methyl-4-thiazolyl)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 769934-10-3 CAPLUS

CN 2-Pyrimidinamine, 4-(4-thiazolyl)-N-[4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 769934-11-4 CAPLUS

CN 2-Thiazolemethanol, 4-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 769934-12-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-(4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769934-13-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chloro-3-methylphenyl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769934-14-7 CAPLUS

CN Ethanone, 1-[3-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 769934-15-8 CAPLUS

CN 2-Thiazolemethanol, 4-[2-(1H-indol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769934-16-9 CAPLUS

CN 1,3-Benzenediamine, N-[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769934-17-0 CAPLUS

CN Phosphonic acid, [[4-[[4-(4-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 769934-18-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 769934-19-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methyl-4-thiazolyl)-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 769934-20-5 CAPLUS

CN Benzeneacetonitrile, 3-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 769934-21-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-bromo-4-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI)
(CA INDEX NAME)




RN 769934-22-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(dimethylamino)methyl]-4-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 769934-23-8 CAPLUS

CN 1,3-Propanediamine, N'-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 769934-24-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[2-(1-piperidinylmethyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 769934-25-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[2-[(4-ethyl-1-piperazinyl)methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 769934-26-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[2-(4-morpholinylmethyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 769934-27-2 CAPLUS

CN 3-Pyrrolidinol, 1-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 769934-28-3 CAPLUS


CN 4-Piperidinol, 1-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 769934-29-4 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769934-30-7 CAPLUS

CN 1-Piperazineethanol, 4-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 769934-31-8 CAPLUS

CN 2-Thiazolecarbonitrile, 4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769934-32-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(bromomethyl)-4-thiazolyl]-N-(3,5-dimethylphenyl)-
(9CI) (CA INDEX NAME)




RN 769934-33-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[2-(methoxymethyl)-4-thiazolyl]-
(9CI) (CA INDEX NAME)




RN 769934-34-1 CAPLUS

CN Glycine, N-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 769934-35-2 CAPLUS

CN Glycine, N-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 769934-36-3 CAPLUS

CN 2-Thiazoleacetic acid, 4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 769934-37-4 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(2,5-dimethyl-4-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 769934-38-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[2-(1-piperidinyl)-4-thiazolyl]-
(9CI) (CA INDEX NAME)




RN 769934-39-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(2-ethyl-4-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 769934-40-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methyl-4-thiazolyl)-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 769934-41-0 CAPLUS

CN Benzonitrile, 4-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 769934-43-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769934-44-3 CAPLUS

CN 2-Thiazolemethanol, 4-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769934-45-4 CAPLUS

CN 2-Thiazolecarboxylic acid, 4-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 769934-46-5 CAPLUS

CN 2-Thiazolecarboxylic acid, 4-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:756664 CAPLUS
 DN 141:243576
 TI Preparation of macrocycle amino compounds and compositions as
 cyclin-dependent protein kinase inhibitors
 IN Ren, Pingda; Adrian, Francisco; Gray, Nathanael S.; Wang, Xia
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004078682	A2	20040916	WO 2004-US6947	20040305
	WO 2004078682	A3	20051208		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,				
	BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,				
	MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,				
	GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU,				
	TJ, TM				

US 2004235841 A1 20041125 US 2004-794454 20040305
 PRAI US 2003-452633P P 20030305

OS MARPAT 141:243576

AB The invention provides a novel class of cyclic compds. I, wherein n is 0-3; R1 hydrogen and alkyl; R2-R3 are independently substituted arylene and hetero-arylene; R4 4 is -XIR6(CH2)mNR7C(O)-, -XNR6(CH2)mNR7C(O)CH2-, -XR6(CH2)mNR7(CH2)mNR7C(O)-, -O(CH2)mNR7C(O)-, -NR6(CH2)mO- and -XNR6(CH2)mNR7CH2-; wherein X is a bond or C-alkylene; m is 1-6; R6 and R7 independently are hydrogen and alkyl; and R5 is halo, alkyl, halo-substituted alkyl, alkoxy and halo-substituted alkoxy and heterocycloalkyl; wherein any heterocycloalkyl of R5 is substituted with a group halo, alkyl, halo-substituted alkyl, alkoxy, halo-substituted alkoxy, heterocycloalkyl-alkyl and -XNR8R9, wherein X is a bond or alkylene; R8 and R9 are independently hydrogen and alkyl; or a salt thereof pharmaceutical compns. comprising such cyclic compds. and methods of using such compds. to treat or prevent diseases and disorders associated with cyclin-dependent kinases (CDKs) activity, particularly diseases associated with the activity of CDK2 and CDK5. Thus, macrocycle II was prepared and tested as CDK2 and CDK5 inhibitors.


IT 752245-59-3P 752245-60-6P 752245-61-7P
 752245-62-8P 752245-63-9P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocycle amino compds. and compns. as cyclin-dependent protein kinase inhibitors)

RN 752245-59-3 CAPLUS


CN Benzoic acid, 3-[[4-[2-amino-4-(trifluoromethyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



Intermediates


RN 752245-60-6 CAPLUS

CN Benzoic acid, 3-[[4-[2-chloro-4-(trifluoromethyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 752245-61-7 CAPLUS

CN Benzoic acid, 3-[[4-[2-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]butyl]amino]-4-(trifluoromethyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 752245-62-8 CAPLUS

CN Benzoic acid, 3-[[4-[2-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]butyl]amino]-4-(trifluoromethyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 752245-63-9 CAPLUS

CN Benzoic acid, 3-[[4-[2-[(4-aminobutyl)amino]-4-(trifluoromethyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:546415 CAPLUS
 DN 141:89104
 TI Preparation of 2-substituted 4-heteroarylpyrimidines as GSK3 inhibitors
 for the treatment of diabetes
 IN Wang, Shudong; Meades, Christopher; Wood, Gavin; Duncan, Kenneth; Zhevela,
 Daniella; Fischer, Peter
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004056368	A1	20040708	WO 2003-GB5558	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502138	AA	20040708	CA 2003-2502138	20031218
AU 2003292444	A1	20040714	AU 2003-292444	20031218
EP 1572211	A1	20050914	EP 2003-768023	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016703	A	20051018	BR 2003-16703	20031218
CN 1720049	A	20060111	CN 2003-80104697	20031218
JP 2006515588	T2	20060601	JP 2004-561646	20031218
US 2005282843	A1	20051222	US 2005-140136	20050526
PRAI GB 2002-29581	A	20021219		
WO 2003-GB5558	W	20031218		

OS MARPAT 141:89104

AB Heteroarylpyrimidines of formula I [X, Y = S, (substituted) N, (substituted) C; R1 = alkyl, aryl, heteroaryl, halo, CF3, CN, (substituted) NH2, alkoxycarbonyl, etc.; R2-R4 = H, alkyl, aryl, heteroaryl, halo, CF3, NO2, OH, alkoxy, acyl, alkoxycarbonyl, (substituted) NH2, SO2-alkyl, etc.] are prepared for use in a medicament for treating diabetes. The compds. of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke. Thus, II was prepared, and had IC50 of 0.005 μ M against GSK3 β .


IT 364334-42-9P 507487-89-0P 717111-31-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylpyrimidines as GSK3 inhibitors)


RN 364334-42-9 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-
(9CI) (CA INDEX NAME)



RN 717111-31-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chloro-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-
(9CI) (CA INDEX NAME)




IT 507488-21-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroarylpyrimidines as GSK3 inhibitors)

RN 507488-21-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methoxy-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-
(9CI) (CA INDEX NAME)



L8 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:430798 CAPLUS
 DN 141:7130
 TI Preparation of pyrimidine derivs. as inhibitors of cyclin-dependent kinases
 IN Wang, Shudong; Meades, Christopher; Wood, Gavin; O'Boyle, Janice; McInnes, Campbell; Fischer, Peter
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043953	A1	20040527	WO 2003-GB4973	20031114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LG, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502190	AA	20040527	CA 2003-2502190	20031114
AU 2003301977	A1	20040603	AU 2003-301977	20031114
EP 1567522	A1	20050831	EP 2003-811029	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016152	A	20050927	BR 2003-16152	20031114
CN 1711258	A	20051221	CN 2003-80103318	20031114
JP 2006514619	T2	20060511	JP 2004-550846	20031114
US 2005192300	A1	20050901	US 2004-991942	20041117
PRAI GB 2002-26583	A	20021114		
WO 2003-GB4973	W	20031114		

OS MARPAT 141:7130

AB The tile compds. I [X1 = S, X2 = N or (substituted)amino or X2 = S, X1 = N or (substituted)amino; Z = NH, NHCO, NHSO₂, NHCH₂, CH₂, CH₂CH₂, CH=CH, SO₂, or SO; R₂ = OXO, or H, (substituted)alkyl, (substituted)aryl, (substituted)aralkyl, halo, NO₂, CN, OH, etc.; R₁, R₃, R₄, R₅, R₆, R₇, and R₈ = H, (substituted)alkyl, (substituted)aryl, (substituted)aralkyl, halo, NO₂, CN, OH, etc.] were prepared as inhibitors of cyclin-dependent kinases (CDKs) for the treatment of proliferative disorders and/or viral disorders. For example, condensation of N'-[5-(3-dimethylamino-acryloyl)-4-methyl-thiazol-2-yl]-N,N-dimethyl-formamidine and N-(4-morpholin-4-yl-phenyl)-guanidine nitrate afforded compound II. In an assay against multiple kinases, II selectively inhibited CDKs, showing an IC₅₀ of 0.48 μ M against CDK2/cyclin E, and 0.44 μ M against CDK2/cyclin A. Addnl. bioassays indicated II possessed anti-proliferative activity against human cancer cell lines, A549, HT29, Saos-2 with IC₅₀ 2.1, 1.7, and 1.9 μ M, resp.


IT 507488-50-8P 693228-71-6P 693228-73-8P
 693228-97-6P 693228-99-8P 693229-41-3P
 693229-57-1P 693229-61-7P 693229-63-9P
 693229-69-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. as CDKs inhibitors)


RN 507488-50-8 CAPLUS

CN Acetamide, 2-chloro-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693228-71-6 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693228-73-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-97-6 CAPLUS

CN Propanamide, 3-amino-N-[4-methyl-5-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693228-99-8 CAPLUS

CN Propanamide, 3-bromo-N-[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-41-3 CAPLUS

CN Acetamide, 2-chloro-N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-57-1 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-61-7 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 693229-63-9 CAPLUS

CN Acetamide, N-[[3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 693229-69-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)

IT 507488-47-3P 507488-51-9P 693228-63-6P
693228-65-8P 693228-67-0P 693228-69-2P


693228-74-9P 693228-75-0P 693228-77-2P
 693228-79-4P 693228-81-8P 693228-83-0P
 693228-85-2P 693228-87-4P 693228-89-6P
 693228-91-0P 693228-93-2P 693228-95-4P
 693229-01-5P 693229-03-7P 693229-05-9P
 693229-07-1P 693229-09-3P 693229-11-7P
 693229-13-9P 693229-15-1P 693229-17-3P
 693229-19-5P 693229-23-1P 693229-25-3P
 693229-27-5P 693229-28-6P 693229-30-0P
 693229-31-1P 693229-33-3P 693229-35-5P
 693229-37-7P 693229-39-9P 693229-42-4P
 693229-43-5P 693229-45-7P 693229-47-9P
 693229-49-1P 693229-51-5P 693229-53-7P
 693229-55-9P 693229-59-3P 693229-65-1P
 693229-67-3P 693229-70-8P 693229-72-0P
 693229-74-2P 693229-76-4P 693229-78-6P
 693229-80-0P 693229-82-2P 693229-84-4P
 693229-86-6P 693229-88-8P 693229-90-2P
 693229-92-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as CDKs inhibitors)


RN 507488-47-3 CAPLUS

CN Methanesulfonamide, N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-51-9 CAPLUS

CN Acetamide, 2-chloro-N-[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693228-63-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-65-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-67-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-69-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-74-9 CAPLUS

CN Ethanol, 2-[2-[4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 693228-75-0 CAPLUS

CN 1-Piperazinepropanol, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693228-77-2 CAPLUS

CN 1-Piperazineethanol, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693228-79-4 CAPLUS

CN Piperazine, 1-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 693228-81-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylanino)-5-thiazolyl]-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 693228-83-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 693228-85-2 CAPLUS


CN Propanamide, 3-amino-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 693228-87-4 CAPLUS

CN Propanamide, 2-amino-3-hydroxy-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 693228-89-6 CAPLUS

CN Butanamide, 2-amino-3-hydroxy-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 693228-91-0 CAPLUS

CN Butanamide, 2-amino-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 693228-93-2 CAPLUS


CN Butanamide, 2-amino-3-hydroxy-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 693228-95-4 CAPLUS

CN Butanamide, 4-amino-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-01-5 CAPLUS

CN 4-Morpholinepropanamide, N-[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-03-7 CAPLUS

CN 4-Morpholinepropanamide, N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-05-9 CAPLUS

CN 1-Piperazinepropanamide, 4-methyl-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-07-1 CAPLUS

CN Acetamide, 2-chloro-N-[5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-09-3 CAPLUS

CN Acetamide, 2-chloro-N-[5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-11-7 CAPLUS

CN Acetamide, 2-(4-methoxyphenyl)-N-[5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-13-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 693229-15-1 CAPLUS


CN Acetamide, N-[5-[2-[[4-(dimethylamino)phenyl]amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]-2-[[2-(2-hydroxyethoxy)ethyl]amino]- (9CI) (CA INDEX NAME).




RN 693229-17-3 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[6-[[3-[[4-methyl-5-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-2-thiazolyl]amino]-3-oxopropyl]amino]-6-oxohexyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 693229-19-5 CAPLUS

CN Methanesulfonamide, N-[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-23-1 CAPLUS

CN Acetamide, 2-chloro-N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-25-3 CAPLUS

CN 4-Morpholinepropanamide, N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-27-5 CAPLUS

CN Propanamide, N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]-3-[[2-(diethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-28-6 CAPLUS

CN Propanamide, N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]-3-[[2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-30-0 CAPLUS

CN 4-Morpholinepropanamide, N-[5-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-31-1 CAPLUS

CN 4-Morpholinepropanamide, N-[5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-33-3 CAPLUS

CN 1-Piperazinepropanamide, N-[5-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 693229-35-5 CAPLUS

CN Acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-37-7 CAPLUS

CN Acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME).




RN 693229-39-9 CAPLUS

CN 1-Piperazineethanol, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- α -methyl- (9CI) (CA INDEX NAME)


RN 693229-42-4 CAPLUS

CN 4-Morpholineacetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-43-5 CAPLUS

CN 1H-1,2,4-Triazole-1-acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-45-7 CAPLUS

CN 1-Pyrrolidineacetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-47-9 CAPLUS

CN 1H-Imidazole-1-acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-49-1 CAPLUS

CN Phenol, 3-[[4-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-51-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-53-7 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 693229-55-9 CAPLUS

CN Benzeneethanol, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-59-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-65-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-67-3 CAPLUS

CN Acetamide, N-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 693229-70-8 CAPLUS

CN Benzenemethanol, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-72-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 693229-74-2 CAPLUS


CN Benzenemethanol, 2-chloro-5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 693229-76-4 CAPLUS


CN Benzenemethanol, 2-chloro-5-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-78-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-80-0 CAPLUS

CN 2-Pyrimidinamine, N-[4-(2-methoxyethoxy)-3-nitrophenyl]-4-[4-methyl-2-(methyamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-82-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-[[2-(4-morpholinyl)ethoxy]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-84-4 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 693229-86-6 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 693229-88-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-90-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 693229-92-4 CAPLUS

CN Benzenemethanol, 3-[[4-(4-methyl-2-(methylamino)-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




IT 364334-85-0 507487-89-0 507487-92-5
507488-00-8 693230-34-1 693230-36-3
693230-39-6 693230-42-1 693230-44-3
693230-49-8 693230-80-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. as CDKs inhibitors)


RN 364334-85-0 CAPLUS

CN Benzenemethanol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507487-92-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)




RN 507488-00-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 693230-34-1 CAPLUS

CN Propanamide, 3-chloro-N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-36-3 CAPLUS

CN Propanamide, 3-bromo-N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-39-6 CAPLUS

CN Propanamide, 3-amino-N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-42-1 CAPLUS

CN Propanamide, 3-bromo-N-[5-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-44-3 CAPLUS

CN Propanamide, 3-bromo-N-[5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-49-8 CAPLUS

CN 1,4-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)



RN 693230-80-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(aminomethyl)-4-methyl-5-thiazolyl]-N-(4-fluoro-3-nitrophenyl)- (9CI) (CA INDEX NAME)




IT 693230-19-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. as CDKs inhibitors)

RN 693230-19-2 CAPLUS

CN Carbamic acid, [3-[[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:430750 CAPLUS
 DN 141:7129
 TI Preparation of 4-heteroarylpyrimidines as specific cyclin-dependent kinase inhibitors for treating viruses
 IN Wang, Shudong; Meades, Christopher; Wood, Gavin; Blake, David; Fischer, Peter
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004043467	A1	20040527	WO 2003-GB4977	20031114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003283585	A1	20040603	AU 2003-283585	20031114
	EP 1581231	A1	20051005	EP 2003-775562	20031114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005288307	A1	20051229	US 2005-129198	20050513
PRAI	GB 2002-26582	A	20021114		
	WO 2003-GB4977	W	20031114		

OS MARPAT 141:7129

AB Title compds. I [wherein one of X1 and X2 = S, and the other of X1 and X2 = N so as to form a thiazolyl ring, R2 = independently as defined below for R1 and R3; one of X1 and X2 = S, and the other of X1 and X2 = NH and derivs. so as to form a 4,5-dihydrothiazolyl ring; R2 = oxo; the bond between C and R2 = double; Z = NH, NHCO, NHSO2, NHCH2, CH2, CH2CH2, CH:CH; R1, R3 = independently H, halo, NO2, CN, OH and derivs., NH2 and derivs., CO2H and derivs., CONH2 and derivs., SO3H, (un)substituted ar/alkyl, aryl, heterocyclyl, etc.; R4, R5, R6, R7, R8 = independently H, halo, NO2, CN, OH and derivs., NH2 and derivs., alkylheteroaryl, SO3H, SO2NH2, CF3, (un)substituted lower alkyl; and their pharmaceutically acceptable salts] were prepared for use in the treatment of viral disorders. For example, II was prepared by cyclocondensation of 3-Dimethylamino-1-(2,4-dimethylthiazol-5-yl)propenone (preparation given) with N-(3-Nitrophenyl)guanidine nitrate (preparation given) in 2-methoxyethanol in the presence of NaOH. Selected I showed high degree of selectivity for inhibition of CDKs. II displayed an average IC50 of 0.23 μ M against CDK2-Cyclin E1 kinase. Thus, I are useful for treating cytomegalovirus, herpes simplex, HIV-I, and varicella-zoster virus.

IT 364333-82-4P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 364334-85-0P, [3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]methanol 364334-88-3P, N,N-Dimethyl-N'-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]benzene-1,4-diamine 507487-89-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-00-8P, [4-(2-Amino-4-


methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(anti-viral agent; preparation of 4-heteroarylpyrimidines as specific cyclin-dependent kinase inhibitors for treating viruses)


RN 364333-82-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-85-0 CAPLUS

CN Benzenemethanol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 507488-00-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)



IT 364333-75-5P, (2-Chlorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-76-6P, (4-Chlorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-77-7P, (3-Chlorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-81-3P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (2-nitrophenyl)amine 364333-83-5P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (4-nitrophenyl)amine 364333-88-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (2-fluorophenyl)amine 364333-89-1P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (4-fluorophenyl)amine 364333-90-4P, (2,4-Difluorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-91-5P, (3,5-Difluorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-92-6P, (3,5-Dichlorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-93-7P, (2,4-Dichlorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-94-8P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3-trifluoromethylphenyl)amine 364333-95-9P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (2-trifluoromethylphenyl)amine 364333-96-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (4-trifluoromethylphenyl)amine 364333-97-1P, (2-Bromophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-98-2P, (3-Bromophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-99-3P, (4-Bromophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364334-00-9P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (2-iodophenyl)amine 364334-01-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3-iodophenyl)amine 364334-02-1P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (4-iodophenyl)amine 364334-04-3P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3-fluorophenyl)amine 364334-05-4P, (3,4-Difluorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364334-06-5P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (2-methoxyphenyl)amine 364334-07-6P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3-

methoxyphenyl)amine 364334-08-7P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](4-methoxyphenyl)amine 364334-09-8P, 3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-10-1P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-14-5P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]-2-nitrophenol 364334-16-7P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]benzene-1,3-diamine 364334-17-8P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzonitrile 364334-18-9P, 3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzonitrile 364334-19-0P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid methyl ester 364334-20-3P, (3-Chloro-4-methylphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364334-21-4P, (3-Chloro-4-methoxyphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364334-22-5P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid 364334-23-6P, [4-Bromo-6-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 364334-24-7P, [4-(2,4-Dimethylthiazol-5-yl)-6-phenylpyrimidin-2-yl](3-nitrophenyl)amine 364334-25-8P, 4-[4-(2,4-Dimethylthiazol-5-yl)-6-phenylpyrimidin-2-ylamino]phenol 364334-26-9P, (3,4-Difluorophenyl)[4-(4-methyl-2-phenylthiazol-5-yl)pyrimidin-2-yl]amine 364334-27-0P, 4-[4-(4-Methyl-2-phenylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-28-1P, [4-(2,4-Dimethylthiazol-5-yl)-6-phenylpyrimidin-2-yl](4-fluorophenyl)amine 364334-29-2P, (4-Fluorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-30-5P, 4-[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-31-6P, [4-(2,4-Dimethylthiazol-5-yl)-6-(4-trifluoromethylphenyl)pyrimidin-2-yl](4-fluorophenyl)amine 364334-32-7P, (4-Chlorophenyl)[4-(2,4-dimethylthiazol-5-yl)-6-(4-trifluoromethylphenyl)pyrimidin-2-yl]amine 364334-33-8P, 4-[4-(2,4-Dimethylthiazol-5-yl)-6-(4-trifluoromethylphenyl)pyrimidin-2-ylamino]-2-nitrophenol 364334-34-9P, (4-Fluorophenyl)[4-(4-methyl-2-(pyridin-3-yl)thiazol-5-yl)pyrimidin-2-yl]amine 364334-35-0P, [4-(2,4-Dimethylthiazol-5-yl)-6-(3-trifluoromethylphenyl)pyrimidin-2-yl](4-fluorophenyl)amine 364334-36-1P, 4-[6-(2,4-Dimethylthiazol-5-yl)-2-(4-fluorophenylamino)pyrimidin-4-yl]-2,6-dimethoxyphenol 364334-37-2P, 4-[6-(2,4-Dimethylthiazol-5-yl)-2-(4-fluorophenylamino)pyrimidin-4-yl]phenol 364334-38-3P, [4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl](3-nitrophenyl)amine 364334-39-4P, (4-Iodophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-41-8P, 4-[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-ylamino]-2-nitrophenol 364334-42-9P, 2-Chloro-4-[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-ylamino]benzoic acid ethyl ester 364334-43-0P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 364334-44-1P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 364334-45-2P, 3-[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-46-3P, 2-Chloro-4-[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid ethyl ester 364334-47-4P, 4-Chloro-3-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid 2-methoxyethyl ester 364334-48-5P, 2-Chloro-4-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid 2-methoxyethyl ester 364334-49-6P, 4-Chloro-3-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid 364334-51-0P, [4-(2-Allylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 364334-52-1P, (3-Bromophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-53-2P,

[4-(2-Allylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine
 364334-54-3P, 3-[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-55-4P, (4-Bromophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-56-5P, (4-Chlorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-57-6P, (3-Methoxyphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-58-7P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 364334-59-8P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl](3-trifluoromethylphenyl)amine 364334-60-1P, 2-Chloro-5-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid ethyl ester 364334-61-2P, 3-Chloro-2-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid ethyl ester 364334-62-3P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](2-fluoro-4-iodophenyl)amine 364334-63-4P, 2-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]-5-methoxyphenol 364334-64-5P, (3-Chloro-4-iodophenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364334-66-7P, 2-Chloro-4-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-67-8P, 5-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]-2-fluorobenzoic acid 2-methoxyethyl ester 364334-68-9P, 2-Chloro-5-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid methyl ester 364334-69-0P, 4-Chloro-3-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid methyl ester 364334-70-3P, 2-Chloro-4-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid methyl ester 364334-71-4P, (3-Iodophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-72-5P, (3-Fluorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-73-6P, (3,4-Difluorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-74-7P, (2,4-Difluorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-75-8P, (3,5-Difluorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-76-9P, (4-Chloro-3-trifluoromethylphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-77-0P, (3-Chlorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-78-1P, (4-Methoxyphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-79-2P, (4-Fluoro-3-nitrophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-80-5P, 4-[4-[2-(4-Nitrophenylamino)thiazol-5-yl]pyrimidin-2-yl]amino]phenol 364334-81-6P, N-[5-[2-(4-Hydroxyphenylamino)pyrimidin-4-yl]-4-methylthiazol-2-yl]acetamide 364334-82-7P, (4-Fluorophenyl)[4-[2-(4-nitrophenylamino)thiazol-5-yl]pyrimidin-2-yl]amine 364334-83-8P, 4-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-84-9P, N-[3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]guanidine 364334-86-1P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-[(pyridin-4-yl)methyl]phenyl]amine 364334-87-2P, [3-(2-Diethylaminoethoxymethyl)phenyl][4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 507487-91-4P, N-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]-N',N'-dimethylbenzene-1,4-diamine 507487-92-5P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-chlorophenyl)amine 507487-93-6P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-methoxyphenyl)amine 507487-94-7P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-fluorophenyl)amine 507487-95-8P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 507487-96-9P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methoxyphenyl)amine 507487-97-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-


chlorophenyl)amine 507487-98-1P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-iodophenyl)amine 507487-99-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-iodophenyl)amine 507488-01-9P, 3-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenol 507488-02-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-iodo-3-nitrophenyl)amine 507488-03-1P, 2-[4-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]ethanol 507488-04-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-bromophenyl)amine 507488-05-3P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-bromophenyl)amine 507488-06-4P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-chloro-3-trifluoromethylphenyl)amine 507488-08-6P, [4-(2-Diethylaminoethoxy)phenyl][4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 507488-09-7P, 2-[4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]ethanol 507488-10-0P, 2-[4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]ethylamino]ethanol 507488-11-1P, 1-(3,4-Dimethoxyphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 507488-12-2P, 5-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]-2-methoxyphenol 507488-13-3P, N'-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N,N-dimethyl-2-nitrobenzene-1,4-diamine 507488-14-4P, 2-Chloro-N'-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]-N,N-dimethylbenzene-1,4-diamine 507488-15-5P, N'-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N,N-dimethyl-2-trifluoromethylbenzene-1,4-diamine 507488-16-6P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-4-methoxy-N',N'-dimethylbenzene-1,3-diamine 507488-17-7P, N,N-Dimethyl-N'-[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]benzene-1,4-diamine 507488-18-8P, (4-Iodo-3-nitrophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 507488-29-1P, (3-Iodo-4-methylphenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-30-4P, (4-Fluoro-3-methylphenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-33-7P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-35-9P, (4-Chlorophenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-36-0P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 507488-37-1P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-methoxyphenyl)amine 507488-38-2P, (3-Chlorophenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-39-3P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methyl-3-nitrophenyl)amine 507488-40-6P, [4-(2-Butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 507488-42-8P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-44-0P, (4-Chlorophenyl)[4-(2-dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-45-1P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 507488-46-2P, (3-Chlorophenyl)[4-(2-dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-48-4P, 2-[4-Methyl-5-[2-(3-nitrophenylamino)pyrimidin-4-yl]thiazol-2-yl]amino]ethanol 507488-49-5P, 2-[4-[5-[2-(4-Fluorophenylamino)pyrimidin-4-yl]-4-methylthiazol-2-yl]amino]ethanol 507488-52-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-nitrophenyl)amine 507488-53-1P, N-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]phenylamine 507488-55-3P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzenesulfonic acid 674333-60-9P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]phenylamine 693290-45-8P, [4-[4-(2,4-Dimethylthiazol-5-

yl)pyrimidin-2-ylamino]phenyl]trimethylammonium iodide
 693290-46-9P, 4-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]benzenesulfonic acid 693290-47-0P, N-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]benzene-1,3-diamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anti-viral agent; preparation of 4-heteroarylpyrimidines as specific cyclin-dependent kinase inhibitors for treating viruses)


RN 364333-75-5 CAPLUS

CN 2-Pyrimidinamine, N-(2-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
 (CA INDEX NAME)




RN 364333-76-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
 (CA INDEX NAME)




RN 364333-77-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
 (CA INDEX NAME)




RN 364333-81-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-nitrophenyl)- (9CI)
 (CA INDEX NAME)




RN 364333-83-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-nitrophenyl)- (9CI)
(CA INDEX NAME)




RN 364333-88-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-fluorophenyl)- (9CI)
(CA INDEX NAME)



RN 364333-89-1 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 364333-90-4 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-


(9CI) (CA INDEX NAME)



RN 364333-91-5 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)

RN 364333-92-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dichlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)


RN 364333-93-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-dichlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 364333-94-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-95-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-96-0 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-97-1 CAPLUS

CN 2-Pyrimidinamine, N-(2-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
(CA INDEX NAME)

RN 364333-98-2 CAPLUS


CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
(CA INDEX NAME)

RN 364333-99-3 CAPLUS

CN 2-Pyrimidinamine, N-(4-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
(CA INDEX NAME)


RN 364334-00-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-iodophenyl)- (9CI)
(CA INDEX NAME)




RN 364334-01-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-iodophenyl)- (9CI)
(CA INDEX NAME)




RN 364334-02-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-iodophenyl)- (9CI)
(CA INDEX NAME)



RN 364334-04-3 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 364334-05-4 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-


(9CI) (CA INDEX NAME)




RN 364334-06-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-methoxyphenyl)- (9CI)
(CA INDEX NAME)


RN 364334-07-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-methoxyphenyl)- (9CI)
(CA INDEX NAME)


RN 364334-08-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-methoxyphenyl)- (9CI)
(CA INDEX NAME)


RN 364334-09-8 CAPLUS
CN Phenol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-10-1 CAPLUS
CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 364334-14-5 CAPLUS
CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)




RN 364334-16-7 CAPLUS
CN 1,3-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 364334-17-8 CAPLUS

CN Benzonitrile, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 364334-18-9 CAPLUS

CN Benzonitrile, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)



RN 364334-19-0 CAPLUS


CN Benzoic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 364334-20-3 CAPLUS


CN 2-Pyrimidinamine, N-(3-chloro-4-methylphenyl)-4-(2,4-dimethyl-5-thiazolyl)-

(9CI) (CA INDEX NAME)




RN 364334-21-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 364334-22-5 CAPLUS

CN Benzoic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-23-6 CAPLUS


CN 2-Pyrimidinamine, 4-bromo-6-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-24-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)-6-phenyl-
(9CI) (CA INDEX NAME)

RN 364334-25-8 CAPLUS


CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-6-phenyl-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)

RN 364334-26-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(4-methyl-2-phenyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)


RN 364334-27-0 CAPLUS

CN Phenol, 4-[[4-(4-methyl-2-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 364334-28-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-phenyl-
(9CI) (CA INDEX NAME)




RN 364334-29-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(methylamino)-5-
thiazolyl]- (9CI) (CA INDEX NAME)



RN 364334-30-5 CAPLUS


CN Phenol, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)



RN 364334-31-6 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[4-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-32-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-33-8 CAPLUS

CN Phenol, 4-[4-(2,4-dimethyl-5-thiazolyl)-6-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)




RN 364334-34-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-35-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-36-1 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 364334-37-2 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 364334-38-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-39-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-iodophenyl)-4-[4-methyl-2-(methyamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-41-8 CAPLUS

CN Phenol, 4-[[4-methyl-2-(methylanino)-5-thiazolyl]-2-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)




RN 364334-42-9 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-methyl-2-(methylanino)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-43-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 364334-44-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methyamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-45-2 CAPLUS

CN Phenol, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-46-3 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-47-4 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-48-5 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-49-6 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-51-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(2-propenylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-52-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-[4-methyl-2-(methylanino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-53-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(2-propenylamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 364334-54-3 CAPLUS


CN Phenol, 3-[[4-[4-methyl-2-(methylanino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 364334-55-4 CAPLUS


CN 2-Pyrimidinamine, N-(4-bromophenyl)-4-[4-methyl-2-(methylanino)-5-

thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-56-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-57-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-58-7 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-59-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-60-1 CAPLUS

CN Benzoic acid, 2-chloro-5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-61-2 CAPLUS

CN Benzoic acid, 3-chloro-2-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-62-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-fluoro-4-iodophenyl)- (9CI) (CA INDEX NAME)




RN 364334-63-4 CAPLUS

CN Phenol, 2-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-5-methoxy-
(9CI) (CA INDEX NAME)




RN 364334-64-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-iodophenyl)-4-(2,4-dimethyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 364334-66-7 CAPLUS

CN Phenol, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 364334-67-8 CAPLUS

CN Benzoic acid, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-fluoro-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-68-9 CAPLUS

CN Benzoic acid, 2-chloro-5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-69-0 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-70-3 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-71-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-iodophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-72-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-73-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-74-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-75-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-76-9 CAPLUS

CN 2-Pyrimidinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-77-0 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-78-1 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-79-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-3-nitrophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-80-5 CAPLUS

CN Phenol, 4-[[4-[2-[(4-nitrophenyl)amino]-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-81-6 CAPLUS

CN Acetamide, N-[5-[2-[(4-hydroxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-82-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[2-[(4-nitrophenyl)amino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-83-8 CAPLUS

CN Phenol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-84-9 CAPLUS

CN Guanidine, [3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)


RN 364334-86-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-87-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-[[2-(diethylamino)ethoxy]methyl]phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 507487-91-4 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]-
N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507487-92-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)




RN 507487-93-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 507487-94-7 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 507487-95-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507487-96-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)


RN 507487-97-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-chlorophenyl)-
(9CI) (CA INDEX NAME)


RN 507487-98-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-iodophenyl)- (9CI)
(CA INDEX NAME)

RN 507487-99-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-iodophenyl)- (9CI)
(CA INDEX NAME)

RN 507488-01-9 CAPLUS

CN Phenol, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)


RN 507488-02-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-iodo-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-03-1 CAPLUS

CN Benzeneethanol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-04-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-bromophenyl)-
(9CI) (CA INDEX NAME)




RN 507488-05-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-bromophenyl)-
(9CI) (CA INDEX NAME)



RN 507488-06-4 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-chloro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507488-08-6 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-4-(2,4-dimethyl-5-


thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-09-7 CAPLUS

CN Benzeneethanol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)


RN 507488-10-0 CAPLUS

CN Ethanol, 2-[[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]ethylamino]-
(9CI) (CA INDEX NAME)


RN 507488-11-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-(2,4-dimethyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)


RN 507488-12-2 CAPLUS

CN Phenol, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methoxy-
(9CI) (CA INDEX NAME)

RN 507488-13-3 CAPLUS


CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-
dimethyl-2-nitro- (9CI) (CA INDEX NAME)

RN 507488-14-4 CAPLUS

CN 1,4-Benzenediamine, 2-chloro-N4-[4-(2,4-dimethyl-5-thiazolyl)-2-
pyrimidinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)


RN 507488-15-5 CAPLUS

CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-
dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 507488-16-6 CAPLUS

CN 1,3-Benzenediamine, N1-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-4-methoxy-N3,N3-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-17-7 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 507488-18-8 CAPLUS


CN 2-Pyrimidinamine, N-(4-iodo-3-nitrophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 507488-29-1 CAPLUS


CN 2-Pyrimidinamine, N-(3-iodo-4-methylphenyl)-4-(2-methoxy-4-methyl-5-

thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-30-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-3-methylphenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-33-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-35-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-36-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507488-37-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 507488-38-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-39-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-methyl-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-40-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(butylamino)-4-methyl-5-thiazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 507488-42-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 507488-44-0 CAPLUS


CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[2-(dimethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 507488-45-1 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(4-

fluorophenyl)- (9CI) (CA INDEX NAME)




RN 507488-46-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(dimethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-48-4 CAPLUS

CN Ethanol, 2-[[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-49-5 CAPLUS


CN Ethanol, 2-[[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-52-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)

RN 507488-53-1 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-phenyl- (9CI) (CA
INDEX NAME)

RN 507488-55-3 CAPLUS

CN Benzenesulfonic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


RN 674333-60-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-phenyl- (9CI) (CA INDEX
NAME)



RN 693290-45-8 CAPLUS


CN Benzenaminium, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)



● I⁻

RN 693290-46-9 CAPLUS


CN Benzenesulfonic acid, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 693290-47-0 CAPLUS


CN 1,3-Benzenediamine, N-[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/809,944




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:324510 CAPLUS
 DN 142:51189
 TI Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors
 AU McInnes, Campbell; Wang, Shudong; Anderson, Sian; O'Boyle, Janice; Jackson, Wayne; Kontopidis, George; Meades, Christopher; Mezna, Mokdad; Thomas, Mark; Wood, Gavin; Lane, David P.; Fischer, Peter M.
 CS Cyclacel Limited, Dundee, DD1 5JJ, UK
 SO Chemistry & Biology (2004), 11(4), 525-534
 CODEN: CBOLE2; ISSN: 1074-5521
 PB Cell Press
 DT Journal
 LA English
 AB A number of selective inhibitors of the CDK4/cyclin D1 complex have been reported recently. Due to the absence of an exptl. CDK4 structure, the ligand and protein determinants contributing to CDK4 selectivity are poorly understood at present. Here, we report the use of computational methods to elucidate the characteristics of selectivity and to derive the structural basis for specific, high-affinity binding of inhibitors to the CDK4 active site. From these data, the hypothesis emerged that appropriate incorporation of an ionizable function into a CDK2 inhibitor results in more favorable binding to CDK4. This knowledge was applied to the design of compds. in the otherwise CDK2-selective 2-anilino-4-(thiazol-5-yl)pyrimidine pharmacophore that are potent and highly selective ATP antagonists of CDK4/cyclin D1. The findings of this study also have significant implications in the design of CDK4 mimic structures based on CDK2.
 IT 693229-69-5P
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (PI; mol. modeling of CDK4 kinase inhibition and design of selective ATP competitive inhibitors)
 RN 693229-69-5 CAPLUS
 CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




IT 693228-63-6P 693228-65-8P 693228-73-8P
 693228-77-2P 693228-83-0P 693229-59-3P
 693229-61-7P 693229-65-1P 693230-49-8P
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (mol. modeling of CDK4 kinase inhibition and design of selective ATP competitive inhibitors)
 RN 693228-63-6 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-65-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 693228-73-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(1-piperazinyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 693228-77-2 CAPLUS

CN 1-Piperazineethanol, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693228-83-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-59-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-61-7 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 693229-65-1 CAPLUS


CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



10/809,944


RN 693230-49-8 CAPLUS

CN 1,4-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:102824 CAPLUS
 DN 140:270811
 TI 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR
 Analysis, X-ray Crystallography, and Biological Activity
 AU Wang, Shudong; Meades, Christopher; Wood, Gavin; Osnowski, Andrew;
 Anderson, Sian; Yuill, Rhoda; Thomas, Mark; Mezna, Mokdad; Jackson, Wayne;
 Midgley, Carol; Griffiths, Gary; Fleming, Ian; Green, Simon; McNae, Iain;
 Wu, Su-Ying; McInnes, Campbell; Zheleva, Daniella; Walkinshaw, Malcolm D.;
 Fischer, Peter M.
 CS Cyclacel Limited, Dundee, DD1 5JJ, UK
 SO Journal of Medicinal Chemistry (2004), 47(7), 1662-1675
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 140:270811
 AB Following the identification through virtual screening of
 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamines as moderately potent
 inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analog
 program was initiated. The first aims were to optimize potency and to
 evaluate the cellular mode of action of lead candidate mols. Here the
 synthetic chemical, the structure-guided design approach, and the
 structure-activity relationships (SARs) that led to the discovery of
 2-anilino-4-(thiazol-5-yl)pyrimidine ATP-antagonistic CDK2 inhibitors,
 many with very low nM Kis against CDK2, are reported. Furthermore, X-ray
 crystal structures of four representative analogs from our chemical series in
 complex with CDK2 are presented, and these structures are used to
 rationalize the observed biochem. SARs. Finally results are reported that
 show, using the most potent CDK2 inhibitor compound from the current series,
 that the observed antiproliferative and proapoptotic effects are consistent
 with cellular CDK2 and CDK9 inhibition.
 IT 364334-09-8DP, complex with CDK2 364334-30-5DP, complex
 with CDK2 364334-88-3DP, complex with CDK2 507487-89-ODP
 , complex with CDK2
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (crystal structure of)
 RN 364334-09-8 CAPLUS
 CN Phenol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA
 INDEX NAME)




RN 364334-30-5 CAPLUS
 CN Phenol, 4-[[4-[4-methyl-2-(methylanino)-5-thiazolyl]-2-pyrimidinyl]amino]-
 (9CI) (CA INDEX NAME)




RN 364334-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



IT 364333-75-5P, (2-Chlorophenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-76-6P, (4-Chlorophenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-77-7P, (3-Chlorophenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-82-4P 364333-83-5P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](4-nitrophenyl)amine 364333-88-0P 364333-89-1P 364333-94-8P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](3-trifluoromethylphenyl)amine 364333-95-9P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](2-trifluoromethylphenyl)amine 364333-96-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 364334-04-3P 364334-09-8P, 3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-10-1P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-16-7P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]benzene 1,3-diamine 364334-18-9P, 3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzonitrile 364334-30-5P, 4-[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-


ylamino]phenol 364334-44-1P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl] (3-nitrophenyl)amine 364334-45-2P, 3-[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-53-2P, [4-(2-Allylamino-4-methylthiazol-5-yl)pyrimidin-2-yl] (3-nitrophenyl)amine 364334-54-3P, 3-[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-83-8P, 4-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-88-3P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]N',N'-dimethylbenzene-1,4-diamine 507487-89-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl] (3-nitrophenyl)amine 507487-91-4P, N-[4-(2-Amino-4-methylthiazol-5-yl)-pyrimidin-2-yl]N',N'-dimethylbenzene-1,4-diamine 507488-13-3P 507488-14-4P 507488-42-8P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl] (3-nitrophenyl)amine 674333-60-9P 674333-61-0P 674333-62-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of 2-anilino-4-(thiazol-5-yl)pyrimidines as CDK inhibitors)


RN 364333-75-5 CAPLUS

CN 2-Pyrimidinamine, N-(2-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 364333-76-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 364333-77-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 364333-82-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI)
(CA INDEX NAME)




RN 364333-83-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-nitrophenyl)- (9CI)
(CA INDEX NAME)



RN 364333-88-0 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-fluorophenyl)- (9CI)
(CA INDEX NAME)



RN 364333-89-1 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)- (9CI)

(CA INDEX NAME)




RN 364333-94-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-95-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-96-0 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-04-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-fluorophenyl)- (9CI)
(CA INDEX NAME)

RN 364334-09-8 CAPLUS


CN Phenol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA
INDEX NAME)

RN 364334-10-1 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA
INDEX NAME)


RN 364334-16-7 CAPLUS

CN 1,3-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 364334-18-9 CAPLUS

CN Benzonitrile, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 364334-30-5 CAPLUS

CN Phenol, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)



RN 364334-44-1 CAPLUS


CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI)
(CA INDEX NAME)



RN 364334-45-2 CAPLUS


CN Phenol, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-

(9CI) (CA INDEX NAME)




RN 364334-53-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(2-propenylamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-54-3 CAPLUS

CN Phenol, 3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-83-8 CAPLUS

CN Phenol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507487-91-4 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-13-3 CAPLUS

CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl-2-nitro- (9CI) (CA INDEX NAME)




RN 507488-14-4 CAPLUS

CN 1,4-Benzenediamine, 2-chloro-N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-42-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 674333-60-9 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 674333-61-0 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-methylphenyl)- (9CI)

(CA INDEX NAME)



RN 674333-62-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(2-pyridinyl)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:282567 CAPLUS
 DN 138:304297
 TI Preparation of thiazolyl substituted aminopyrimidines as plant protection agents
 IN Mueller, Urs; Eberle, Martin; Pillonel, Christian; Lutz, William; Stanetty, Peter
 PA Syngenta Participations Ag, Switz.
 SO PCT Int. Appl., 128 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003029249	A1	20030410	WO 2002-IB3868	20020919
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2460160	AA	20030410	CA 2002-2460160	20020919
	EP 1434776	A1	20040707	EP 2002-800204	20020919
	EP 1434776	B1	20060628		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013010	A	20041005	BR 2002-13010	20020919
	US 2005038059	A1	20050217	US 2004-491231	20040924
PRAI	GB 2001-23589	A	20011001		
	WO 2002-IB3868	W	20020919		

OS MARPAT 138:304297


AB The title compds. [I; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, haloalkyl, etc.; NR1R2 = (un)substituted (un)saturated ring which may contain O or S as a ring member, or form N:CR9NR10R11; R3 = H, halo, alkyl; R4 = H, alkyl, haloalkyl, etc.; R5 = H, OH, halo, etc.; R6 = H, alkyl, haloalkyl; R7 = (un)substituted thienyl, pyridyl, aryl; R8 = H, alkyl, alkenyl, etc.; R9 = H, alkyl, haloalkyl, etc.; R10 = alkyl, haloalkyl, alkoxyalkyl, etc.; R11 = alkyl, cycloalkyl, aryl, etc.], useful as fungicides, were prepared. Thus, a multi-step synthesis of I [NR1R2 = N:C(Me)NMe2; R3-R6 = H; R7 = Ph; R8 = H], starting from 4-methyl-2-methylthiopyrimidine and Me benzoate, was given. The compds. I showed good activity in twelve different tests (biol. data given).

IT 509086-70-8P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of thiazolyl substituted aminopyrimidines as plant protection agents)

RN 509086-70-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-phenyl- (9CI) (CA INDEX NAME)




IT 509086-63-9P 509086-64-0P 509086-65-1P
 509086-66-2P 509086-67-3P 509086-68-4P
 509086-69-5P 509086-71-9P 509086-72-0P
 509086-73-1P 509086-74-2P 509086-75-3P
 509086-76-4P 509086-77-5P 509086-78-6P
 509086-79-7P 509086-80-0P 509086-81-1P
 509086-82-2P 509086-83-3P 509086-84-4P
 509086-85-5P 509086-86-6P 509086-87-7P
 509086-88-8P 509086-89-9P 509086-90-2P
 509086-91-3P 509086-92-4P 509086-93-5P
 509086-94-6P 509086-95-7P 509086-96-8P
 509086-97-9P 509086-98-0P 509086-99-1P
 509087-00-7P 509087-01-8P 509087-02-9P
 509087-03-0P 509087-04-1P 509087-05-2P
 509087-06-3P 509087-07-4P 509087-08-5P
 509087-09-6P 509087-11-0P 509087-12-1P
 509087-14-3P 509087-15-4P 509087-16-5P
 509087-17-6P 509087-18-7P 509087-19-8P
 509087-20-1P 509087-21-2P 509087-23-4P
 509087-24-5P 509087-25-6P 509087-26-7P
 509087-27-8P 509087-28-9P 509087-29-0P
 509087-30-3P 509087-32-5P 509087-43-8P
 509087-44-9P 509087-45-0P 509087-46-1P
 509087-47-2P 509087-48-3P 509087-80-3P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazolyl substituted aminopyrimidines as plant protection agents)


RN 509086-63-9 CAPLUS

CN Ethanimidamide, N,N-dimethyl-N'-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-64-0 CAPLUS

CN Acetamide, N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-65-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(3-methylbutyl)amino]-4-phenyl-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 509086-66-2 CAPLUS

CN 3-Butyn-2-ol, 4-[3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 509086-67-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3',4'-dimethoxy[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 509086-68-4 CAPLUS

CN Benzenemethanol, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-
 α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 509086-69-5 CAPLUS

CN Benzenemethanol, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-
 (9CI) (CA INDEX NAME)




RN 509086-71-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-chlorophenyl)-
 (9CI) (CA INDEX NAME)




RN 509086-72-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 509086-73-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 509086-74-2 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(4-methyl-1-piperazinyl)-4-phenyl-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 509086-75-3 CAPLUS


CN Benzonitrile, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-

(9CI) (CA INDEX NAME)




RN 509086-76-4 CAPLUS

CN Benzenemethanol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-α-methyl- (9CI) (CA INDEX NAME)




RN 509086-77-5 CAPLUS

CN Phenol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509086-78-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 509086-79-7 CAPLUS

CN Ethanone, 1-[3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509086-80-0 CAPLUS

CN Ethanone, 1-[3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)




RN 509086-81-1 CAPLUS

CN Benzenemethanol, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-alpha-methyl- (9CI) (CA INDEX NAME)




RN 509086-82-2 CAPLUS

CN 1(3H)-Isobenzofuranone, 6-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509086-83-3 CAPLUS

CN Ethanone, 1-[3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 509086-84-4 CAPLUS

CN Benzoic acid, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 509086-85-5 CAPLUS

CN Phenol, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 509086-86-6 CAPLUS

CN Phenol, 5-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)




RN 509086-87-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 509086-88-8 CAPLUS

CN Ethanone, 1-[3-[[4-[2-(ethylamino)-4-phenyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509086-89-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-phenyl-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 509086-90-2 CAPLUS

CN Acetamide, N-[5-[2-[(1,3-dihydro-3-oxo-5-isobenzofuranyl)amino]-4-pyrimidinyl]-4-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-91-3 CAPLUS


CN Propanamide, N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-92-4 CAPLUS
 CN Butanamide, 3-methyl-N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-93-5 CAPLUS
 CN Butanamide, N-[5-[2-[[3-(ethylamino)phenyl]amino]-4-pyrimidinyl]-4-phenyl-2-thiazolyl]-2,2,3,3,4,4,4-heptafluoro- (9CI) (CA INDEX NAME)



RN 509086-94-6 CAPLUS
 CN Propanamide, 2,2,3,3,3-pentafluoro-N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-95-7 CAPLUS
 CN Acetamide, 2,2,2-trifluoro-N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-96-8 CAPLUS

CN Ethanehydrazonamide, N,N-dimethyl-N'-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-97-9 CAPLUS

CN Methanehydrazonamide, N,N-dimethyl-N'-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 509086-98-0 CAPLUS


CN Cyclopropanecarboxamide, N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 509086-99-1 CAPLUS


CN Propanamide, 3-chloro-2,2-dimethyl-N-[4-phenyl-5-[2-(phenylamino)-4-

pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509087-00-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-morpholinyl)-4-phenyl-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 509087-01-8 CAPLUS

CN Benzonitrile, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-02-9 CAPLUS

CN Benzenemethanol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 509087-03-0 CAPLUS

CN Benzenemethanol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-04-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 509087-05-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 509087-06-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 509087-07-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 509087-08-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 509087-09-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-[3-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 509087-11-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 509087-12-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 509087-14-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(ethylamino)-4-(4-fluorophenyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509087-15-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[4-(4-fluorophenyl)-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509087-16-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-methoxyphenyl)-5-thiazolyl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 509087-17-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-methoxyphenyl)-5-thiazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 509087-18-7 CAPLUS

CN Benzonitrile, 3-[[4-[2-amino-4-(4-methoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-19-8 CAPLUS

CN Ethanone, 1-[3-[[4-[2-amino-4-(4-methoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509087-20-1 CAPLUS

CN Benzoic acid, 3-[[4-[2-amino-4-(4-methoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 509087-21-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-(4-methoxyphenyl)-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 509087-23-4 CAPLUS

CN Benzoic acid, 3-[[4-[2-amino-4-(4-methylphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 509087-24-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(3,4-dimethoxyphenyl)-5-thiazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 509087-25-6 CAPLUS

CN Benzonitrile, 3-[[4-[2-amino-4-(3,4-dimethoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-26-7 CAPLUS

CN Ethanone, 1-[3-[[4-[2-amino-4-(3,4-dimethoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509087-27-8 CAPLUS

CN Benzoic acid, 3-[[4-[2-amino-4-(3,4-dimethoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 509087-28-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(3-methylphenyl)-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 509087-29-0 CAPLUS

CN Benzonitrile, 3-[[4-[2-amino-4-(3-methylphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-30-3 CAPLUS

CN Ethanone, 1-[3-[[4-[2-amino-4-(3-methylphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509087-32-5 CAPLUS

CN Butanamide, 2,2,3,3,4,4,4-heptafluoro-N-[4-(3-methylphenyl)-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509087-43-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 509087-44-9 CAPLUS

CN Ethanone, 1-[3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509087-45-0 CAPLUS

CN Benzonitrile, 3-[[4-(2-amino-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-46-1 CAPLUS

CN Acetamide, N-[5-[2-[[3-[(acetyloxy)methyl]phenyl]amino]-4-pyrimidinyl]-4-(4-fluorophenyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509087-47-2 CAPLUS

CN Benzeneacetonitrile, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-48-3 CAPLUS

CN Benzeneacetonitrile, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 509087-80-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




IT 509087-34-7P 509087-38-1P 509087-39-2P
509087-40-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of thiazolyl substituted aminopyrimidines as plant protection
agents)


RN 509087-34-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-iodophenyl)- (9CI)
(CA INDEX NAME)




RN 509087-38-1 CAPLUS

CN Carbamic acid, [4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 509087-39-2 CAPLUS

CN Carbamic acid, [5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-4-phenyl-2-
thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 509087-40-5 CAPLUS

CN Carbamic acid, [5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-4-phenyl-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:282566 CAPLUS
 DN 138:304296
 TI Preparation of N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines
 as specific cyclin-dependent kinase inhibitors useful as antitumor agents
 IN Wang, Shudong; Meades, Christopher; Wood, Gavin; Osnowski, Andrew;
 Fischer, Peter Martin
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003029248	A1	20030410	WO 2002-GB4383	20020927
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2460909	AA	20030410	CA 2002-2460909	20020927
	EP 1430051	A1	20040623	EP 2002-762582	20020927
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012944	A	20041013	BR 2002-12944	20020927
	JP 2005508931	T2	20050407	JP 2003-532496	20020927
	CN 1617870	A	20050518	CN 2002-818729	20020927
	NZ 531596	A	20050826	NZ 2002-531596	20020927
	US 2004259894	A1	20041223	US 2004-810767	20040326
PRAI	GB 2001-23377	A	20010928		
	GB 2001-23629	A	20011002		
	WO 2002-GB4383	W	20020927		

AB The present invention relates to sixty-two 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compns. containing them

and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like. 72-H MTT in vitro cytotoxicity and CDK2/E and CDK4/D1 inhibition IC50 values are reported for most of the 62 claimed compds. Kinase specificity for N4-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]-N1,N1-dimethyl-2-nitrobenzene-1,4-diamine and 2-[N-(4-N,N-Dimethylamino-3-chlorophenyl)]-4-(2,4-dimethylthiazol-5-yl)pyrimidinamine was tested for 16 kinases. In vitro antiproliferative activity of [4-(2-amino-4-methylthiazol-5-yl)pyrimidin-2-yl] (3-iodophenyl)amine, 2-[4-[4-(2-amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]ethanol and [4-(2-amino-4-methylthiazol-5-yl)pyrimidin-2-yl] (3-bromophenyl)amine are tabulated for 26 cell lines. Although the methods of preparation are not claimed, 18 example preps. and characterization data for .apprx.60 compds. are included.

IT 364334-88-3P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N',N'-dimethylbenzene-1,4-diamine 507487-89-0P, [4-(2'-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl] (3-nitrophenyl)amine


507488-00-8P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of N-thiazolpyrimidinyl-N-phenylamines as specific cyclin-dependent kinase inhibitors useful as antitumor agents)


RN 364334-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 507488-00-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



IT 507487-91-4P, N-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]-N',N'-dimethylbenzene-1,4-diamine 507487-92-5P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-chlorophenyl)amine 507487-93-6P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-methoxyphenyl)amine 507487-94-7P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-fluorophenyl)amine 507487-95-8P,


[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 507487-96-9P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methoxyphenyl)amine 507487-97-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-chlorophenyl)amine 507487-98-1P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-iodophenyl)amine 507487-99-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-iodophenyl)amine 507488-01-9P, 3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenol 507488-02-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-iodo-3-nitrophenyl)amine 507488-03-1P, 2-[4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]ethanol 507488-04-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-bromophenyl)amine 507488-05-3P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-bromophenyl)amine 507488-06-4P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-chloro-3-trifluoromethylphenyl)amine 507488-08-6P 507488-09-7P, 2-[4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]ethanol 507488-10-0P, 2-[[4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl](ethyl)amino]ethanol 507488-11-1P, (3,4-Dimethoxyphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 507488-12-2P, 5-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-2-methoxyphenol 507488-13-3P, N4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N1,N1-dimethyl-2-nitrobenzene-1,4-diamine 507488-14-4P 507488-15-5P, N4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N1,N1-dimethyl-2-trifluoromethylbenzene-1,4-diamine 507488-16-6P, N1-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-4-methoxy-N3,N3-dimethylbenzene-1,3-diamine 507488-17-7P, N,N-Dimethyl-N'-[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]benzene-1,4-diamine 507488-18-8P, (4-Iodo-3-nitrophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 507488-19-9P, 4-[[4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenol 507488-21-3P, [4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-22-4P, (4-Iodophenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-23-5P, (4-Fluorophenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-24-6P, (4-Chlorophenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-25-7P, [4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methoxyphenyl)amine 507488-26-8P, 3-[[4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenol 507488-27-9P, (4-Fluoro-3-nitrophenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-28-0P, (4-Chloro-3-methylphenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-29-1P, (3-Iodo-4-methylphenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-30-4P, (4-Fluoro-3-methylphenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-31-5P, [4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methyl-3-nitrophenyl)amine 507488-32-6P, N-[4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]-N',N'-dimethylbenzene-1,4-diamine 507488-33-7P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-35-9P, (4-Chlorophenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-36-0P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 507488-37-1P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-methoxyphenyl)amine 507488-38-2P, (3-Chlorophenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-39-3P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methyl-3-

nitrophenyl)amine 507488-40-6P, [4-(2-Butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 507488-42-8P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-44-0P, (4-Chlorophenyl)[4-(2-dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-45-1P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 507488-46-2P, (3-Chlorophenyl)[4-(2-dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-47-3P, N-[4-Methyl-5-[2-(3-nitrophenylamino)pyrimidin-4-yl]thiazol-2-yl]methanesulfonamide 507488-48-4P, 2-[[4-Methyl-5-[2-(3-nitrophenylamino)pyrimidin-4-yl]thiazol-2-yl]amino]ethanol 507488-49-5P, 2-[[5-[2-(4-Fluorophenylamino)pyrimidin-4-yl]-4-methylthiazol-2-yl]amino]ethanol 507488-50-8P, 2-Chloro-N-[4-methyl-5-[2-(3-nitrophenylamino)pyrimidin-4-yl]thiazol-2-yl]acetamide 507488-51-9P, 2-Chloro-N-[5-[2-(4-fluorophenylamino)pyrimidin-4-yl]-4-methylthiazol-2-yl]acetamide 507488-52-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-nitrophenyl)amine 507488-53-1P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](phenyl)amine 507488-55-3P, 4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-thiazolpyrimidinyl-N-phenylamines as specific cyclin-dependent kinase inhibitors useful as antitumor agents)


RN 507487-91-4 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 507487-92-5 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 507487-93-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-methoxyphenyl)-

(9CI) (CA INDEX NAME)




RN 507487-94-7 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)

RN 507487-95-8 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507487-96-9 CAPLUS

CN 2-Pyrimidinamine,, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)


RN 507487-97-0 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-chlorophenyl)-
 (9CI) (CA INDEX NAME)




RN 507487-98-1 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-iodophenyl)- (9CI)
 (CA INDEX NAME)



RN 507487-99-2 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-iodophenyl)- (9CI)
 (CA INDEX NAME)




RN 507488-01-9 CAPLUS
 CN Phenol, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
 (CA INDEX NAME)




RN 507488-02-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-iodo-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-03-1 CAPLUS

CN Benzeneethanol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 507488-04-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-bromophenyl)- (9CI) (CA INDEX NAME)



RN 507488-05-3 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-bromophenyl)-

(9CI) (CA INDEX NAME)




RN 507488-06-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-chloro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507488-08-6 CAPLUS

CN 2-Pyrimidinamine, N-[4-(2-(diethylamino)ethoxy)phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-09-7 CAPLUS


CN Benzeneethanol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-10-0 CAPLUS
 CN Ethanol, 2-[[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 507488-11-1 CAPLUS
 CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)



RN 507488-12-2 CAPLUS
 CN Phenol, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)




RN 507488-13-3 CAPLUS
 CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl-2-nitro- (9CI) (CA INDEX NAME)




RN 507488-14-4 CAPLUS

CN 1,4-Benzenediamine, 2-chloro-N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-15-5 CAPLUS

CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 507488-16-6 CAPLUS


CN 1,3-Benzenediamine, N1-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-4-methoxy-N3,N3-dimethyl- (9CI) (CA INDEX NAME)



RN 507488-17-7 CAPLUS


CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[4-methyl-2-(methylamino)-5-

thiazolyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 507488-18-8 CAPLUS

CN 2-Pyrimidinamine, N-(4-iodo-3-nitrophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-19-9 CAPLUS

CN Phenol, 4-[[4-(2-methoxy-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-21-3 CAPLUS


CN 2-Pyrimidinamine, 4-(2-methoxy-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-22-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-iodophenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)

RN 507488-23-5 CAPLUS


CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)

RN 507488-24-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)


RN 507488-25-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methoxy-4-methyl-5-thiazolyl)-N-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 507488-26-8 CAPLUS

CN Phenol, 3-[[4-(2-methoxy-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 507488-27-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-3-nitrophenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)- (9CI) (CA INDEX NAME)



RN 507488-28-0 CAPLUS


CN 2-Pyrimidinamine, N-(4-chloro-3-methylphenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)- (9CI) (CA INDEX NAME)



RN 507488-29-1 CAPLUS


CN 2-Pyrimidinamine, N-(3-iodo-4-methylphenyl)-4-(2-methoxy-4-methyl-5-

thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-30-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-3-methylphenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-31-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methoxy-4-methyl-5-thiazolyl)-N-(4-methyl-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-32-6 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2-methoxy-4-methyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-33-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-35-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-36-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507488-37-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 507488-38-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-39-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-methyl-3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 507488-40-6 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(butylamino)-4-methyl-5-thiazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 507488-42-8 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-44-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[2-(dimethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-45-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 507488-46-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(dimethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-47-3 CAPLUS

CN Methanesulfonamide, N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-48-4 CAPLUS

CN Ethanol, 2-[[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-49-5 CAPLUS

CN Ethanol, 2-[[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-50-8 CAPLUS

CN Acetamide, 2-chloro-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-51-9 CAPLUS

CN Acetamide, 2-chloro-N-[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-52-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-53-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 507488-55-3 CAPLUS

CN Benzenesulfonic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:273687 CAPLUS
 DN 139:127415
 TI Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS
 Structural Basis for Ligand-Induced Disordering of the Activation Loop
 AU Wu, Su Ying; McNae, Iain; Kontopidis, George; McClue, Steven J.; McInnes,
 Campbell; Stewart, Kevin J.; Wang, Shudong; Zheleva, Daniella I.;
 Marriage, Howard; Lane, David P.; Taylor, Paul; Fischer, Peter M.;
 Walkinshaw, Malcolm D.
 CS Structural Biochemistry Group, The University of Edinburgh, Edinburgh, EH9
 3JR, UK
 SO Structure (Cambridge, MA, United States) (2003), 11(4), 399-410
 CODEN: STRUE6; ISSN: 0969-2126
 PB Cell Press
 DT Journal
 LA English
 OS CASREACT 139:127415
 AB A family of 4-heteroaryl-2-amino-pyrimidine CDK2 inhibitor lead compds.
 was discovered with the new database-mining program LIDAEUS through in
 silico screening. Four compds. with IC50 values ranging from 17 to 0.9
 µM were selected for x-ray crystal anal. Two distinct binding modes
 are observed, one of which resembles the hydrogen bonding pattern of bound
 ATP. In the second binding mode, the ligands trigger a conformational
 change in the activation T loop by inducing movement of Lys33 and Asp145
 side chains. The family of mols. discovered provides an excellent
 starting point for the design and synthesis of tight binding inhibitors,
 which may lead to a new class of antiproliferative drugs.
 IT 364333-96-0
 RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action);
 PRP (Properties); BIOL (Biological study)
 (CDK inhibitors discovery using LIDAEUS program detailing structural
 basis for ligand-induced disordering of activation loop)
 RN 364333-96-0 CAPLUS
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 364333-96-0D, complexed with CDK2
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (CDK inhibitors discovery using LIDAEUS program detailing structural
 basis for ligand-induced disordering of activation loop)
 RN 364333-96-0 CAPLUS
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:117808 CAPLUS
 DN 138:170248
 TI Preparation of 4-(thiazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors
 IN Fraley, Mark E.; Hoffman, William F.; Hartman, George D.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011838	A1	20030213	WO 2002-US23882	20020727
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004181066	A1	20040916	US 2004-485291	20040129
PRAI	US 2001-309407P	P	20010801		
	WO 2002-US23882	W	20020727		
OS	MARPAT 138:170248				
AB	<p>The present invention relates to title compds. I [wherein R1a = H, (un)substituted alkyl, OR8, or N(R8)2; R1 and R2 = independently H, halo, CF3, (CH2)tR9COR8, COR9, (CH2)tOR8, CN, (CH2)tNR7R8, (CH2)CONR7R8, CO2R8, (CH2)tSOO-2(CH2)tNR7R8, or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, alkenyl, or alkynyl; R3 = H, CN, halo, N(R8)2, OR8, or (un)substituted (ar)alkyl or aryl; R7 = H or (un)substituted (ar)alkyl; R8 = independently H or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or aralkyl; or NR7R8 = (un)substituted heterocyclyl; R9 = independently (un)substituted alkyl, heterocyclyl, or aryl; W = aryl or heterocyclyl; m = 0-2; n = independently 0-6; p = 0-4; t = independently 0-6; or pharmaceutically acceptable salts, hydrates, or stereoisomers thereof], which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions. For example, cyclization of 2-bromo-1-[2-(methylthio)pyrimidin-4-yl]ethanone (3-step preparation given) with thiourea in EtOH gave 5-bromo-4-[2-(methylthio)pyrimidin-4-yl]-1,3-thiazol-2-amine•HBr. Oxidation to the methylsulfinyl derivative using oxone followed by substitution with 3,5-dimethylaniline afforded II. In bioassays, I inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC values between 0.01 M and 5.0 M. Thus, I are useful for the treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals (no data).</p>				
IT	<p>496913-75-8P, 4-(2-Amino-5-bromo-1,3-thiazol-4-yl)-N-(3,5-dimethylphenyl)pyrimidin-2-amine 496913-80-5P, 4-(2-Amino-1,3-thiazol-4-yl)-N-(3,5-dimethylphenyl)pyrimidin-2-amine 496913-88-3P, 4-(2-Amino-5-phenyl-1,3-thiazol-4-yl)-N-(3,5-dimethylphenyl)pyrimidin-2-amine 496913-96-3P,</p>				

2-Amino-4-[2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl]-1,3-thiazole-5-carbonitrile 496914-06-8P, 4-[2-[(3,5-Dimethylphenyl)amino]pyrimidin-4-yl]-1,3-thiazole-5-carbonitrile
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tyrosine kinase inhibitor; preparation of (thiazolyl)pyrimidinamine tyrosine kinase inhibitors by reacting (methylsulfinyl)- or (methylsulfonyl) (thiazolyl)pyrimidines with amines)


RN 496913-75-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-5-bromo-4-thiazolyl)-N-(3,5-dimethylphenyl)-(9CI) (CA INDEX NAME)




RN 496913-80-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 496913-88-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-5-phenyl-4-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 496913-96-3 CAPLUS

CN 5-Thiazolecarbonitrile, 2-amino-4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 496914-06-8 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:927427 CAPLUS
 DN 138:14054
 TI Preparation of thiazole compounds as inhibitors of protein kinases
 IN Cochran, John; Nanthakumar, Suganthini; Harrington, Edmund; Wang, Jian
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096905	A1	20021205	WO 2002-US16352	20020523
	WO 2002096905	C1	20050728		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2446756	AA	20021205	CA 2002-2446756	20020523
	US 2003119856	A1	20030626	US 2002-154118	20020523
	US 6762179	B2	20040713		
	EP 1392684	A1	20040303	EP 2002-737123	20020523
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2006516110	T2	20060622	JP 2003-500084	20020523
	US 2005004152	A1	20050106	US 2004-891912	20040713
PRAI	US 2001-295158P	P	20010601		
	US 2002-154118	A3	20020523		
	WO 2002-US16352	W	20020523		
OS	MARPAT 138:14054				
AB	Thiazole compds. [I; wherein R1 = H, (substituted) (C1-C6)alkyl, CN, halogen, NO2, (substituted) (C1-C4)alkylidene; Ar1 = (substituted) 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially saturated, or aryl ring, 3-7 membered heterocyclic ring, 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring] were prepared For example, (II) was prepared in three steps from 2-acetylthiazole. These compds. are inhibitors of protein kinases, particularly inhibitors of GSK3, Aurora2, and Syk mammalian protein kinases. For example, compound II showed IC50 ≤ 0.5 μM against Syk mammalian protein kinase.				
IT	477769-08-7P	477769-09-8P	477769-10-1P		
	477769-11-2P	477769-12-3P	477769-13-4P		
	477769-14-5P	477769-15-6P	477769-16-7P		
	477769-17-8P	477769-18-9P	477769-19-0P		
	477769-20-3P	477769-21-4P	477769-22-5P		
	477769-23-6P	477769-24-7P	477769-25-8P		
	477769-26-9P	477769-27-0P	477769-28-1P		
	477769-29-2P	477769-30-5P	477769-31-6P		
	477769-33-8P	477769-34-9P	477769-35-0P		
	477769-36-1P	477769-37-2P	477769-38-3P		
	477769-39-4P	477769-40-7P	477769-41-8P		
	477769-42-9P	477769-43-0P	477769-44-1P		


477769-45-2P 477769-46-3P 477769-47-4P
 477769-48-5P 477769-49-6P 477769-50-9P
 477769-51-0P 477769-52-1P 477769-53-2P
 477769-54-3P 477769-55-4P 477769-56-5P
 477769-57-6P 477769-58-7P 477769-59-8P
 477769-60-1P 477769-61-2P 477769-62-3P
 477769-63-4P 477769-64-5P 477769-65-6P
 477769-66-7P 477769-67-8P 477769-68-9P
 477769-69-0P 477769-70-3P 477769-71-4P
 477769-72-5P 477769-73-6P 477769-74-7P
 477769-75-8P 477769-76-9P 477769-77-0P
 477769-78-1P 477769-79-2P 477769-80-5P
 477769-81-6P 477769-82-7P 477769-83-8P
 477769-84-9P 477769-85-0P 477769-86-1P
 477769-87-2P 477769-88-3P 477769-89-4P
 477769-90-7P 477769-91-8P 477769-92-9P
 477769-93-0P 477769-94-1P 477769-95-2P
 477769-96-3P 477769-97-4P 477769-98-5P
 477769-99-6P 477770-00-6P 477770-01-7P
 477770-02-8P 477770-03-9P 477770-04-0P
 477770-05-1P 477770-06-2P 477770-07-3P
 477770-08-4P 477770-09-5P 477770-10-8P
 477770-11-9P 477770-12-0P 477770-13-1P
 477770-14-2P 477770-15-3P 477770-16-4P
 477770-17-5P 477770-18-6P 477770-19-7P
 477770-20-0P 477770-21-1P 477770-22-2P
 477770-23-3P 477770-24-4P 477770-25-5P
 477770-26-6P 477770-27-7P 477770-28-8P
 477770-29-9P 477770-30-2P 477770-31-3P
 477770-32-4P 477770-33-5P 477770-34-6P
 477770-35-7P 477770-36-8P 477770-37-9P
 477770-38-0P 477770-39-1P 477770-40-4P
 477770-41-5P 477770-42-6P 477770-43-7P
 477770-44-8P 477770-45-9P 477770-46-0P
 477770-47-1P 477770-48-2P 477770-49-3P
 477770-50-6P 477770-51-7P 477770-52-8P
 477770-53-9P 477770-54-0P 477770-55-1P
 477770-56-2P 477770-57-3P 477770-58-4P
 477770-59-5P 477770-60-8P 477770-61-9P
 477770-62-0P 477770-63-1P 477770-64-2P
 477770-65-3P 477770-66-4P 477770-67-5P
 477770-68-6P 477770-69-7P 477770-70-0P
 477770-71-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of thiazole compds. as inhibitors of protein kinases)


RN 477769-08-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3,4-dichlorophenyl)methoxy]phenyl]-4-(2-
 thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-09-8 CAPLUS

CN 2-Pyrimidinamine, N-(2'-methoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 477769-10-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-phenoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-11-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-[[4-(methylsulfonyl)phenyl]methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-12-3 CAPLUS

CN 2-Pyrimidinamine, N-(2'-fluoro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 477769-13-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-(phenylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-14-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(4-pyridinylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-15-6 CAPLUS

CN 2-Pyrimidinamine, N-(4'-phenoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-16-7 CAPLUS

CN 2-Pyrimidinamine, N-[4-(phenylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-17-8 CAPLUS

CN Phenol, 3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477769-18-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 477769-19-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-phenoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-20-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3-aminophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-21-4 CAPLUS

CN 2-Pyrimidinamine, N-(3'-fluoro-5'-methoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-22-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-nitrophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-23-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-(1,3-benzodioxol-5-ylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-24-7 CAPLUS

CN 2-Pyrimidinamine, N-(2',4'-difluoro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-25-8 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-26-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-(2-pyridinylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)


RN 477769-27-0 CAPLUS

CN 2-Pyrimidinamine, N-(2',5'-dichloro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-28-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-29-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-pyridinylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)


RN 477769-30-5 CAPLUS

CN 2-Pyrimidinamine, N-(2',3'-dichloro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-31-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-33-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 477769-34-9 CAPLUS


CN 2-Pyrimidinamine, N-(6-chloro-2-pyridinyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 477769-35-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-pyrrol-1-yl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-36-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 477769-37-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-iodophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-38-3 CAPLUS

CN 2-Pyrimidinamine, N-(4'-ethoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-39-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-40-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-nitrophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-41-8 CAPLUS

CN 2-Pyrimidinamine, N-(2'-ethoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 477769-42-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)




RN 477769-43-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-aminophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-44-1 CAPLUS

CN 2-Pyrimidinamine, N-(2',5'-dimethyl[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-45-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-nitrophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-46-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-fluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-47-4 CAPLUS

CN 2-Pyrimidinamine, N-(3'-ethoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-48-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-49-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-methoxyphenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-50-9 CAPLUS

CN 2-Pyrimidinamine, N-[4'-(methanesulfonyl)[1,1'-biphenyl]-3-yl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-51-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-52-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 477769-53-2 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 3'--[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477769-54-3 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-55-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-pyridinyloxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-56-5 CAPLUS

CN 2-Pyrimidinamine, N-(2',6'-dimethoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-57-6 CAPLUS

CN 2-Pyrimidinamine, N-2-naphthalenyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-58-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-(2-pyridinyloxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-59-8 CAPLUS

CN 2-Pyrimidinamine, N-(2',5'-dimethoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-60-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477769-61-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-(4-pyridinyloxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-62-3 CAPLUS

CN [1,1'-Biphenyl]-3,3'-diamine, N-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477769-63-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 477769-64-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-nitrophenoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-65-6 CAPLUS

CN 2-Pyrimidinamine, N-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)


RN 477769-66-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,6-dichlorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-67-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-aminophenoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-68-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-pyridinyl)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-69-0 CAPLUS

CN 2-Pyrimidinamine, N-(2,6-difluorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477769-70-3 CAPLUS


CN 2-Pyrimidinamine, N-[6-(phenylthio)-2-pyridinyl]-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 477769-71-4 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 3'-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 477769-72-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-methylphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477769-73-6 CAPLUS


CN 2,6-Pyridinediamine, N-phenyl-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 477769-74-7 CAPLUS

CN [1,1'-Biphenyl]-2-ol, 3'-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 477769-75-8 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-76-9 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-N-(3-phenoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-77-0 CAPLUS


CN [1,1'-Biphenyl]-3-ol, 3'-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 477769-78-1 CAPLUS
 CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-79-2 CAPLUS
 CN 2-Pyrimidinamine, N-[1,1'-biphenyl]-3-yl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-80-5 CAPLUS
 CN [1,1'-Biphenyl]-4-ol, 2-methoxy-3'--[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 477769-81-6 CAPLUS
 CN 2-Pyrimidinamine, N-[3-(cyclohexylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-82-7 CAPLUS
 CN 2-Pyrimidinamine, N-[3-(1-naphthalenyl)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-83-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-(1H-indol-5-yl)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-84-9 CAPLUS

CN Benzonitrile, 3-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 477769-85-0 CAPLUS


CN 2-Pyrimidinamine, N-(6-phenyl-2-pyridinyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 477769-86-1 CAPLUS

CN [1,1'-Biphenyl]-3,4'-diamine, N4',N4'-dimethyl-N3-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477769-87-2 CAPLUS

CN Benzoic acid, 4-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]methyl]-2-methoxyphenyl]-2-methyl ester (9CI) (CA INDEX NAME)




RN 477769-88-3 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-N-[3-(phenylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-89-4 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 3'-[[5-methyl-4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477769-90-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3,4-difluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-91-8 CAPLUS

CN [1,1'-Biphenyl]-3-methanol, 3'-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 477769-92-9 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-N-[3-(3-pyridinyl)phenyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 477769-93-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-chlorophenyl)methoxy]phenyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 477769-94-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-(1,3-benzodioxol-5-yl)phenyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 477769-95-2 CAPLUS

CN [1,1'-Biphenyl]-3,3'-diamine, N-[5-methyl-4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477769-96-3 CAPLUS

CN 1,3-Benzenediamine, N-[(2,6-dichlorophenyl)methyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477769-97-4 CAPLUS

CN 2-Pyrimidinamine, N-[3'-(phenylmethoxy)[1,1'-biphenyl]-3-yl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-98-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy[1,1'-biphenyl]-3-yl)-5-methyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-99-6 CAPLUS

CN 1,3-Benzenediamine, N-[(2,6-difluorophenyl)methyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-00-6 CAPLUS

CN Ethanone, 1-[3'-[[4-(2-thiazolyl)-2-pyrimidinyl]amino][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)




RN 477770-01-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-02-8 CAPLUS

CN 1,3-Benzenediamine, N-(3-nitrophenyl)-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-03-9 CAPLUS

CN 2-Pyrimidinamine, N-(3'-fluoro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 477770-04-0 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-4-(2-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 477770-05-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3-fluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-06-2 CAPLUS

CN [1,1'-Biphenyl]-4-methanol, 3'--[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477770-07-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3,5-difluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-08-4 CAPLUS

CN 2-Pyrimidinamine, N-(3',4'-dimethyl[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-09-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-fluorophenoxy)-4-methoxyphenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-10-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-11-9 CAPLUS

CN 2-Pyrimidinamine, N-(4'-fluoro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-12-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-chlorophenoxy)-4-methoxyphenyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 477770-13-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(4-fluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 477770-14-2 CAPLUS

CN 2-Pyrimidinamine, N-(4'-chloro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 477770-15-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-(4-chlorophenoxy)-4-methoxyphenyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 477770-16-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2,3-dichlorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-17-5 CAPLUS

CN 2-Pyrimidinamine, N-(4'-methoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-18-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxy-5-phenoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-19-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-methylphenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-20-0 CAPLUS

CN 2-Pyrimidinamine, N-(4'-methyl[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)


RN 477770-21-1 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxy-5-phenoxyphenyl)-5-methyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477770-22-2 CAPLUS


CN 4-Piperidinemethanol, 1-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 477770-23-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477770-24-4 CAPLUS

CN 1-Piperazineethanol, 4-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 477770-25-5 CAPLUS

CN 3-Piperidinol, 1-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 477770-26-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(4-morpholinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-27-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-[3-(4-thiomorpholinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 477770-28-8 CAPLUS


CN 4-Piperidinemethanol, 1-[3-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 477770-29-9 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477770-30-2 CAPLUS

CN 4-Piperidinol, 1-[3-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 477770-31-3 CAPLUS

CN 1-Butanone, 4-[4-(hydroxymethyl)-1-piperidinyl]-1-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-32-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(3-amino-1-piperidinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-33-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(4-ethyl-1-piperazinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-34-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(1-piperazinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-35-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-[4-(4-pyridinylmethyl)-1-piperazinyl]propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-36-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(1-pyrrolidinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-37-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(1H-imidazol-1-yl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-38-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(4-methyl-1H-imidazol-1-yl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-39-1 CAPLUS

CN 1,3-Benzenediamine, N-[3-(4-morpholinyl)propyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-40-4 CAPLUS

CN Butanamide, 4-(dimethylamino)-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-41-5 CAPLUS


CN 1-Piperidinebutanamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 477770-42-6 CAPLUS


CN 4-Morpholineacetamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

RN 477770-43-7 CAPLUS

CN 1-Piperazinebutanamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)


RN 477770-44-8 CAPLUS

CN 1-Piperidinebutanamide, 4-(hydroxymethyl)-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 477770-45-9 CAPLUS


CN 1H-Pyrrole-1-butanamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 477770-46-0 CAPLUS


CN 1-Piperazinebutanamide, 4-(2-hydroxyethyl)-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-47-1 CAPLUS

CN Acetamide, 2-[(2-hydroxyethyl)amino]-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-48-2 CAPLUS

CN Acetamide, 2-[(3-hydroxypropyl)amino]-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-49-3 CAPLUS

CN Carbamic acid, [3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 477770-50-6 CAPLUS

CN Carbamic acid, [3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, (tetrahydro-2-furanyl)methyl ester (9CI) (CA INDEX NAME)




RN 477770-51-7 CAPLUS

CN Carbamic acid, [3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, (tetrahydro-2H-pyran-2-yl)methyl ester (9CI) (CA INDEX NAME)




RN 477770-52-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-53-9 CAPLUS

CN Ethanol, 2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 477770-54-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-55-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-56-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1-piperidinyl)ethoxy]phenyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 477770-57-3 CAPLUS

CN 4-Piperidinol, 1-[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]-
(9CI) (CA INDEX NAME)



RN 477770-58-4 CAPLUS


CN 4-Piperidinol, 1-[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 477770-59-5 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477770-60-8 CAPLUS

CN 1-Piperazineethanol, 4-[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 477770-61-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1-piperazinyl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-62-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(3-piperidinyloxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-63-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(dimethylamino)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-64-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-65-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(diethylamino)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-66-4 CAPLUS

CN Ethanol, 2-[methyl[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 477770-67-5 CAPLUS


CN 2-Pyrimidinamine, N-[3-[3-[(2-methoxyethyl)amino]propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477770-68-6 CAPLUS


CN 1,3-Benzenediamine, N-[2-[(2-methoxyethyl)amino]ethyl]-N'-[4-(2-thiazolyl)-

2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-69-7 CAPLUS

CN 1,3-Benzenediamine, N-[2-(diethylamino)ethyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-70-0 CAPLUS

CN Ethanol, 2-[methyl[2-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 477770-71-1 CAPLUS


CN 1-Piperazineethanol, 4-[2-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:641097 CAPLUS
 DN 138:122613
 TI Structure-Activity Relationship Studies of Ethyl 2-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF- κ B Mediated Gene Expression
 AU Palanki, Moorthy S. S.; Gayo-Fung, Leah M.; Shevlin, Graziella I.; Erdman, Paul; Sato, Mark; Goldman, Mark; Ransone, Lynn J.; Spooner, Cheryl
 CS Celgene Signal Research Division, San Diego, CA, 92121, USA
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(18), 2573-2577
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 138:122613
 AB Several analogs of Et 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate (I) were synthesized and tested as inhibitors of AP-1 and NF- κ B mediated transcriptional activation in Jurkat T cells. From our SAR work, Et 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))-N-methylamino]-4-(trifluoromethyl)-pyrimidine-5-carboxylate was identified as a novel and potent inhibitor.
 IT 188936-89-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn of pyrrolinylaminopyrimidine analogs from β -keto esters and their activity as inhibitors of AP-1 and NF- κ B mediated gene expression)
 RN 188936-89-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 2-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl)amino]-4-(2-thiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:730738 CAPLUS
 DN 135:288789
 TI 2-Substituted 4-heteroaryl-pyrimidines with activity as inhibitors of cyclin-dependent kinases and their preparation and use in the treatment of proliferative disorders
 IN Fischer, Peter Martin; Wang, Shudong
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072745	A1	20011004	WO 2001-GB1423	20010328
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2401748	AA	20011004	CA 2001-2401748	20010328
	GB 2361236	A1	20011017	GB 2001-7758	20010328
	GB 2361236	B2	20020424		
	EP 1274705	A1	20030115	EP 2001-915544	20010328
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003528872	T2	20030930	JP 2001-570655	20010328
	NZ 521068	A	20050429	NZ 2001-521068	20010328
	US 2002019404	A1	20020214	US 2001-823075	20010329
	US 6531479	B2	20030311		
	US 2003149057	A1	20030807	US 2002-327540	20021220
	US 6699854	B2	20040302		
PRAI	GB 2000-7636	A	20000329		
	GB 2000-15117	A	20000620		
	WO 2001-GB1423	W	20010328		
	US 2001-823075	A3	20010329		

OS MARPAT 135:288789

AB The invention relates to 2-substituted 4-heteroaryl-pyrimidines I and their pharmaceutically acceptable salts [wherein: X1 = CH and X2 = S; or 1 of X1 and X2 = S and the other = N; Z = NH, NHCO, NHSO2, NHCH2, CH2, CH2CH2, or CH:CH; R1, R2, R3 = H, alkyl, aryl, aralkyl, heterocyclyl, halo, NO2, cyano, OH, alkoxy, aryloxy, NH2, NHR', N(R')(R''), NHCOR', NH(aryl), N(aryl)2, COOH, COOR', COO(aryl), CONH2, CONHR', CON(R')(R''), CONH(aryl), CON(aryl)2, SO3H, SO2NH2, CF3, COR', or CO(aryl), wherein alkyl, aryl, aralkyl, heterocyclyl, and NH(aryl) groups may be further substituted with 1 or more halo, NO2, cyano, OH, OMe, NH2, COOH, CONH2, and/or CF3; at least 1 of R1 and R2 ≠ H when either X1 or X2 = S; R4, R5, R6, R7, R8 = H, (un)substituted alkyl, halo, NO2, cyano, OH, (un)substituted alkoxy, NH2, NHR', alkyl-aryl, alkyl-heteroaryl, NH(C:NH)NH2, N(R')3+, N(R')(R''), COOH, COOR', CONH2, CONHR', CON(R')(R''), SO3H, SO2NH2, CF3, or (CH2)nO(CH2)mNR'R'', (CH2)nCO2(CH2)mOR''' wherein n = 0, 1, 2, or 3; m = 1, 2 or 3; R', R'', R''' = alkyl]. The invention also relates to preparation of I, pharmaceutical

compns. containing them, and their use as inhibitors of cyclin-dependant kinases (CDKs), and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like. Examples include 22 syntheses and a variety of bioassays. For instance, 4-FC6H4NH₂ was treated with HNO₃ and cyanamide in EtOH to give 47% 4-FC6H4NHC(:NH)NH₂.HNO₃ (II). Sep., 5-acetyl-2,4-dimethylthiazole was condensed with N,N-dimethylformamide di-Me acetal to give 79% 3-dimethylamino-1-(2,4-dimethylthiazol-5-yl)propenone (III). Cyclocondensation of II with III in refluxing MeOCH₂CH₂OH in the presence of NaOH gave title compound IV in 89% yield. In an assay against multiple kinases, IV selectively inhibited CDKs, showing an IC₅₀ of 0.019 μ M against CDK2/cyclin E, and 0.47 μ M against CDK4/cyclin D1, vs. >20 μ M against PCK α and SAPK2 α . Addnl. bioassays of I showed antiproliferative and cytotoxic activity.


IT 364333-82-4P 364334-16-7P 364334-85-0P
364334-88-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of heteroarylpyrimidines as CDK-inhibiting antiproliferative and anticancer agents)

RN 364333-82-4 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI)
(CA INDEX NAME)



2 D'45


RN 364334-16-7 CAPLUS

CN 1,3-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 364334-85-0 CAPLUS

CN Benzenemethanol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 364334-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 364333-75-5P 364333-76-6P 364333-77-7P
 364333-81-3P 364333-83-5P 364333-88-0P
 364333-89-1P 364333-90-4P 364333-91-5P
 364333-92-6P 364333-93-7P 364333-94-8P
 364333-95-9P 364333-96-0P 364333-97-1P
 364333-98-2P 364333-99-3P 364334-00-9P
 364334-01-0P 364334-02-1P 364334-03-2P
 364334-04-3P 364334-05-4P 364334-06-5P
 364334-07-6P 364334-08-7P 364334-09-8P
 364334-10-1P 364334-14-5P 364334-17-8P
 364334-18-9P 364334-19-0P 364334-20-3P
 364334-21-4P 364334-22-5P 364334-23-6P
 364334-24-7P 364334-25-8P 364334-26-9P
 364334-27-0P 364334-28-1P 364334-29-2P
 364334-30-5P 364334-31-6P 364334-32-7P
 364334-33-8P 364334-34-9P 364334-35-0P
 364334-36-1P 364334-37-2P 364334-38-3P
 364334-39-4P 364334-41-8P 364334-42-9P
 364334-43-0P 364334-44-1P 364334-45-2P
 364334-46-3P 364334-47-4P 364334-48-5P
 364334-49-6P 364334-51-0P 364334-52-1P
 364334-53-2P 364334-54-3P 364334-55-4P
 364334-56-5P 364334-57-6P 364334-58-7P
 364334-59-8P 364334-60-1P 364334-61-2P
 364334-62-3P 364334-63-4P 364334-64-5P
 364334-66-7P 364334-67-8P 364334-68-9P
 364334-69-0P 364334-70-3P 364334-71-4P
 364334-72-5P 364334-73-6P 364334-74-7P
 364334-75-8P 364334-76-9P 364334-77-0P
 364334-78-1P 364334-79-2P 364334-80-5P
 364334-81-6P 364334-82-7P 364334-83-8P
 364334-84-9P 364334-86-1P 364334-87-2P


364334-89-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroarylpyrimidines as CDK-inhibiting antiproliferative and anticancer agents)


RN 364333-75-5 CAPLUS

CN 2-Pyrimidinamine, N-(2-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 364333-76-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 364333-77-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
(CA INDEX NAME)




RN 364333-81-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-nitrophenyl)- (9CI)
(CA INDEX NAME)




RN 364333-83-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-nitrophenyl)- (9CI)
(CA INDEX NAME)




RN 364333-88-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-fluorophenyl)- (9CI)
(CA INDEX NAME)



RN 364333-89-1 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 364333-90-4 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-


(9CI) (CA INDEX NAME)



RN 364333-91-5 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)

RN 364333-92-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dichlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)


RN 364333-93-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-dichlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 364333-94-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-95-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-96-0 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-97-1 CAPLUS
 CN 2-Pyrimidinamine, N-(2-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
 (CA INDEX NAME)




RN 364333-98-2 CAPLUS
 CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
 (CA INDEX NAME)



RN 364333-99-3 CAPLUS
 CN 2-Pyrimidinamine, N-(4-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)
 (CA INDEX NAME)




RN 364334-00-9 CAPLUS
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-iodophenyl)- (9CI)
 (CA INDEX NAME)




RN 364334-01-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-iodophenyl)- (9CI)
(CA INDEX NAME)




RN 364334-02-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-iodophenyl)- (9CI)
(CA INDEX NAME)



RN 364334-03-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-2-pyridinyl- (9CI) (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 364334-04-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 364334-05-4 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 364334-06-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 364334-07-6 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 364334-08-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-methoxyphenyl)- (9CI)
(CA INDEX NAME)

RN 364334-09-8 CAPLUS


CN Phenol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA
INDEX NAME)

RN 364334-10-1 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA
INDEX NAME)


RN 364334-14-5 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-nitro-
(9CI) (CA INDEX NAME)




RN 364334-17-8 CAPLUS

CN Benzonitrile, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 364334-18-9 CAPLUS

CN Benzonitrile, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME).



RN 364334-19-0 CAPLUS


CN Benzoic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-,
methyl ester (9CI) (CA INDEX NAME)



RN 364334-20-3 CAPLUS


CN 2-Pyrimidinamine, N-(3-chloro-4-methylphenyl)-4-(2,4-dimethyl-5-thiazolyl)-

(9CI) (CA INDEX NAME)




RN 364334-21-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 364334-22-5 CAPLUS

CN Benzoic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-23-6 CAPLUS


CN 2-Pyrimidinamine, 4-bromo-6-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-24-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)-6-phenyl-
(9CI) (CA INDEX NAME)

RN 364334-25-8 CAPLUS


CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-6-phenyl-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)

RN 364334-26-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(4-methyl-2-phenyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)


RN 364334-27-0 CAPLUS

CN Phenol, 4-[[4-(4-methyl-2-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 364334-28-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-phenyl-
(9CI) (CA INDEX NAME)




RN 364334-29-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(methylamino)-5-
thiazolyl]- (9CI) (CA INDEX NAME)



RN 364334-30-5 CAPLUS


CN Phenol, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)



RN 364334-31-6 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[4-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-32-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-33-8 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-6-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)




RN 364334-34-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-(9CI) (CA INDEX NAME)




RN 364334-35-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)




RN 364334-36-1 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2,6-dimethoxy-(9CI) (CA INDEX NAME)




RN 364334-37-2 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 364334-38-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-39-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-iodophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-41-8 CAPLUS

CN Phenol, 4-[[4-[4-methyl-2-(methyamino)-5-thiazolyl]-2-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)




RN 364334-42-9 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-[4-methyl-2-(methyamino)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-43-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 364334-44-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methyamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-45-2 CAPLUS

CN Phenol, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-46-3 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-47-4 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-48-5 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-49-6 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-51-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(2-propenylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-52-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-[4-methyl-2-(methylenamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-53-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(2-propenylamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 364334-54-3 CAPLUS


CN Phenol, 3-[[4-[4-methyl-2-(methylenamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 364334-55-4 CAPLUS


CN 2-Pyrimidinamine, N-(4-bromophenyl)-4-[4-methyl-2-(methylenamino)-5-

thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-56-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[4-methyl-2-(methyamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-57-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[4-methyl-2-(methyamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-58-7 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methyamino)-5-thiazolyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-59-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-60-1 CAPLUS

CN Benzoic acid, 2-chloro-5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-61-2 CAPLUS

CN Benzoic acid, 3-chloro-2-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-62-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-fluoro-4-iodophenyl)- (9CI) (CA INDEX NAME)




RN 364334-63-4 CAPLUS

CN Phenol, 2-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-5-methoxy-(9CI) (CA INDEX NAME)




RN 364334-64-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-iodophenyl)-4-(2,4-dimethyl-5-thiazolyl)-(9CI) (CA INDEX NAME)




RN 364334-66-7 CAPLUS

CN Phenol, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-5-methoxy-(9CI) (CA INDEX NAME)




RN 364334-67-8 CAPLUS

CN Benzoic acid, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-fluoro-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-68-9 CAPLUS

CN Benzoic acid, 2-chloro-5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-69-0 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-70-3 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-71-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-iodophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-72-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-73-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-74-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-75-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-76-9 CAPLUS


CN 2-Pyrimidinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-77-0 CAPLUS
 CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-78-1 CAPLUS
 CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 364334-79-2 CAPLUS
 CN 2-Pyrimidinamine, N-(4-fluoro-3-nitrophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-80-5 CAPLUS
 CN Phenol, 4-[[4-[2-[(4-nitrophenyl)amino]-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-81-6 CAPLUS

CN Acetamide, N-[5-[2-[(4-hydroxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-82-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[2-[(4-nitrophenyl)amino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-83-8 CAPLUS

CN Phenol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-84-9 CAPLUS

CN Guanidine, [3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)


RN 364334-86-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-87-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-[[2-(diethylamino)ethoxy]methyl]phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)



RN 364334-89-4 CAPLUS

CN Benzenaminium, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N,N,N-trimethyl- (9CI) (CA INDEX NAME)



RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:911230 CAPLUS
 DN 134:71598
 TI Preparation of 2-arylamino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFR kinase.
 IN Batchelor, Mark James; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 PA Celltech Chiroscience Limited, UK
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000078731	A1	20001228	WO 2000-GB2382	20000619
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6579983	B1	20030617	US 2000-596952	20000616
	CA 2375182	AA	20001228	CA 2000-2375182	20000619
	BR 2000011770	A	20020305	BR 2000-11770	20000619
	EP 1187816	A1	20020320	EP 2000-940569	20000619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	DE 10084704	T	20020529	DE 2000-10084704	20000619
	GB 2369360	A1	20020529	GB 2001-30563	20000619
	JP 2003502406	T2	20030121	JP 2001-504897	20000619
	ES 2188429	A1	20030616	ES 2001-50085	20000619
	ES 2188429	B2	20050616		
	AU 778533	B2	20041209	AU 2000-55488	20000619
	BG 106116	A	20020731	BG 2001-106116	20011119
	ZA 2001009841	A	20020429	ZA 2001-9841	20011129
	NO 2001006162	A	20020218	NO 2001-6162	20011217
	US 2002147339	A1	20021010	US 2002-151518	20020520
	HK 1048815	A1	20050429	HK 2003-101022	20030212
	US 2004180914	A1	20040916	US 2004-812293	20040329
PRAI	GB 1999-14258	A	19990618		
	US 2000-596952	A1	20000616		
	WO 2000-GB2382	W	20000619		
	US 2002-151518	B1	20020520		
OS	MARPAT 134:71598				
AB	Title compds. [I; Ar = (substituted) aryl, heteroaryl; R1 = H, alkyl; R2 = X1R3; X1 = bond, linker atom or group; R3 = (substituted) aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom. group] and the salts, solvates, hydrates and N-oxides thereof, were prepared Thus, 3,4,5-trimethoxyphenylguanidinium nitrate (preparation given), 1-phenyl-2-cyano-3-dimethylaminopropen-1-one, and NaOH were refluxed in EtOH to give 5-cyano-4-phenyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine. I inhibited KDR kinase and FGFR kinase with IC50 ≤1 μM.				
IT	314268-96-7P 314268-97-8P 314268-98-9P 314268-99-0P 314269-00-6P 314269-01-7P				

314269-02-8P 314269-03-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-arylamino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFr kinase)


RN 314268-96-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(2-thiazolyl)-2-[(3,4,5-trimethoxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 314268-97-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(2-thiazolyl)-2-[[4-(1H-1,2,4-triazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 314268-98-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3,4-dimethoxyphenyl)amino]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 314268-99-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(2-thiazolyl)-2-[[4-[2-(1H-1,2,4-triazol-1-yl)ethoxy]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 314269-00-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(2-thiazolyl)-2-[[4-[2-(1H-1,2,3-triazol-1-

yl)ethoxy]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 314269-01-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(2-thiazolyl)-2-[[4-[2-(2H-1,2,3-triazol-2-yl)ethoxy]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 314269-02-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 314269-03-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(4-fluorophenyl)amino]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:505664 CAPLUS
 DN 131:144609
 TI Preparation of pyrimidinecarboxylates and analogs as transcription factor activation inhibitors
 IN Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy S. S.; Ransone-Fong, Lynn J.
 PA Signal Pharmaceuticals, Inc., USA
 SO U.S., 32 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5935966	A	19990810	US 1997-807677	19970227
	US 5852028	A	19981222	US 1995-574406	19951218
	WO 9709325	A1	19970313	WO 1996-US14089	19960830
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	WO 9838171	A1	19980903	WO 1998-US3616	19980224
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9866667	A1	19980918	AU 1998-66667	19980224
PRAI	US 1995-3109P	P	19950901		
	US 1995-574406	A2	19951218		
	WO 1996-US14089	W	19960830		
	US 1997-807677	A	19970227		
	WO 1998-US3616	W	19980224		

OS MARPAT 131:144609


AB Title compds. [I; 1 of R2,R4 = NRR9 and the other = H, halo, alkyl, aryl, etc.; R = (un)substituted phthalimido, -maleimido, etc.; R5 = CO2R7, COR8, 4-methyl-2-oxazolyl, etc.; R6 = H, F, Me, CF3, CH2Ph; R7 = H, (ar)alkyl, aryl, etc.; R8 = (ar)alkyl, aryl, etc.; R9 = (ar)alkyl, CO2R7, etc.; Z = bond, O, NH] were prepared Thus, EtCOCH2CO2Et was condensed with (H2N)2CO/HC(OEt)3 and the product cyclized to give, in 2 addnl. steps, I (R4 = Et, R5 = CO2Et, R6 = H) (II; R2 = NHNH2) which was cyclocondensed with citraconic anhydride to give II [R2 = (methylmaleimido)amino]. Data for biol. activity of I were given.

IT 188936-89-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidinecarboxylates and analogs as transcription factor activation inhibitors)

RN 188936-89-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl)amino]-4-(2-thiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)




2 D₄

RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:608604 CAPLUS
 DN 129:216625
 TI Preparation of pyrimidinecarboxylates for treating inflammatory conditions
 IN Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy S. S.; Ransone-Fong, Lynn J.
 PA Signal Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9838171	A1	19980903	WO 1998-US3616	19980224
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5935966	A	19990810	US 1997-807677	19970227
	AU 9866667	A1	19980918	AU 1998-66667	19980224
PRAI	US 1997-807677	A	19970227		
	US 1995-3109P	P	19950901		
	US 1995-574406	A2	19951218		
	WO 1996-US14089	W	19960830		
	WO 1998-US3616	W	19980224		
OS	MARPAT 129:216625				
AB	The title compds. [I; R2 = R2a when R4 = R4a, and R2 = R2b when R4 = R4b; R2b, R4a = H, halo, C1-8 alkyl, etc.; R2a, R4b = II-V; R5 = CO2R7, C(O)R8, etc.; R6 = H, Me, PhCH2, F, CF3; R7 = H, C1-8 alkyl, etc.; R8 = (un)substituted C1-8 alkyl, C6-12 aryl, C7-12 aralkyl; R9 = H, C1-8 alkyl, etc.; R10, R11 = H, (un)substituted C1-8 alkyl, C6-12 aryl], useful as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases such as rheumatoid arthritis, osteoarthritis, transplant rejection, sepsis, ARDS, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease, glomerulonephritis, lupus, uveitis, chronic hepatitis, trauma, oxidative stress, cell death, irradiation damage, ischemia, reperfusion, cancer, and viral infection, were prepared Thus, reaction of Et 2-hydrazino-4-trifluoromethylpyrimidine-5-carboxylate with citraconic anhydride in CHCl3 afforded 39% I [R2 = III (R9 = R11 = H; R10 = Me); R4 = CF3; R5 = H; R6 = CO2Et] which showed IC50 of 0.7 μ M against activation of transcription factors NF κ B and AP-1.				
IT	188936-89-2P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidinecarboxylates for treating inflammatory conditions)				
RN	188936-89-2 CAPLUS				
CN	5-Pyrimidinecarboxylic acid, 2-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl)amino]-4-(2-thiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)				



25-66

RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:457074 CAPLUS
 DN 127:81461
 TI Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors
 IN Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 PA Celltech Therapeutics Limited, UK; Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9719065	A1	19970529	WO 1996-GB2854	19961120
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5958935	A	19990928	US 1996-753041	19961119
	AU 9676314	A1	19970611	AU 1996-76314	19961120
	EP 862560	A1	19980909	EP 1996-939171	19961120
	EP 862560	B1	20030402		
	R: CH, DE, ES, FR, GB, IT, LI				
	ES 2195020	T3	20031201	ES 1996-939171	19961120
	US 6235746	B1	20010522	US 1999-249760	19990216
PRAI	GB 1995-23675	A	19951120		
	US 1996-753041	A3	19961119		
	WO 1996-GB2854	W	19961120		

OS MARPAT 127:81461

AB The title compds. [I; R1 = H, halo, (un)substituted alkyl, etc.; R2, R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = H, alkyl; R5 = H, (un)substituted alkyl, alkenyl, alkynyl; R6 = H, halo, (un)substituted NH2, etc.; X = a direct bond, a linker atom, group; R7 = (un)substituted aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom.


group], selective protein kinase inhibitors, particularly the kinases p56lck, p59fyn, ZAP-70 and protein kinase C, and useful in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role, were prepared Thus, treatment of 4-[3-(3-phthalimidopropoxy)phenyl]-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine with N2H4.H2O in EtOH afforded I.2HCl [R1 = MeO; R2, R3 = Me; R4-R6 = H; R7 = H2N(CH2)3; X = O] which showed IC50 of 22 nM in the protein kinase assay.

IT 191727-12-5P 191727-26-1P 191727-35-2P
 191727-40-9P 191727-46-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors)


RN 191727-12-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 191727-26-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-benzothiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 191727-35-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-thiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 191727-40-9 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 191727-46-5 CAPLUS

CN 5-Thiazoleethanol, 4-methyl-2-[2-[(3,4,5-trimethoxyphenyl)amino]-4-

10/809,944

pyrimidinyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:302930 CAPLUS
 DN 126:277492
 TI Preparation of pyrimidinecarboxylates and related compounds for treating inflammatory conditions
 IN Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy S. S.; Ransone-Fong, Lynn J.
 PA Signal Pharmaceuticals, Inc., USA; Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy, S. S.; Ransone-Fong, Lynn J.
 SO PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9709325	A1	19970313	WO 1996-US14089	19960830
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	US 5852028	A	19981222	US 1995-574406	19951218
	CA 2230896	AA	19970313	CA 1996-2230896	19960830
	AU 9670130	A1	19970327	AU 1996-70130	19960830
	AU 726058	B2	20001026		
	JP 11512390	T2	19991026	JP 1996-511324	19960830
	US 5935966	A	19990810	US 1997-807677	19970227
PRAI	US 1995-3109P	P	19950901		
	US 1995-574406	A	19951218		
	WO 1996-US14089	W	19960830		

OS MARPAT 126:277492

AB The title compds. [I; R2 = R2a when R4 = R4a, and R2 = R2b when R4 = R4b; R2b, R4a = H, halo, (un)substituted C1-8 alkyl, etc.; R2a, R4b = II, III, N(R9)NHC(O)R10, N(R9)NHC(O)C(R10):CHR11 (wherein R9 = H, (un)substituted C1-8 alkyl, etc.; R10, R11 = H, (un)substituted C1-8 alkyl, C6-12; n = 0-4; A = halo, OH, COOH, etc.); R5 = C(O)OR7, C(O)R8 (wherein R7 = H, (un)substituted C1-8 alkyl, etc.; R8 = (un)substituted C1-8 alkyl, C6-12 aryl, C7-12 aralkyl), etc.; R6 = H, Me, F, etc.], anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases such as rheumatoid arthritis, osteoarthritis, transplant rejection, sepsis, ARDS, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease, glomerulonephritis, lupus, uveitis, chronic hepatitis, trauma, oxidative stress, ischemia, reperfusion, cancer and viral infection, were prepared. Thus, refluxing of Et 2-hydrazino-4-trifluoromethylpyrimidine with citraconic anhydride in CHCl3 afforded IV which showed IC50 of 0.7 μ M against transcription factors NF κ B and AP-1.

IT 188936-89-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrimidinecarboxylates and related compds. for treating inflammatory conditions)

RN 188936-89-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-


10/809,944

1-yl)amino]-4-(2-thiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)




2 D 40

L8 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:495435 CAPLUS
 DN 125:184908
 TI Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)
 AU Zimmermann, Juerg; Caravatti, Giorgio; Mett, Helmut; Meyer, Thomas; Mueller, Marcel; Lydon, Nicholas B.; Fabbro, Dorian
 CS CIBA Pharmaceuticals Div., Oncology Virology Res. Dep., Ciba-Geigy Limited, Basel, CH-4002, Switz.
 SO Archiv der Pharmazie (Weinheim, Germany) (1996), 329(7), 371-376
 CODEN: ARPMAS; ISSN: 0365-6233
 PB VCH
 DT Journal
 LA English
 AB Phenylamino-pyrimidines represent a novel class of inhibitors of protein kinase C with a high degree of selectivity vs. other serine/threonine and tyrosine kinases. Steady state kinetic anal. of N-(3-[1-imidazolyl]-phenyl)-4-(3-pyridyl)-2-pyrimidinamine, which showed potent inhibitory activity, revealed competitive kinetics relative to ATP. The adjacent H-bond acceptor of the pyrimidine moiety next to an H-bond donor of the phenylamine was found to be crucial for inhibitory activity. N-(3-Nitro-phenyl)-4-(3-pyridyl)-2-pyrimidinamine preferentially inhibited PKC- α (IC₅₀ = 0.79 μ M) and not the other subtypes tested. The inhibition consts. of PKC- α and the antiproliferative effect on T24 human bladder carcinoma cells showed a qual. correlation, although with some exceptions.
 IT 181065-62-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylamino-pyrimidine derivs. as a new class of potent and selective inhibitors of protein kinase C)
 RN 181065-62-3 CAPLUS
 CN 2-Pyrimidinamine, N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-(2-thiazolyl)-(9CI) (CA INDEX NAME)



Handwritten:
~~Search~~
 Search and

L8 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1974:108415 CAPLUS
 DN 80:108415
 TI Vilsmeier-Haack reaction. VIII. Synthesis of new heterocyclic derivatives from benzothiazole, 6-methoxybenzoxazole, naphth-1,2-oxazole and naphth-2,1-oxazole
 AU Jayanth, M. R.; Naik, H. A.; Tatke, D. R.; Seshadri, S.
 CS Dep. Chem. Technol., Univ. Bombay, Bombay, India
 SO Indian Journal of Chemistry (1973), 11(11), 1112-14
 CODEN: IJOCAP; ISSN: 0019-5103
 DT Journal
 LA English
 AB The Vilsmeier-Haack reaction was utilized to synthesize malonaldehyde derivs. (e.g. I and II) of benzothiazole, 6-hydroxy- and 6-methoxybenzoxazole, naphth-1,2-oxazole, and naphth-2,1-oxazoles. The malonaldehydes were converted into a variety of heterocycles by reaction with suitable reagents. The corresponding cyanoacetaldehyde derivs. were also made and reacted with phenylhydrazine to yield the 5-amino-1-phenylpyrazoles. The pyrimidine derivs. were strongly fluorescent.
 IT 51864-30-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 51864-30-3 CAPLUS
 CN 2-Pyrimidinamine, 5-(2-benzothiazolyl)-N-phenyl- (9CI) (CA INDEX NAME)



=> => d his

(FILE 'HOME' ENTERED AT 12:21:00 ON 03 AUG 2006)

FILE 'REGISTRY' ENTERED AT 12:21:11 ON 03 AUG 2006

L1 STRUCTURE UPLOADED
 L2 0 S L1 SSS SAM
 L3 STRUCTURE UPLOADED
 L4 50 S L3.SSS SAM
 L5 STRUCTURE UPLOADED
 L6 50 S L5 SSS SAM
 L7 1187 S L5 SSS FUL

FILE 'CAPLUS' ENTERED AT 12:27:55 ON 03 AUG 2006

L8 35 S L7

FILE 'CAOLD' ENTERED AT 12:29:32 ON 03 AUG 2006

=> s 17

L9 0 L7

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.44	352.22


FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-26.25

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:29:42 ON 03 AUG 2006



chain nodes :
7 8 9

ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

chain bonds :
3-7 7-8

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-20 17-18 18-19 19-20 21-22
21-25 22-23 23-24 24-25

exact/norm bonds :
3-7 7-8 11-15 14-15 16-20 19-20 21-25 24-25

exact bonds :
11-12 12-13 13-14 16-17 17-18 18-19 21-22 22-23 23-24

normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :
containing 1 : 11 : 16 : 21 :

G1:[*1],[*2],[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom

25:Atom

Generic attributes :

8:

Saturation : Saturated

=>

Uploading C:\Program Files\Stnexp\Queries\10809944 (c).str



chain nodes :

7 8 9

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

chain bonds :

3-7 7-8

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-20

17-18 18-19 19-20 21-22 21-25 22-23 23-24 24-25

exact/norm bonds :

3-7 7-8 11-15 14-15 16-20 19-20 21-25 24-25

exact bonds :

11-12 12-13 13-14 16-17 17-18 18-19 21-22 22-23 23-24

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 11 : 16 : 21 :

G1:[*1],[*2],[*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom

Generic attributes :

8:

Saturation : Saturated

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam\

COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID

The query entered contains both search terms created by structure-building or screen commands and text search terms. L#s created via the STRUCTURE or SCREEN commands must be searched in the structures files separately from text terms or profiles. The L# answer sets from structure searches can be used in crossover searches and can be combined with text terms.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:39:36 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 341 TO ITERATE

100.0% PROCESSED 341 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5713 TO 7927

PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 14:40:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 6233 TO ITERATE

100.0% PROCESSED 6233 ITERATIONS

142 ANSWERS

SEARCH TIME: 00.00.01

L3 142 SEA SSS FUL L1

=> => s l3

L4 5 L3

=> d l4 1-5 bib,ab,hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:79402 CAPLUS
 DN 144:171020
 TI Preparation of aminothiazole moiety-containing heterocyclic compounds as selective inhibitors of Cdk4 and Cdk6
 IN Iwasawa, Yoshikazu; Shibata, Jun; Shimamura, Tadashi; Kurihara, Hideki; Mita, Takashi; Kawanishi, Nobuhiko; Hashihayata, Takashi; Kawamura, Mikako; Sagara, Takeshi; Arai, Sachie; Hirai, Hiroshi
 PA Banyu Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 178 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006008874	A1	20060126	WO 2005-JP9593	20050519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI JP 2004-178974 A 20040521

OS MARPAT 144:171020

AB The title compds. I [X is O, S, NH, or CH₂; Y₁, Y₂, Y₃, Y₄ and Y₅ are each independently CH or N with at least one of Y₁ - Y₅ being N; Z₁ and Z₂ are each independently CH or N; n is an integer of 1 to 3; R₁ is C₃-8 (un)substituted cycloalkyl, C₆-10 (un)substituted aryl, an (un)substituted aliphatic or aromatic heterocycle, etc.; R₂ and R₃ are each independently hydrogen, lower (un)substituted alkyl, lower (un)substituted alkenyl, etc.; and R₄ is hydrogen, lower alkyl, C₃-6 cycloalkyl, etc.] are prepared. Thus, the title compound II was prepared in a multistep process starting from 5-methyl-2-pyrazinecarboxylic acid. Compds. of this invention showed IC₅₀ values of 3.9 nM to 20 nM against Cdk4 (cyclin dependent kinase 4).

IT 874473-17-3P 874473-18-4P 874473-31-1P
 874474-20-1P 874474-22-3P 874474-24-5P
 874474-26-7P 874474-28-9P 874474-29-0P
 874474-31-4P 874474-33-6P 874474-34-7P
 874474-36-9P 874474-38-1P 874474-40-5P
 874474-42-7P 874474-44-9P 874474-46-1P
 874474-48-3P 874474-50-7P 874474-52-9P
 874474-54-1P 874474-56-3P 874474-58-5P
 874474-60-9P 874474-62-1P 874474-64-3P
 874474-66-5P 874474-68-7P 874474-70-1P
 874474-72-3P 874474-74-5P 874474-76-7P
 874474-78-9P 874474-80-3P 874474-82-5P
 874474-84-7P 874474-86-9P 874474-88-1P
 874474-90-5P 874474-92-7P 874474-94-9P
 874474-96-1P 874474-98-3P 874475-00-0P
 874475-02-2P 874475-04-4P 874475-70-4P
 874475-88-4P 874475-90-8P 874475-92-0P


874475-94-2P 874475-96-4P 874475-98-6P
 874475-99-7P 874476-01-4P 874476-03-6P
 874476-05-8P 874476-07-0P 874476-09-2P
 874476-11-6P 874476-13-8P 874476-14-9P
 874476-27-4P 874476-29-6P 874476-45-6P
 874476-50-3P 874476-51-4P 874476-52-5P
 874476-53-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of aminothiazole moiety-containing heterocyclic compds. as
 selective inhibitors of Cdk4 and Cdk6)

RN 874473-17-3 CAPLUS


CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[(ethylamino)methyl]pyrazinyl]amin
 o]-5-thiazolyl]-6-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874473-18-4 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[(4-methyl-1-
 piperazinyl)methyl]pyrazinyl]amino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874473-31-1 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[6-[[5-[2-(cyclohexylamino)-6-methyl-4-
 pyrimidinyl]-2-thiazolyl]amino]-3-pyridinyl]methyl]-, (2S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 874474-20-1 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[(1-methylethyl)amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-19-8

CMF C22 H30 N8 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-22-3 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[(1-methylethyl)amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

1[pyrazinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 874474-21-2
CMF C26 H34 N8 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 874474-24-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-23-4
CMF C24 H30 N8 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-26-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-(1-pyrrolidinylmethyl)pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 874474-25-6

CMF C23 H30 N8 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874474-28-9 CAPLUS


CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[(cyclopropylamino)methyl]pyrazinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-27-8

CMF C22 H28 N8 S

10/809,944




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-29-0 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[(ethylamino)methyl]pyrazinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874473-17-3

CMF C21 H28 N8 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-31-4 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[(dimethylamino)methyl]pyrazinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-30-3

CMF C21 H28 N8 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874474-33-6 CAPLUS


CN Ethanol, 2-[[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]methylamino]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874474-32-5

CMF C22 H30 N8 O S

10/809,944




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-34-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[(4-methyl-1-piperazinyl)methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 874473-18-4

CMF C24 H33 N9 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

10/809,944


CRN 76-05-1
CMF C2 H F3 O2



RN 874474-36-9 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[[[(1,4-dioxan-2-ylmethyl)amino]methyl]pyrazinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 874474-35-8
CMF C24 H32 N8 O2 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 874474-38-1 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-37-0

CMF C24 H32 N8 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-40-5 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-
[(methylamino)methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate
(9CI) (CA INDEX NAME)

CM 1

CRN 874474-39-2

CMF C20 H26 N8 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-42-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[[3-[(dimethylamino)methyl]-1-piperidinyl]methyl]pyrazinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-41-6

CMF C27 H39 N9 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874474-44-9 CAPLUS


CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[[1-(tetrahydro-2-furanyl)ethyl]amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-43-8

CMF C25 H34 N8 O S

10/809,944




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-46-1 CAPLUS

CN 4-Piperidinol, 1-[[[5-[[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874474-45-0

CMF C24 H32 N8 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-48-3 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[(cyclohexylmethylamino)methyl]pyrazinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-47-2

CMF C26 H36 N8 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874474-50-7 CAPLUS


CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[(3-methyl-3-oxetanyl)amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-49-4

CMF C23 H30 N8 O S

10/809,944




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874474-52-9 CAPLUS


CN 3-Pyrrolidinol, 1-[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-, (3S)-, trifluoroacetate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 874474-51-8

CMF C23 H30 N8 O S

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874474-54-1 CAPLUS


CN 3-Pyrrolidinol, 1-[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-, (3R)-, trifluoroacetate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 874474-53-0

CMF C23 H30 N8 O S

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874474-56-3 CAPLUS


CN 3-Pyrrolidinol, 1-[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-5-methyl-, (3R,5R)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874474-55-2

CMF C24 H32 N8 O S

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-58-5 CAPLUS

CN Acetamide, N-[1-[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 874474-57-4

CMF C25 H33 N9 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-60-9 CAPLUS

CN 1-Piperazineethanol, 4-[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874474-59-6

CMF C25 H35 N9 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874474-62-1 CAPLUS


CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[4-(phenylmethyl)-1-

10/809,944

piperazinyl)methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1


CRN 874474-61-0
CMF C30 H37 N9 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 874474-64-3 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-(1-piperazinylmethyl)pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 874474-63-2
CMF C23 H31 N9 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-66-5 CAPLUS

CN Ethanone, 1-[1-[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-4-phenyl-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-65-4

CMF C32 H38 N8 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-68-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 874474-67-6

CMF C28 H39 N9 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874474-70-1 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-, ethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-69-8

CMF C27 H36 N8 O2 S

10/809,944




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-72-3 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-(4-morpholinylmethyl)pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 874474-71-2

CMF C23 H30 N8 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-74-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[[5-([4,4'-bipiperidin]-1-ylmethyl)pyrazinyl]amino]-5-thiazolyl]-N-cyclohexyl-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-73-4

CMF C29 H41 N9 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874474-76-7 CAPLUS


CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[(cyclopentylamino)methyl]pyrazinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-75-6

CMF C24 H32 N8 S

10/809,944




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-78-9 CAPLUS

CN Ethanol, 2-[[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]amino]-, trifluoroacetate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 874474-77-8

CMF C21 H28 N8 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-80-3 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[5-[3-(dimethylamino)-1-pyrrolidinyl]methyl]pyrazinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-79-0

CMF C25 H35 N9 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-82-5 CAPLUS

CN 1,2-Ethanediamine, N'-[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-N,N-dimethyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-81-4

CMF C23 H33 N9 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-84-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[methyl[(1-methyl-2-piperidinyl)methyl]amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-83-6

CMF C27 H39 N9 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-86-9 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[[1-(2-thienyl)ethyl]amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-85-8

CMF C25 H30 N8 S2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-88-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-, ethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-87-0

CMF C26 H35 N9 O2 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-90-5 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[[(2-methyl-4-thiazolyl)methyl]amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-89-2

CMF C24 H29 N9 S2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-92-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[methyl[(1-methyl-3-piperidinyl)methyl]amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-91-6

CMF C27 H39 N9 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-94-9 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[2-(trifluoromethyl)-1-pyrrolidinyl]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-93-8

CMF C24 H29 F3 N8 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-96-1 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[methyl[(4-methyl-2-thiazolyl)methyl]amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-95-0

CMF C25 H31 N9 S2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874474-98-3 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[[1-(4-methyl-2-thiazolyl)ethyl]amino]methyl]pyrazinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-97-2

CMF C25 H31 N9 S2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874475-00-0 CAPLUS


CN 2-Pyrimidinamine, 4-[2-[[5-[[4-(2-benzoxazolyl)-1-piperidinyl]methyl]pyrazinyl]amino]-5-thiazolyl]-N-cyclohexyl-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874474-99-4

CMF C31 H35 N9 O S

10/809,944




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874475-02-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[5-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]pyrazinyl]methyl]-4-oxo-, ethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874475-01-1

CMF C27 H34 N8 O3 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874475-04-4 CAPLUS


CN Cyclohexanol, 4-[[4-methyl-6-[2-[[5-[(4-methyl-1-piperazinyl)methyl]pyrazinyl]amino]-5-thiazolyl]-2-pyrimidinyl]amino]-, trans-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874475-03-3

CMF C24 H33 N9 O S

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 874475-70-4 CAPLUS

CN Cyclohexanol, 4-[[4-methyl-6-[2-(2-pyridinylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874475-88-4 CAPLUS


CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-2-pyridinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874475-87-3

CMF C26 H36 N8 S

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874475-90-8 CAPLUS


CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[5-[[(3R)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-2-pyridinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874475-89-5

CMF C26 H36 N8 S

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874475-92-0 CAPLUS


CN 2-Piperazinecarboxylic acid, 4-[[6-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]-3-pyridinyl]methyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874475-91-9

10/809,944

CMF C26 H34 N8 O2 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874475-94-2 CAPLUS

CN 4-Piperidinemethanol, 1-[[[6-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]-3-pyridinyl]methyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874475-93-1

CMF C26 H35 N7 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874475-96-4 CAPLUS

CN 2-Piperidinemethanol, 1-[[6-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]-3-pyridinyl]methyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874475-95-3

CMF C26 H35 N7 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874475-98-6 CAPLUS


CN 3-Piperidinol, 1-[[6-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]-3-pyridinyl]methyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874475-97-5

CMF C25 H33 N7 O S

10/809,944




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874475-99-7 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[6-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]-3-pyridinyl]methyl]-, (2S)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874473-31-1

CMF C25 H33 N7 O S

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874476-01-4 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[6-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]-3-pyridinyl]methyl]-, (2R)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874476-00-3

CMF C25 H33 N7 O S

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874476-03-6 CAPLUS


CN 2-Pyrimidinamine, 4-[2-[[5-[[[(3R)-3-amino-1-pyrrolidinyl]methyl]-2-pyridinyl]amino]-5-thiazolyl]-N-cyclohexyl-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874476-02-5

CMF C24 H32 N8 S

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874476-05-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[[5-[[[(3S)-3-amino-1-pyrrolidinyl]methyl]-2-pyridinyl]amino]-5-thiazolyl]-N-cyclohexyl-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 874476-04-7

CMF C24 H32 N8 S

Absolute stereochemistry.

10/809,944




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874476-07-0 CAPLUS

CN 3-Piperidinemethanol, 1-[[[6-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]-3-pyridinyl]methyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874476-06-9


CMF C26 H35 N7 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 874476-09-2 CAPLUS
CN 4-Piperidinol, 1-[[6-[[5-[2-(cyclohexylamino)-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]-3-pyridinyl]methyl]-4-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 874476-08-1
CMF C31 H37 N7 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 874476-11-6 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-2-pyridinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874476-10-5
CMF C29 H35 N9 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874476-13-8 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[5-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]-2-pyridinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874476-12-7

CMF C28 H34 N10 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 874476-14-9 CAPLUS

CN 3-Pyridinemethanol, 6-[[5-[2-[(trans-4-hydroxycyclohexyl)amino]-6-methyl-4-pyrimidinyl]-2-thiazolyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 874476-27-4 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[6-[(dimethylamino)methyl]-2-pyridinyl]amino]-5-thiazolyl]-6-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874476-26-3

CMF C22 H29 N7 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 874476-29-6 CAPLUS


CN 2-Pyrimidinamine, N-cyclohexyl-4-methyl-6-[2-[[6-[(methylamino)methyl]-2-pyridinyl]amino]-5-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 874476-28-5

CMF C21 H27 N7 S






●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874476-50-3 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[2-[[5-[2-(cyclohexylamino)-4-pyrimidinyl]-2-thiazolyl]amino]-4-pyridinyl]methyl]-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874476-51-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-[[5-[2-(cyclohexylamino)-4-pyrimidinyl]-2-thiazolyl]amino]-4-pyridinyl]methyl]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874476-52-5 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-[[4-[[4-(phenylmethyl)-1-piperazinyl]methyl]-2-pyridinyl]amino]-5-thiazolyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874476-53-6 CAPLUS

CN Piperazine, 1-acetyl-4-[[2-[[5-[2-(cyclohexylamino)-4-pyrimidinyl]-2-thiazolyl]amino]-4-pyridinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 874477-04-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

```
(preparation of aminothiazole moiety-containing heterocyclic compds. as
selective inhibitors of Cdk4 and Cdk6)
```

RN 874477-04-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(5-bromo-2-pyridinyl)(methoxymethyl)amino]-5-thiazolyl]-N-cycloheptyl-5-methyl- (9CI) (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:857595 CAPLUS
 DN 141:350190
 TI Preparation of thiazoles as inhibitors of protein kinases
 IN Brenchley, Guy; Farmer, Luc J.; Harrington, Edmund Martin; Knegt, Ronald; O'Donnell, Michael; Salituro, Francesco G.; Studley, John R.; Wang, Jian
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 139 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

*Common In
 Copending*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087699	A2	20041014	WO 2004-US9166	20040325
	WO 2004087699	A3	20041209		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004225977	A1	20041014	AU 2004-225977	20040325
	CA 2523126	AA	20041014	CA 2004-2523126	20040325
	US 2005004150	A1	20050106	US 2004-809946	20040325
	EP 1605946	A2	20051221	EP 2004-758338	20040325
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-457468P	P	20030325		
	WO 2004-US9166	W	20040325		

OS MARPAT 141:350190

AB The title compds. [I; R1, R2 = R, halo, CN, NO2, etc.; R = H, (un)substituted alkyl; Ar1 = (un)substituted aryl, heteroaryl, etc.; R3, R4 = ZR7; or R3 and R4 are taken together to form (un)substituted (un)saturated 3-8 membered ring having 0-3 heteroatoms; Z = a bond, alkylidene, etc.; R7 = halo, CN, NO2, etc.], useful of inhibitors of protein kinases, were prepared E.g., a multi-step synthesis of II, starting from benzothiazole, was given. The compds. I were tested against SYK and ZAP-70 kinases (data given for representative compds. I). The invention also provides pharmaceutically acceptable compns. comprising said compds. I and methods of using the compns. in the treatment of various disease, conditions, or disorders.


IT 774228-81-8P 774229-12-8P 774229-32-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazoles as inhibitors of protein kinases)


RN 774228-81-8 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774229-12-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 774229-32-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:857594 CAPLUS
 DN 141:332212
 TI Preparation of aminopyrimidinyl-substituted thiazoles useful as inhibitors of protein kinases
 IN Farmer, Luc J.; Harrington, Edmund Martin; Salituro, Francesco G.; Wang, Jian
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Appel PC

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087698	A2	20041014	WO 2004-US9061	20040325
	WO 2004087698	A3	20041209		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004225965	A1	20041014	AU 2004-225965	20040325
	CA 2523125	AA	20041014	CA 2004-2523125	20040325
	US 2004235834	A1	20041125	US 2004-809944	20040325
	EP 1610793	A2	20060104	EP 2004-758287	20040325
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-457218P	P	20030325		
	WO 2004-US9061	W	20040325		
OS	CASREACT 141:332212; MARPAT 141:332212				
AB	Title compds. I [R1-2 = halo, CN, NO2; etc.; Ar1 = aryl, etc.; R3-4 = ZR7; Z = bond, alkylidene; R7 = halo, NO2, CN, alkoxy, etc.] are prepared General procedures are provided, e.g., [4-[2-((3,5-dimethylphenyl)amino)pyrimidin-4-yl]thiazol-2-yl]methanol. Selected example compds. of the invention exhibit Ki < 5 µM for Syk kinase. I are useful for the treatment of autoimmune disorders.				
IT	769934-42-1P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of aminopyrimidinyl-substituted thiazoles useful as inhibitors of protein kinases for autoimmune disorders)				
RN	769934-42-1 CAPLUS				
CN	2-Pyrimidinamine, N-cyclopentyl-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)				

10/809,944



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:412940 CAPLUS
 DN 141:7105
 TI Preparation of thienyl- and thiazolecarboxamides as inhibitors of ROCK, ERK, GSK, and AGC protein kinases
 IN Cao, Jingrong; Gao, Huai; Green, Jeremy; Marhefka, Craig
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 222 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041813	A1	20040521	WO 2003-US34319	20031030
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2504320	AA	20040521	CA 2003-2504320	20031030
	AU 2003288956	A1	20040607	AU 2003-288956	20031030
	US 2004122016	A1	20040624	US 2003-696862	20031030
	EP 1558607	A1	20050803	EP 2003-781448	20031030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1732164	A	20060208	CN 2003-80108111	20031030
	JP 2006514684	T2	20060511	JP 2005-502202	20031030
	NO 2005002595	A	20050627	NO 2005-2595	20050530
PRAI	US 2002-422441P	P	20021030		
	US 2003-476433P	P	20030606		
	US 2003-476691P	P	20030606		
	US 2003-479903P	P	20030619		
	WO 2003-US34319	W	20031030		

OS MARPAT 141:7105

AB Title compds. [I; B = Q4, Q5, Q6; R1 = halo, cyano, NO2, VmR; Z1, Z3 = N, CRz; Z2 = N, CR1; Rz = halo, cyano, NO2, UnR'; R2 = UnR'; X1, X2 = CR4, N; R4 = halo, cyano, NO2, VmR; U, V = (substituted) alkylidene optionally interrupted by NR, O, S, CS, SO, SO2, CO2, etc.; m, n = 0, 1; R = H, (substituted) aliphatic; R' = R, (unsatd.) (heterocyclic) mono- or bicyclic ring; Q1 = CO, SO2, CONR, SO2NR; R3 = Q2Ar1; R2Q1R3 = atoms to form a cyclic group; Ar1 = (unsatd.) (heterocyclic) mono- or bicyclic ring; with provisos], were prepared Thus, 2-chloro-N-(4-pyridin-4-ylthiazol-2-yl)acetamide and N-methylaniline were stirred overnight in DMF at 70° to give 2-(methylphenylamino)-N-(4-pyridin-4-ylthiazol-2-yl)acetamide. Certain I were shown to inhibit ROCK I, ERK2, GSK3, and PKA with Ki <1 µM.

IT 692881-96-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of thiophene- and thiazolecarboxamides as inhibitors of ROCK, ERK, GSK, and AGC protein kinases)

10/809,944

RN 692881-96-2 CAPLUS

CN Benzeneacetamide, N-[4-[2-(cyclopropylamino)-4-pyrimidinyl]-2-thiazolyl]-2-fluoro- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:154244 CAPLUS

DN 138:187786

TI Preparation of pyrimidinylthiazoles as antiinflammatories.

IN Love, Christopher John; Van Wauwe, Jean Pierre Frans; De Brabander, Marc J.; Moses, Roger Clive; Goncharenko, Mykhalyo; Cooymans, Ludwig Paul; Vandermaesen, Nele; Diels, Gaston Stanislas Marcella; Sibley, Anthony William; Noula, Caterina

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003015776	A1	20030227	WO 2002-EP8956	20020809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2451981	AA	20030227	CA 2002-2451981	20020809
	EP 1418911	A1	20040519	EP 2002-767360	20020809
	EP 1418911	B1	20060510		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002011910	A	20041019	BR 2002-11910	20020809
	JP 2005504767	T2	20050217	JP 2003-520735	20020809
	CN 1633294	A	20050629	CN 2002-815776	20020809
	NZ 530772	A	20060331	NZ 2002-530772	20020809
	US 2004254192	A1	20041216	US 2004-486820	20040211
	NO 2004000631	A	20040312	NO 2004-631	20040212
	ZA 2004001164	A	20050512	ZA 2004-1164	20040212
PRAI	EP 2001-203088	A	20010813		
	WO 2002-EP8956	W	20020809		

OS MARPAT 138:187786

AB Use of title compds. [I; Z = halo, alkyl; hydroxyalkyl, carboxyalkyl, cyanoalkyl, aminoalkyl, aminoalkyl, aminocarbonylalkyl, alkoxyalkyl, polyhaloalkyl, alkoxy, cyano, amino, aminocarbonyl, aminocarbonyl, alkyloxycarbonyl, alkylcarbonyloxy, etc.; Q = (substituted) cycloalkyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, imidazopyridyl, etc.; L = substituted Ph, (substituted) monocyclic 5-6 membered partially saturated or aromatic heterocycle, bicyclic partially saturated or aromatic heterocycle] for the manufacture

of a medicament for the prevention or the treatment of diseases mediated through tumor necrosis factor-alpha (TNF- α) and/or interleukin-12 (IL-12), is claimed. Thus, Me 3-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]-3-oxopropanoate was added to a mixture prepared from NaOMe and diguanidine carbonate in EtOCH₂CH₂OH followed by 3 h reflux to give 76% 5-(2-aminopyrimidin-4-yl)-4-methyl-2-(4-

trifluoromethylphenyl)thiazole. The latter at 10⁻⁸ M gave 92% inhibition of IL-12p70.


IT 499796-65-5P 499796-66-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinylthiazoles as antiinflammatories)


RN 499796-65-5 CAPLUS

CN 2-Pyrimidinamine, N-(1-methyl-4-piperidinyl)-4-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 499796-66-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d his

(FILE 'HOME' ENTERED AT 14:38:54 ON 03 AUG 2006)

FILE 'REGISTRY' ENTERED AT 14:39:04 ON 03 AUG 2006

L1 STRUCTURE UPLOADED
 L2 7 S L1 SSS SAM
 L3 142 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 14:40:37 ON 03 AUG 2006

L4 5 S L3

FILE 'CAOLD' ENTERED AT 14:41:11 ON 03 AUG 2006

=> s 13

L5 0 L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.44

194.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.75

STN INTERNATIONAL LOGOFF AT 14:41:22 ON 03 AUG 2006